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This thesis examines issues related to functional movement disorders (FMD) and consists of 
three papers: a literature review, a research paper and a critical appraisal of the research 
process. 
The scoping literature review explored the characteristics of psychological 
interventions for FMD in research studies in the last 20 years. It found that FMD was 
conceptualised differently across the studies and interventions employed various techniques 
to target different assumed FMD mechanisms. The review identified that although 
psychological wellbeing, co-morbid physical symptoms and quality of life are important 
factors influencing and influenced by FMD, they are often not monitored in research studies. 
Acceptability of the interventions has also not been measured despite preliminary evidence of 
their low uptake and high dissatisfaction with psychological explanations of FMD. A number 
of recommendations have been made for future studies to improve design and evaluation of 
psychological interventions for this population.  
The research paper explored lived experiences of people with FMD. Ten semi-
structured interviews were analysed using Interpretative Phenomenological Analysis. Three 
superordinate themes were generated: (1) The tug of war with the secret agent within: the 
power struggle with symptoms; (2) Navigating risks of disclosing the diagnosis: stigma and 
self-preservation (3) Pursuing hope, knowledge and treatments against helplessness and 
passivity. The findings indicate that people with FMD may face many internal and 
interpersonal battles whilst trying to maintain hope, a sense of control and identity. A sense 
of oppression, loss of control and stigma were explained in the context of discriminatory 
power distribution in the society and healthcare settings. Recommendations for research and 
clinical practice focus on facilitating patients’ empowerment and access to adequate 




treatments in FMD-informed services. 
The critical appraisal discusses the studies’ finding in the context of interpersonal and 
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Psychological interventions for functional movement disorders – a systematic 
scoping review 
Abstract  
Purpose: To synthesise available research in relation to the main characteristics of 
psychological interventions for people with functional movement disorders (FMD).  
Method: A scoping review methodology was adopted. PubMed, CINAHL, 
PsycINFO and Scopus databases were systematically searched. Studies reporting 
psychological interventions for FMD published from year 2000 in peer-reviewed 
journals in English were included. Data was extracted in relation to therapeutic 
modality of the interventions, techniques employed, theoretical conceptualisation of 
FMD, outcome domains and measures, and methods of evaluating intervention 
effectiveness and acceptability. 
Results: 921 articles were identified, of which 23 were eligible. Cognitive behavioural 
therapy was the most commonly employed intervention. The theoretical 
conceptualisation of FMD varied across the studies, which employed various 
therapeutic techniques to target different assumed underlying processes or their impact. 
Comorbid symptoms, psychological wellbeing and quality of life were often not 
monitored. Acceptability of interventions was mostly not examined. The effectiveness 
of interventions was reported on the basis of statistical significance, without calculating 
effect sizes or clinically significant changes across all domains. 
Conclusion: Future research should examine specific therapeutic techniques and their 
impact on the hypothesised processes involved in FMD. A variety of psychosocial and 
physical outcomes should be measured and analysed in terms of effect sizes and 
clinically significant changes to capture meaningful changes in the syndromic nature of 
FMD. The acceptability should be routinely measured to build up evidence for socially 
valid and feasible interventions. Development of a competence framework for 
psychological interventions is needed to guide clinicians and set standards for practice. 
Keywords: functional movement disorder, functional neurological disorder, 
psychogenic disorder, conversion disorder, psychological intervention, psychotherapy, 
literature review 
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Introduction 
Functional movement disorders (FMD) involve altered movement control, such as tremor, 
dystonia, limb weakness, gait disturbance, spasms or fixed postures. They belong to a wider 
category of functional neurological disorders (FND) and frequently occur alongside other 
sensory or cognitive functional symptoms, neurological disorders, physical illnesses and 
psychological difficulties [1]. They are described as a disruption to the nervous system’s 
functioning, rather than structural damage or an organic disease, and are often explained 
metaphorically as a ‘brain software’ issue [2].  
FMD have incidence of four to five cases per 100 000 of population per year [3] and 
the wider FND account for around 16% of all neurology referrals in the UK [4].  The 
symptoms are often persistent and disabling [5] though people affected are regularly left 
without effective treatments [6]. The prognosis remains poor [7-9] with mortality higher [8] 
and general health and quality of life lower [10] than comparable organic neurological 
disorders.  
Traditionally FMD have been explained by psychoanalytic theories as a conversion of 
psychological distress, conflict or trauma into physical symptoms that symbolised the threat, 
unmet need or unexpressed impulses [11]. Psychological therapy targeting the assumed 
underlying trauma or psychological ‘disturbance’ was thus the treatment of choice. With 
time, the traditional conversion model has been challenged as lacking empirical evidence and 
reductionistic [12,13]. In the move away from the emphasis on psychological distress as the 
key causal factor in FMD, the criterion of an identifiable psychological stressor has been 
removed from the formal diagnosis in the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) [14]. However, the term ‘conversion disorder’ and ’psychogenic 
movement disorder’ are still used synonymously with FMD and the role of stress is 
   PSYCHOLOGICAL INTERVENTIONS FOR FMD                                                                                         1-4 
 
commonly accepted as influencing FMD trajectory [15]. Nevertheless, there has been a 
growing recognition that, unlike in other somatoform disorders, distress and physiological 
arousal alone fail to explain FMD and for some people it has less relevance [16].  
Increased appreciation of the complex multifactorial determinants of FMD [17] 
alongside advances in neuroimaging and pathophysiological studies [18-22] facilitated the re-
emergence and developments of neurobiological theories [23] which shifted the focus 
towards broader biopsychosocial models incorporating more neurobiological and 
psychosocial factors in FMD. The newer models built on previous insights and many 
described FMD as a brain circuit disorder with altered network activity and connectivity, 
altered metabolic demand during tasks, and expressed in the context of predisposing, 
precipitating and perpetuating factors: genetic, neurological, cognitive, emotional and 
environmental [1,3,20,24].  
The changes in conceptualisation of FMD instigated changes in recommended 
treatments, from mainly insight-oriented psychotherapy to multidisciplinary approaches [1,3]. 
The most robust evidence currently exists for specialist physical rehabilitation with 
psychological input [25]. Current evidence to support particular psychological interventions 
for FMD is growing but limited with most studies involving cognitive behavioural therapy 
(CBT). However, the available research is insufficient to support CBT at the evidence-base 
level [16]. Additionally the focus and type of CBT may vary, from generic stress-focused to 
specialist protocols developed for particular FMD symptoms. The most robust evidence for 
CBT amongst the wider category of FND is for non-epileptic seizures and yet the most 
recent, and the biggest, randomised controlled trial (RCT) failed to find significant change in 
the frequency of seizures when compared to standardised medical care. It did however show 
significant improvements in distress, quality of life, somatic symptoms and impression of 
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overall clinical improvement as rated by patients and clinicians [26]. The changes in these 
domains are  likely to be important to patients’ overall functioning and wellbeing but their 
correspondence with patients’ initial treatment goals has not been examined. Furthermore, 
this particular CBT approach was based on assumption of avoidance of fear as associated 
with seizures and hence targeted this process via exposure and challenging seizure-related 
thoughts. However, it is possible that whilst this approach reduced anxiety and avoidance as 
some of the perpetuating factors, the targeted processes or techniques had limited influence 
on the factors initiating seizures. Therefore an exploration of theoretical assumptions and 
therapeutic targets might be of crucial importance when designing and evaluating 
interventions. Indeed, there is an increased emphasis on delivering interventions across 
different FNDs according to the specific symptoms and their various underlying processes 
[27].  
The patients’ perspectives have been under-represented in this debate but their 
dissatisfaction with psychological explanations for their physical symptoms has been 
frequently reported [28,29] suggesting a discord between clinicians’ and patients’ 
conceptualisations of FMD and goals for treatment. Carson illustrated the frustration and 
invalidation of patients in a metaphor of going to a garage with a flat tyre but being 
persuaded to buy shock absorbers first [16]. However, the acceptability of psychological 
interventions for FMD has not been systematically studied. Adopting biopsychosocial models 
of FMD which emphasize the different interactions of a variety of factors offer the 
opportunity to match various psychological interventions and their different therapeutic 
targets and techniques to the individual needs of the person. Collaborative formulation of the 
predisposing, precipitating and perpetuating factors relevant to each individual person could 
guide the choice of the target area of functioning that is most likely to generate positive 
changes, meaningful to the patient. 
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The dynamically evolving understanding of FMD, dissatisfaction with traditional 
psychological explanations and poor prognosis of people with FMD warrant a closer 
examination of contemporary psychological interventions for this population. There has been 
no knowledge synthesis in the research literature to describe what psychological interventions 
entail, which assumed underlying or maintaining processes are targeted, nor which 
goals/outcomes are expected and evaluated. Such an overview would help identify areas in 
need of revision, in line with modern insights, expert consensus and acceptability to patients. 
This is especially important now, in the context of renewed interest and research activity, to 
guide future investigations by posing the right questions. Therefore the current study was 
proposed to examine characteristics of  psychological interventions for FMD in research 
studies conducted in the last 20 years using scoping review methodology.  
Methods 
A scoping review has been adopted as a well-suited methodology to answer broad 
exploratory research questions, especially in an area of new emerging evidence [30]. 
Systematic scoping reviews offer similar rigour to traditional systematic reviews and 
are concerned with mapping out and understanding complex topics from a broader 
perspective, contextualising and synthesising the data. They aim to identify gaps in the 
evidence and facilitate generation of new questions that would advance the field [31].  
This systematic scoping review was guided by Arksey and O’Malley’s six step 
framework [32,33] and guidance for conducting systematic scoping reviews produced by the 
Joanna Briggs Institute (JBI) [34]. Quality assessment is usually not conducted in scoping 
reviews as not pertinent to the research question [30,33] and was not conducted here. 
Step 1: Research question  
The research question was: What are the key characteristics of psychological interventions 
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used in research studies for FMD? This broad question includes two foci of the review that 
guided the search strategy, data extraction and synthesis: 
(1) What therapeutic approaches and tools are used, and on what theoretical 
propositions about FMD?  
(2) Which outcomes are targeted and measured? How is effectiveness and 
acceptability evaluated? 
The aim is to provide an overview of the current theoretical and methodological 
aspects of the available research to stimulate discussion, guide further research and aid the 
development of psychological interventions.  
Step 2: Identifying relevant studies 
A systematic search of four databases (PubMed, CINAHL, PsycINFO and Scopus) was 
conducted on 8th March 2020. Google Scholar was also searched and the references of key 
papers were hand searched for additional studies. The search strategy was developed and 
refined in consultation with the university’s subject specialist librarian. It combined the two 
main concepts: FMD and psychological interventions, including their various terminologies. 
Where available, the database thesauruses, subject headings, truncation and main terms 
‘explosion’ were used (see Table 1).   
 
[Table 1 around here] 
 
Free text searches were conducted in the titles, abstracts and keywords of the articles and 
combined with the subject headings searches. The search strategy is presented in Table 2 and 
detailed searches for each database are attached in Appendix 1-B.  
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[Table 2 around here] 
 
Step 3: Study selection  
The search criteria included studies of any design, including case studies, which report an 
application of psychological intervention for FMD in people aged 18 and over. Participants 
had to have had at least one functional movement symptom for which they were treated, such 
as limb weakness, paralysis, spasms, tremor, gait disturbance, myoclonus or dystonia. 
Psychological intervention was defined as a specialist intervention delivered by a mental 
health professional and intended to improve or manage the participants' FMD. To be included 
in the study the interventions had to use psychological theoretical frameworks and could be in 
the form of psychological formulation, psychotherapy, counselling, psychoeducation, skills 
training or consultation. Interventions could be direct or indirect (with other professionals or 
family engaged in the person's treatment), standalone or part of a wider multidisciplinary 
treatment. The review was narrowed to papers published in English and in peer-reviewed 
journals since 2000. This timeframe was selected to capture contemporary evidence. Studies 
were excluded if the symptoms could be attributed to a known organic aetiology. Full 
inclusion and exclusion criteria are presented in Table 3.  
 
[Table 3 around here] 
 
The literature search returned 921 papers after de-duplication. The author first 
screened the records by reading the titles and abstracts and retrieved the full article text if the 
study appeared to meet the inclusion criteria. At this stage 889 records were excluded and the 
remaining 34 were further assessed for eligibility by reading the full texts. The study 
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supervisor was consulted to resolve any emerging ambiguity regarding the inclusion of a 
study. As a result of this process eleven studies were excluded [16,35-44] and 231 studies 
were included in the final analysis [45-67] (see Figure 1).  
 
[Figure 1 around here] 
 
Step 4: Charting the data  
This step involved an iterative process of extracting and charting data from the papers and 
supplementary materials provided by the authors [32]. The categories of data extracted are 
presented in Table 4. Characteristics of the studies’ sample, methodology and intervention’s 
structure and modality were taken directly from the authors’ descriptions in relevant sections. 
Passages of text relating to the conceptualisation of FMD symptoms and the interventions’ 
techniques and targets were searched for across the entire article. Direct quotes were used in 
the data charting table unless this was not practical due to the amount of relevant text – in 
such cases a summary was constructed by the researcher.  
 
[Table 4 around here] 
 
 
1 One of the included studies with n=9 involved one participant who was 17 years old and therefore strictly did not meet the 
aged 18 or over inclusion criterion. The decision was reached to include this study as it was likely this breach of the 
inclusion criteria would have minimal to no impact on the review findings. 45. Hinson VK, Weinstein S, Bernard 
B, et al. Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders [Article]. 
Parkinsonism and Related Disorders. 2006;12(3):177-180.  
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Step 5: Collating, summarising and reporting the results 
An overview of the collated data guided the analytical process and decisions about aspects or 
subsets of studies to be summarised, compared and synthesised based on particular 
characteristics of interest [68]. The quantitative analysis in this review was limited to 
calculating basic descriptive statistics. Textual data was categorised whenever possible. 
Changes in FMD terminology and number of published studies over time were summarised 
and presented in visual graphs. Characteristics of the studies’ design, conceptualisation of 
symptoms, psychological interventions and their evaluation methods were presented using a 
narrative synthesis.  
Step 6: Consultation 
This stage was an iterative process of consulting with the study supervisor to discuss the 
charted and synthesised data from methodological perspectives. An additional clinical and 
theoretical perspective was sought from a consultant clinical neuropsychologist and a clinical 
psychologist. Two experts by experience were also consulted on a draft of results to inform 
the discussion of the findings. 
Results 
A total of 23 articles published since 2000 were included in this review (see Table 1 for an 
overview). The studies combined involved 517 participants and were undertaken in five 
countries: USA (n=9), UK (n=5), The Netherlands (n=2), Canada (n=2), joint studies 
between Canada and USA (n=2) and UK and Italy (n=1). 
 
[Table 5 around here] 
 
Figure 2 shows the recent growth in publications, with more than half (61%) in the 
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last four years. The studies used different terms to describe FMD. In the first decade terms 
used were ‘conversion’, ‘somatisation’, ‘factitious’, and ‘psychogenic’ whereas from 2016 
onwards, the terms ‘functional’ or ‘conversion’ were used exclusively (see Figure 3).  
Seventeen studies reported interventions for mixed movement symptoms, two for 
dystonia, two for paralysis, one for myoclonus, and one for tremor. See Table 5 for the 
characteristics of the studies. 
 






[Figure 3 around here] 
 
Design of studies 
Over half (61%, n=14) of the 23 included studies used retrospective designs, mainly case 
reports (n=9). Nine studies used prospective designs, including four RCTs: two on the use of 
hypnosis [66,67], one on psychodynamic psychotherapy (PDP) [61], and one utilising CBT 
[47]. Seven studies involved a comparison group and out of these, only two had active 
psychological interventions as a comparator [65,67]. Fewer than half of the studies (n=11) 
conducted follow-up assessments. Out of these, five followed up their participants six months 
or more after the treatment [54,58,62,66,67]. Sample sizes were generally small, ranging 
from 1 to 45 participants, with the exception of one retrospective study of n=174 [46]. The 
mean sample size was 22, median 14 and mode 1.  
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Type and settings of interventions  
Interventions were conducted in out-patient (n=15) and in-patient (n=8) services. Fifteen 
studies reported standalone psychological interventions with the remaining eight delivered as 
part of multidisciplinary treatments.  
 The most utilised form of intervention was individual therapy (n=20). The use of 
psychoeducation groups was reported in two studies [63,67]. Two studies offered co-
treatment sessions with other professionals – physiotherapists, occupational therapists and 
neurologists – as a way of integrating multidisciplinary treatment or to facilitate adherence to 
the main rehabilitation model [49,51]. Three studies reported indirect interventions - 
consultation by a psychologist to other therapists and staff in multidisciplinary in-patient 
settings [51,58,65]. In two of them consultation was offered in combination with direct work  
and in one study it was the only psychological input [65].  
Duration of interventions varied from one to 50 sessions. In in-patient settings, the 
duration of psychological interventions was mostly tied to the duration of the admission, 
which also varied, from five days to 18 weeks (see Table 6). 
 
[Table 5 around here]. 
 
  
[Table 6 around here] 
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Therapeutic targets, tools and symptom conceptualisation  
The findings are presented according to the papers’ stated therapeutic modality. However, 
multidisciplinary treatments (MDT) can offer a broader approach to symptoms and target 
multiple FMD processes or their impact. Psychological interventions offered as part of such 
treatment might be separate or intertwined with other techniques, making it difficult to extract 
its distinctive elements. Therefore, the studies were divided into two groups: psychological 
interventions as standalone treatments and as part of MDT. Description of each study’s  
symptom conceptualisation and therapeutic tools is presented in Table 6.  
When describing conceptualisation of symptoms, only material that was explicitly present in 
the current papers was included, to avoid potential pitfalls of misinterpretation or making 
incorrect inferences. Similarly, some interventions modified previously published treatment 
manuals for other FNDs but it was decided to only include the description of techniques 
explicitly stated in the current papers as the extent of the adaptations could not be assumed. 
Standalone psychological interventions 
Cognitive behavioural therapies. There were seven CBT, two ACT and one DBT study in 
this category.  
One CBT study [47] did not describe symptom conceptualisation or therapeutic techniques. 
The remaining six studies [46,50,52,55,59,64] shared many common techniques, such as 
identifying links between symptoms and cognitions, emotions, behavioural responses and the 
environment, symptom re-attribution or reducing behavioural avoidance and three studies 
[52,59,64] modified previously published manuals of CBT for NES [69-72]. However, the 
therapeutic priorities, emphasis on particular techniques or development of additional ones 
varied, often depending on the theoretical assumptions about main underlying or contributing 
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mechanism in FMD.  Some CBT papers [50,55,59] reported targeting movement control 
directly through motor strategies, such as tapping with a non-tremulous body region to 
interfere with symptom expression [59]. The focus on practising the correct, yet feared 
movement was at the centre of Gros et al.’s study [55], where CBT for obsessive compulsive 
disorder was used on the understanding that FMD symptoms are compulsions that developed 
to manage health-related anxiety triggered by past injuries or disability. A unique, strategic 
symptom displacement technique was developed by Krupnik et al [50] and involved 
practising alternative movements (e.g. tying a knot on a rope) in the presence of symptom 
triggers to redirect attention and correct the brain’s erroneous prediction of the symptomatic 
movement emergence (spasm). It was based on the Bayesian model of predictive coding in 
FND [73] and proposed symptoms to be a result of an altered brain activity in which 
abnormal movements are predicted and generated in error and in response to excessive 
somatically directed attention. Krupnik et al. also employed cognitive strategies to influence 
the brain’s predictions via education about the symptoms’ nature and to demonstrate the 
mind’s influence on symptoms, e.g. during distraction.  
Other CBT studies reported mainly cognitive strategies to alter cognitive or emotional 
processes and responses. For example, O’Connell et al.’s paper [46] quotes errors in attention 
and symptom attribution as contributing to symptoms development as well as their temporal 
relationship with stress and anxiety. The intervention was described as aiming to challenge 
the identified ‘cognitive distortions’ and build insight and acceptance of a ‘psychological 
understanding’ of symptoms through psychoeducation. Greater emphasis on the role of affect 
in FMD seemed present in Espay et al’s study where increased activation of brain regions 
associated with subliminal emotional processing is proposed to be linked with symptom 
expression [52]. The authors proposed that identification and management of the implicit, 
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emotionally laden automatic thoughts emerging during symptom exacerbation may help 
reduce the hyperactivation of the affected brain regions and reduce symptoms.  
A similar perception of FMD as a way of coping with unexpressed and avoided affect was 
described in a case study of a psychoeducational intervention combining ACT and Morita 
therapy concepts [63]. The  aim was to increase awareness and acceptance of internal 
experiences, and reduce experiential avoidance. Mindfulness, psychoeducation about 
controllability of actions - but not internal states - and identifying primary values, were used 
to connect with emotional experience and facilitate a shift towards a productive, valued 
behavioural actions. An individual ACT therapy as the sole therapeutic approach was used in 
Graham’s case study [57]. Whilst the therapeutic goals of increasing openness to and 
awareness of own internal experience and strengthening engagement with one's values was 
similar to the previous study, Graham considered FMD aetiology as complex and 
multifaceted and the exploration or challenging patient’s illness beliefs was not required. 
Attentional processes were considered as potentially implicated in symptom maintenance and 
thus directly attending to them was suggested as unhelpful. Instead, altering symptom-
focused attention indirectly was hypothesised as useful to reduce symptoms’ interference 
with functioning and wellbeing.  
The only study of DBT [48] described FMD as a function of emotional dysregulation and 
therefore targeted mainly emotional processes through skills training in emotional awareness 
and regulation. 
Hypnosis, PDP and body-focused therapy. Five studies, employing hypnosis [66],  PDP 
[45,56,61] and body-focused therapy [53], conceptualised the movement symptoms as a 
symbolic representation of  a difficult affect, a psychological conflict or an unmet need. PDP 
and hypnosis promoted insight into the unconscious phenomena through exploration of early 
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life events, underlying conflicts or unexpressed feelings as well as supporting the 
development of new coping strategies to deal with threatening memories or feelings. 
Additionally, the hypnosis study used symptom-oriented hypnotic techniques, attempting to 
alter cue conditioning for the specific motor symptoms and reinforcing reduction of 
symptoms with praise [66]. The body-focused intervention [53] employed mainly movement 
and sensory exercises to build a sense of strength and safety in the body. This aimed to work 
through the traumatic past experiences by providing an alternative somatic experience 
without explicit verbal exploration. 
Psychological interventions as part of multidisciplinary treatments  
Cognitive behavioural interventions. Five CBT-informed studies were included in this 
category. One of them [58] combined CBT with ACT and reported symptoms as 
manifestations of anxiety, stress and depression. Other studies reported more nuanced and 
multifactorial conceptualisation whilst acknowledging cognitive/psychological factors as 
important in the way symptoms are expressed [62]. Stress and psychopathology was seen as 
often insufficient to explain symptoms [54] or as maintaining rather than causing them [49]. 
The CBT interventions involved identification and management of triggers and associated 
unhelpful thoughts, emotional and behavioural responses, in some cases aiming to build a 
‘more psychological understanding’ of symptoms [60] or changing illness beliefs and re-
attribution of symptoms, although not necessarily to psychological trauma or adverse events 
[62]. Yam’s study rooted in CBT and ACT [58] described a two-pronged psychological 
intervention: individual therapy, addressing anxiety and distress through relaxation, 
mindfulness, exploration of thoughts and emotions, psychoeducation and identifying values 
to guide committed action; and consultation to other therapists to guide behavioural strategies 
based on reinforcement of correct movement and planned ignoring of non-functional 
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movements. Lidstone et al [49] assembled an integrated intervention whereby the physical, 
neurological and psychological interventions were interwoven and delivered by three 
professionals together: a neurologist, a neuropsychiatrist and a physiotherapist. This 
corresponded with their conceptualisation of symptoms as a maladaptive integration of 
different brain functions in FMD (see Table 6 for detail) [49]. The psychological elements 
involved desensitisation and uncoupling of sensory triggers from motor symptoms, 
addressing the fear of symptoms through attentional redirection exercises, and integrated 
body-focused work to address any psychological difficulties, e.g. anxiety, lack of confidence 
or sense of agency.  
Behavioural interventions. Both studies utilising behavioural interventions [51,65] described 
FMD in terms of a maladaptively conditioned behavioural strategy in response to stress. They 
used indirect interventions to support physical therapies and rewarded functional movement. 
They also used planned ignoring or withdrawal of positive reinforcement for no progress or 
'non-functional' behaviours (safety strategies, e.g. use of wheelchair, walking aids). One of 
the studies also provided individual therapy to improve stress management [51]. In the other 
study the authors introduced aversive elements, such as stating that a lack of progress or an 
attempt at a ‘premature discharge’ would be a proof of psychiatric aetiology and would 
require a long psychiatric treatment. The therapists explicitly endorsed lying and deception as 
necessary to actively discourage ‘dysfunctional behaviours’ [65].  
Hypnosis. Moene et al.’s study [67] described symptoms as an expression of a psychological 
need or conflict. Hypnosis was delivered in addition to group psychotherapy and skills 
training, and utilised insight-oriented techniques facilitating exploration of past events and 
associated unexpressed emotions as well as symptom-oriented techniques, aiming to alter the 
cue-conditioning of triggers and symptomatic movements.  
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Evaluation of interventions 
In this review FMD outcomes were categorised into six domains: (1) functional movement 
symptoms (FMS) (2) psychological wellbeing (3) co-morbid symptoms (4) life impact 
(quality of life, functioning and participation) (5) resource use (health and social) and (6) 
acceptability. The first five domains were selected according to previous recommendations in 
the literature [74]. The sixth – acceptability – was chosen as an important although often 
neglected aspect of evaluation of clinical treatments [75] offering insight into how well an 
intervention will be received by the recipients and the extent to which it might meet their 
needs [76]. The guidance for evidence-based practice issued by the American Psychological 
Association recommends that evaluation of interventions should involve acceptability 
alongside evaluation of efficacy [77]. In FMD this is particularly important given the frequent 
disagreement between patients and treatment providers regarding the diagnosis [78], 
perceived acceptability of treatments [79] and dissatisfaction with psychological explanations 
[29]. Outcome domains, measures and methods of evaluating effectiveness in the included 




[Table 7 around here] 
 
FMS  
Although all but one article [53] reported reductions in FMS at the end of the interventions, 
over half of the studies (n=13), including all case studies and four group studies, did not use 
any standardised measures to monitor symptoms. These studies created Likert-type scales to 
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assess changes reported in clinical records or used verbal reports [46,48,50,51,53,55-58,62-
65]. The remaining 11 studies utilised the following standardised measures: Psychogenic 
Movement Disorder Rating Scale (PMDRS) (n=5) [45,47,52,59,61], Clinical Global 
Impression Scale (CGI) (n=3) [49,54,61], Video Rating Scale for Motor Conversion 
Symptoms (VRMS) (n=2) [66,67] and Modified Rankin Scale (MRS) (n=1) [60]. Only two 
of those measures were designed to evaluate FMS – PMDRS [80] and VRMS [81] – though 
their validity and reliability were only investigated in single studies by their authors. All case 
studies used verbal self-report and clinician observation. In the group studies only two 
included patient-rated questionnaires [54,62]. 
In the 14 group studies, interventions were evaluated mainly using statistical 
significance of mean changes in groups’ scores between admission and end of treatment 
(n=10) and between treatment groups, where this was part of the design. Only one study 
calculated and reported treatment effect sizes [67]. Ten studies provided information on the 
proportion of participants who experienced improvement (see table 7). Only three group 
studies [45-47] reported the number of participants with worsening of symptoms and one 
case study reported an emergence of new functional symptoms after therapy ended [50].  
Co-morbid physical symptoms  
Presence of co-morbid symptoms was reported in 16 studies [46,48-51,53-56,58,60,62,63,65-
67] with pain and fatigue being the most common. However, these were mostly not 
monitored despite their recognised association with worse outcomes in FMD [82,83]. Only 
five studies measured changes in co-morbid somatic symptoms [50,53,64].  
Psychological wellbeing (PW) 
18 studies reported co-morbidity of psychological difficulties or psychiatric diagnoses prior 
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to the interventions, with the most common being depression, anxiety or PTSD. 
Nine studies did not monitor outcomes for psychological wellbeing 
[51,52,54,56,58,60,62,64,65]. Six of these were multidisciplinary inpatient treatments 
[51,54,58,60,62,65]. Eight group [45-47,49,59,61,66,67] and four case studies [48,50,53,57] 
used validated standardised measures to monitor symptoms of anxiety, depression, traumatic 
stress symptoms or used generic measures covering a range of psychosocial difficulties. 
Even though the authors of group studies often reported prevalence of co-morbid 
psychiatric diagnoses, it was unclear what proportion of participants had clinically significant 
psychological difficulties at the start of the interventions. Only mean scores for the whole 
groups were reported and analysed. All group studies used statistical significance to evaluate 
improvement in PW. There was no report of the proportion of participants who had clinically 
significant changes in PW. Only one study reported  proportion of cases with worsening PW 
[47].  Only two case studies conducted ‘reliable change’ and ‘clinically significant change’ 
analyses to assess the significance of improvements [48,57]. 
Life impact (LI) 
Various aspects of the life impact of symptoms were measured in eight group 
[45,47,49,54,60,62,66,67] and six case studies [50,51,53,57,58,64]. The authors used 
observation, occupational therapy records and self-reported description in two case studies 
[51,58]. The remaining studies employed standardised and validated measures to monitor 
quality of life and participation. Some of the studies reported global functioning and 
symptom interference whilst others focused on specific domains, like activities of daily living 
or achievement of pre-set goals. Employment status was reported in three case studies 
[50,58,64] and one group study [62].  
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The eight group studies measuring LI used statistical significance of the change in 
group means without calculating effect sizes. Only one study reported the proportion of 
people whose LI was rated as ‘improved’ [60]. In the six case studies measuring LI, two 
reported only changes in employment status [50,64], one monitored achievement of goals set 
in therapy regarding daily activities [51], one reported changes in scores without further 
analysis [53], one reported changes in category/severity of limitations [58] and one used the 
analysis of reliable change and clinical significance of change [57]. 
Resource use 
The use of health and social resources was generally not measured. One study reported 
healthcare utilisation [54] and another one receipt of financial benefits after treatment [62]. 
Both studies analysed statistical significance of the change in group mean.  
Acceptability 
Acceptability was not explicitly measured by most of the studies. Only two studies surveyed 
their participants about overall satisfaction with the treatment and the therapists [54,62]. Data 
on discontinuation and drop-out of treatments was provided by eight out of 14 group studies. 
Discontinuation rates ranged from 0% to 33% with the median at 30%. Comparing data was 
difficult due to different designs, recruitment protocols and reporting strategies. For example, 
one study of PDP included participants who had completed only one session and did not 
report these as discontinuing treatment [56]. Both studies that clearly reported uptake rate of 
the intervention after the initial assessment registered it at 50% [45,46]. Rates of accepting a 
referral for psychological intervention in naturalistic studies were unknown.  
Discussion 
This scoping review has described how psychological interventions for FMD have been used 
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and evaluated in research studies over the last 20 years. Twenty-three studies met the 
inclusion criteria and were examined.  
FMD terminology 
This review identified a notable shift away from the term ‘psychogenic’ towards the term 
’functional’ since 2016.  This is in line with the overall trend in the modern FMD literature 
which shows the term ‘functional’ is more acceptable to patients [84], is favoured by 
neurologists, and reflects the multifactorial, biopsychosocial models of FMD [17,24]. 
However, the term ‘conversion’ was also relatively common despite its similarities with the 
‘psychogenic’ term.  The use of ‘conversion’ term and theory is still extensive especially in 
psychiatric and mental health literature [85-88], and is used synonymously with the 
‘functional’ label in the psychiatric diagnostic manual DSM-5. This suggests that the 
traditional debate between different disciplines about the extent to which ‘psychological’ 
factors account for the symptoms is still ongoing [88,89]. Reflective of that is the newest 
version of the International Classification of Diseases 11th Edition (ICD-11) where FMD 
feature in neurological categories as ‘functional’ and  in psychiatric categories under 
‘dissociative’ disorders.  
Characteristics of the interventions – theoretical considerations  
Amongst the 23 included studies, there was a dominance of interventions rooted in the 
cognitive behavioural tradition (n=17), particularly CBT (n=12). The remaining six studies 
were made up of PDP (n=3) [45,56,61], hypnosis (n=2) [66,67] and body oriented 
psychotherapy [53].  
Many studies, across all therapeutic modalities, perceived FMS as associated with deficits in 
overall emotional functioning, such as emotional awareness and regulation or more 
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specifically with the processing of stressors or adverse life events and hence targeted these 
processes in their interventions. However, modern complex multifactorial models of FMD 
posit that many individuals with FMD do not have any identified or relevant premorbid 
distress, adversity or psychopathology [87,90,91]. Additionally, some authors who used such 
affect-focussed conceptualisations, noted ‘compliance as a major concern’ [92, p.437] which 
might suggest problems with the acceptability of such an approach. This is consistent with 
complaints from the patients themselves [29]. However, a recent review [93] of experimental 
studies and neuroimaging supports the role of the emotion-motion link in generating and 
perpetuating FMD through enhanced functional connectivity of the motor-limbic circuits in 
the brain during preconscious (‘bottom-up’) emotional processing. Limbic hyperactivation, 
autonomic hyperarousal, altered interoception (sensory detection) of bodily emotional 
responses and disrupted ‘top-down’ regulation are thought to influence neural circuits 
involved in awareness and control of lower-level processes such as motor function [93]. The 
conclusions from neuroimaging studies are uncertain though, mainly due to the use of reverse 
inference [94] and lack of adjustment for distress and mood, which are likely to obscure the 
specific effect of FMD [93]. Nevertheless, the current expert consensus acknowledges the 
importance of emotional processes in FMD expression [1,24,93] but there has been little 
direct examination of whether or which of the emotional processes need to be targeted in 
therapy to exert influence on different domains of FMD outcomes. Many studies in this 
review employed various techniques and therapeutic approaches to target one or a selection 
of these processes, and all but one claimed some reduction or removal of movement 
symptoms. However, some studies reported a reduction in FMS without reducing 
psychological distress (and thus possibly limbic and autonomic arousal) [47,66,67]. This 
might challenge the utility or necessity of the distress-focused techniques, especially for those 
people who cannot identify emotional triggers. Further research should examine the relevance 
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and impact of the specific techniques on FMD outcomes and the motor-limbic brain 
connectivity.  
Some studies placed more emphasis on altered cognitive processes as implicated in 
generation or maintenance of FMD in line with the neurocognitive models of attentional and 
agency dysregulation in FMS and supported by electrophysiological studies [24,73,95]. 
Those studies mainly employed CBT-informed interventions and were mostly concerned with 
the processes of attending to and appraising of bodily sensations, including FMS, and were 
less concerned with the person’s past or present circumstances unless it directly impacted on 
their coping with or beliefs about the symptoms. However, despite many similarities in 
therapeutic approach, the actual targets and techniques varied. When the focus was on pre-
cognitive, bottom-up neurological processes, the strategies involved altering behaviours and 
bodily sensations to influence attention and correct the brain’s predictions and evaluations. 
The top-down strategies aimed to influence the person’s illness beliefs and attention through 
reasoning and education. One case study employed both though indicated that there was no 
change after the initial top-down approach [50]. Another CBT study quoted common 
‘resistance’ to the promoted explanations about symptoms [46]. This suggests that targeting 
symptom beliefs might act as barriers to engagement for some patients. However, education 
is widely regarded as crucial and therapeutic by many authors in the field [96,97] although 
this was examined in the context of neurological, rather than ‘psychological’ explanations of 
FMD. It is unclear which aspects of (psycho)education could be useful and for whom this 
might help or hinder improvements in symptoms and engagement in therapy. An ACT case 
study [57], which did not require changing the person’s beliefs to achieve change in 
functioning and quality of life, provides a promising alternative when shared understanding 
of FMS between patients and practitioners is difficult to establish and which might otherwise 
exclude a patient from treatment. More research is also needed to explore acceptability and 
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effectiveness of approaches that do not require challenging patients’ beliefs.  
Authors of studies that were part of multidisciplinary treatments often quoted broader, 
more nuanced conceptualisations of FMD, though the techniques employed in their CBT did 
not differ from the standalone treatments, apart from Lidstone et al.’s study [49]. The authors 
designed a bespoke integrated multidisciplinary intervention in which CBT was intertwined 
with neurology and physiotherapy input, affording the authors the unique opportunity to 
respond to emerging physical and psychological needs session by session, based on 
individual formulations.  
Psychological intervention were also integrated with other disciplines’ input in the 
two behavioural interventions delivered in in-patient rehabilitation settings [51,65]. They 
involved active guidance and support for the physical therapists and other staff to ensure 
adherence to the behavioural model. However, one of those studies [65] used the label 
‘factitious’ interchangeably with ‘conversion’ to describe FMD which implies an association 
with feigning and voluntary control over symptoms. Such conceptualisation by the authors, 
who were also clinicians delivering the intervention, might have affected their choice of an 
ethically dubious intervention, which involved deceit, coercion and aversive, potentially 
distressing elements as an incentive to discontinue FMD [65]. Additionally, although DSM-5 
and the current literature [98] distinguish functional disorder from factitious disorder, some 
authors state there is no reliable way of making a differential diagnosis [99]. Other authors 
endorse the term ‘face-saving interventions’ to describe treatments for FMD [100] which 
suggests that the interventions assume some overlap between feigning and functional 
symptoms. Indeed, the second behavioural study in this review, conducted in 2019, described 
the intervention as ‘a graceful way out’ of symptoms [51, p.662]. The conceptualisations of 
FMD as a learnt behaviour reinforced by secondary gains might be particularly susceptible to 
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implicit or explicit associations with feigning or manipulation. This is likely to invite 
negative moral judgements [101] and influence the clinicians’ attitude and patients’ 
experience of care [29].  
In a qualitative study reporting the experiences of people with FMD, perceptions of 
being judged by healthcare professionals as feigning were common [29]. However, although 
some behavioural conceptualisations of FMD might lead to unfounded conclusions and 
questionable attitudes, behavioural techniques may still be useful and effective in treatment. 
Indeed, many behavioural techniques or principles were used across other studies in this 
review without similar ethical issues. Examples of such techniques include using de-coupling 
of altered movement from its identified cues in hypnosis [66,67] and CBT [50] or 
desensitisation of feared movements in CBT [64]. The use of positive reinforcement is also 
used in physiotherapy to re-train normal movement function [102]. Future research should 
investigate employment of behavioural interventions alongside holistic theoretical 
frameworks to avoid reductionistic approaches. If a sole behavioural intervention is 
investigated, acceptability of the procedures should be closely monitored.  
This review has highlighted that conceptualisations of FMD in psychological 
interventions vary between and within different therapy modalities. Whilst many find some 
support in research examining processes implicated in FMD, their relevance to therapeutic 
outcomes is unclear. It is also possible that some therapeutic techniques can be acceptable 
and effective even when particular ‘psychological explanations’ are rejected by patients. 
Lastly, the decision of whether a ‘psychological explanation’ is necessary might become 
obsolete if practitioners and researchers adopted the language of ‘neuro-bio-psycho-social 
explanations’ instead. 
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Measures and evaluation of interventions 
This review indicated the predominant use of snapshot clinician-rated or independently-rated 
measures for FMD. This presents challenges due to the changeability in symptoms and the 
discrepancy between subjective and objective experience of FMD symptoms [103]. Adopting 
more patient-reported measures as potentially more meaningful, has previously been 
proposed [74]. The lack of medium- or long-term follow-up in most of the included studies 
presents another challenge, given the often waxing and waning nature of FMD and possibility 
of new symptoms emerging [3,17,104]. Indeed, one of the case studies reported new 
functional symptoms five months after resolution of the original symptoms [50]. 
Additionally, co-morbid symptoms were largely not monitored in the included studies, even 
though poor long-term prognosis and poor quality of life have been associated with the many 
co-morbidities in FMD, especially fatigue and pain [25,83,105]. Recent recommendations for 
treatments by leading professionals and researchers in the field promote interventions tailored 
to patients' specific movement symptoms and their co-morbidities. This is due to their 
bidirectional interaction in influencing outcomes and a potential for common underlying 
mechanisms [17].  
Similarly, psychological co-morbidities have been reported as being high in FMD. 
However, nearly half of the studies did not monitor psychological wellbeing, even when 
psychopathology was seen as driving FMD [58]. Amongst the studies conducted in in-patient 
settings, 75% did not monitor PW. This is surprising for various reasons: hospitalisation in 
itself can be a distressing experience and these participants were likely to have more severe 
FMD with more impact on PW. In addition many in-patient centres are located far from 
patients’ homes and families depriving them of social support [104], and the potential role of 
stress on the trajectory of FMD was acknowledged in most studies. In the only study that 
reported rates of worsening PW, 30% of the participants were affected [47], which suggests a 
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need for clear reporting and monitoring of the potential detrimental effects of the 
interventions. The number and outcomes of those who had clinically significant PW 
symptoms at the start of the intervention were also not reported. In the group studies only 
statistical significance of changes in the group means were investigated which might lead to 
important insights being missed if participants varied significantly in their PW at the start. 
Some authors reported the PW group mean symptomatology as relatively low to begin with, 
therefore it would not be expected to reduce significantly [66,67]. However another author 
argued that initial low scores reflect the individual’s lack of insight and are likely to worsen 
during the course of the treatment [50]. More data of the trajectory of PW outcomes during 
and after psychological treatments for FMD could help understand these processes better and 
inform treatment delivery.   
Quality of life is often reported to remain low despite improvement in movement 
symptoms [47,54] and yet LI was measured in only half of the group studies. There was a 
lack of data on the proportion of people whose LI improved and to what extent. It is unclear 
whether the lack of sufficient improvements in QoL is due to insufficient improvement in 
movement symptoms or whether direct work on LI is needed to facilitate adaptive 
adjustments or transitioning from treatment. The measures of LI were varied and 
incomparable as different aspects were monitored: general quality of life, employment status 
or performance on specific tasks. Assessing it in a consistent manner could help highlight and 
address emerging issues as many people continue to experience at least some symptoms after 
rehabilitation or therapy [54].  
The evaluation of the interventions in group studies was mostly undertaken through 
analyses of statistical significance without calculating effect sizes. Relying on p values and 
null hypothesis testing has been increasingly criticised in psychological research as 
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potentially misleading and clinically unhelpful when not informed by theoretical framework 
and clinical judgement of what constitutes a clinically significant change [106]. Analysis of 
estimation is promoted instead as more informative, clinically meaningful and less biased 
[106], especially in the case of small studies which might not detect significant changes due 
to lack of sufficient statistical power. Calculating the effect sizes would provide important 
insights into the size of the impact of an intervention which would inform more informed 
choices when designing and delivering psychological interventions.  
Acceptability 
The numbers of patients who refuse psychological interventions at the point of referral are 
unknown. However, the two studies that reported rates of uptake after the initial assessment 
at only 50% provide preliminary support to clinical observations, reporting them to be low 
[56]. This review offers a hypothesis, to be further examined, that although the dropout rates 
seem comparable with those reported in studies of psychological interventions for mental 
health presentations [107-110], long-term conditions [111] and neurological conditions [46], 
the rejection of the intervention might be occurring prospectively at the point of referral or 
assessment. This has been previously noted for people with FMD and other functional 
symptoms [112,113]. Frequent disagreement with the diagnosis [78] is also likely to impact 
the uptake of treatment, especially if FMD is explained as entirely attributable to 
psychological factors [49]. There is sufficient initial evidence of barriers to acceptability of 
psychological interventions to warrant closer investigation. Acceptability and social validity 
of an intervention is thought crucial to its effectiveness and feasibility [114,115] and thus 
systematic research and measurement could help identify implementation barriers [116]. 
Prospective (anticipated), concurrent (during the intervention) and retrospective assessments 
of acceptability should be employed [117]. This could be achieved by questioning the 
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participants about whether the treatment goals (e.g. targeting assumed underlying emotional 
processing dysfunction, improving quality of life whilst living with FMD), procedures 
(techniques) and outcomes (the size of change in an important aspect of life) are acceptable, 
relevant and meaningful to the participants [114]. This information should then be used to 
design, improve and evaluate further interventions [116].  
Development of a stakeholders’ consensus competence framework for psychological 
interventions in FMD would help guide clinicians in the changing landscape of emerging 
insights into functional disorders and their implications for psychological practice. In 
addition, changing the question from increasing patients’ acceptance of ‘psychological 
explanations’ to improving the acceptability of the interventions to patients might help shift 
the focus towards collaborative care and enhanced engagement.  
Limitations, strengths and implications for practice 
This scoping review included only studies written in English from a few western countries. 
The qualitative data was limited and relied on the authors’ selective reporting of particular 
therapeutic techniques and understanding of FMD. Some psychological interventions 
constituted part of multidisciplinary treatments and it was impossible to establish whether 
they used the same or different formulations of symptoms. Similarly, in reports of 
retrospective studies it is difficult to state whether the descriptions reflected the actual 
interventions or general ideas about the therapeutic models. Not including grey literature 
introduces publication bias and is likely to have excluded some of the approaches practised in 
clinical settings. Additionally, the literature search, data extraction and analysis were 
conducted by one researcher only. This introduces risk of inadvertent omissions of relevant 
studies or data within them. Where sections of text were summarised/interpreted this also 
increased the risk of bias and independent checks by other researchers would have enhanced 
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reliability of the findings. However, this review is the first study to summarise the research in 
this area in a systematic way, covering conceptual underpinnings as well as methodological 
and clinical aspects of evaluation of psychological interventions for FMD.  
Although as a scoping study it has limited ability to make clinical recommendations, 
it points to important issues of acceptability of psychological interventions and a wide range 
of available and changing conceptualisations of FMD. A revision of the emphasis on any 
single ‘psychological explanation’ of FMD is needed, and knowledge of  wider 
biopsychosocial frameworks should be promoted to reflect the diversity and lack of certainty 
in this field. There is a role for psychological practitioners to promote multidisciplinary 
working where possible. Where psychological interventions are offered as standalone 
treatments, their breadth and variety affords the opportunity to match them with particular 
needs of the patient. It should be guided by a collaborative formulation whereby the 
understanding of symptoms, therapeutic techniques and priorities take into account the 
person’s unique circumstances and preferences as well as being based on recent 
developments in the field.  
Conclusions 
This scoping review has found that FMD is conceptualised differently across different 
psychological interventions which then employ different therapeutic techniques  to achieve 
different goals. Whilst standalone psychological interventions are not able to target the 
multiple bio-psychosocial factors involved in FMD, they offer a variety of therapeutic tools 
that could be matched with the patients’ individual needs, circumstances, preferences and 
goals. However, more research is needed to examine specific therapeutic techniques, and to 
develop interventions embedded in contemporary frameworks. The acceptability of 
psychological interventions has not been systematically examined though the preliminary 
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data suggests low uptake. Research studies are needed to explore acceptability of particular 
techniques, treatment goals and theoretical assumptions to build up evidence for socially 
valid and feasible interventions. A variety of psychosocial and physical domains need to be 
measured to capture relevant outcomes affected by the syndromic nature of FMD. Analysis of 
effect sizes and clinically significant change is required to conduct meaningful evaluation and 
comparison between different interventions. 
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Table 1. Subject headings used in database searches, where available 
Concept MESH Terms/subject headings/thesaurus searches 
Psychological intervention Psychotherapy, counselling. 
FMD Conversion disorder, hysteria, movement disorder, 
functional disease, motor dysfunction. 
 
Table 2. Free text search strategy used in database searches  
Combined with ‘OR’: 
AND 
Combined with ‘OR’: 
AND 

























Table 3. Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
 
(1) Published in peer reviewed journals in English 
from 2000 onwards. 
(2) Reported application and evaluation of a 
psychological intervention in the treatment of 
people aged 18 and over; including 
multidisciplinary or combined approaches 
with an active psychology input, e.g. 
psychoeducation, psychotherapy or 
consultation.  
(3) Participants given diagnosis of FMD, 
including different diagnostic terms such as 
FND, FNSD, conversion symptoms/disorder, 
psychogenic symptoms/disorder, or hysteria. 
(4) FMD was the main concern and a target of 
treatment. 
(5) Symptoms consisted of altered main 
movement function, such as: spasms, tremor, 
paralysis, limb weakness, dystonia, or gait 
disturbance. 
 
(6) Opinion, theoretical paper or clinical 
guidelines. 
(7) Treatments without an active 
psychological intervention or where the 
intervention was not described or 
evaluated, only mentioned. 
(8) Psychological intervention not part of the 
study, e.g. a referral made to an external 
source. 
(9) Symptoms reported to be a ‘functional 
overlay' in an organic disorder. 
(10) A comorbid condition was the primary 
target for treatment. 
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• Standalone or 
multidisciplinary 






• Individual or 
group 

























Domain measured:  
• Movement symptoms 
• Comorbid symptoms 
• Psychological wellbeing 
• Life impact 




• Outcome measures 
• How effectiveness reported: statistical 
significance, clinical significance or other 
 
 





Design Diagnosis and symptoms, duration, comorbidities 







A case report Conversion disorder: left sided paralysis, bilateral tremor. 
Comorbidity: PNES, dissociative amnesia, depression, anxiety, 
headaches, fibromyalgia. 
Duration: 8 weeks. 
 
Dalocchio, C. 









Functional movement disorder (conversion disorder), mostly tremor 
(75%).  
Comorbidity: not reported. 
Duration: mean 1.5 years. 
 









Functional tremor;  
Comorbidity - depression (5/15, 33%); PTSD (4/15, 26%); excluded 
from the study if had any other comorbid FND. 
Duration: 2.3 ± 1.6 (range, 1–4) years. 
 
Graham, C.D. 





A case study Functional propriospinal myoclonus – limb weakness and pelvic 
spasms 
Comorbidity: low mood, sleep dysfunction; no other health complaints. 
Duration: 12 months. 
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A case report Psychogenic movement disorder PMD: neck and hand tremor; 
freezing movements - cataplexy-type state. 
Comorbidity: speech disruption, neck pain, OCD, personality disorder, 
major depressive disorder. 
Duration: not reported. 
 








A case report FNSD-based cataplexia and paralysis symptoms.  
Comorbidity: mast cell activation disease, gastroparesis with possible 
irritable bowel syndrome, autonomic nervous system dysfunction, sleep 
apnoea and attention deficits. 
Duration: not reported. 
 









Psychogenic movement disorder (conversion disorder): tremor, 
myoclonus, dystonia, bradykinesia (slowness of movement), tics, gait 
disorders. 
Comorbidities: major depressive disorder (n=5, 55%), PTSD (n=2, 
22%), personality disorder (n=2, 22%), anxiety disorder (n=1, 11%) and 
bipolar disorder (n=1, 11%). 
Duration: ranged from less than 8 months (n=8, 88.9%) to 78 months 
(n=1, 11.1%). 
 









Functional movement disorder: abnormal gait (31.2%), hyperkinetic 
movements - tremor, chorea or myoclonus (31.2%), dystonia (31.2%), 
weakness 6.3%.  
Comorbidity: depression (81.3%) and anxiety (62.5%), PTSD 35.5%; 
84.4% - comorbid physical health conditions.  
Duration: mean 7.4 (+-10.8) years 
 
Kompoliti, K. 








Psychogenic movement disorder: conversion disorder (n=8), 
somatoform disorder (n=5), and somatization disorder (n=2). symptoms: 
(n=6, 40%) tremor, (n=5, 33.3%) myoclonus, (n=1, 6.6%) dystonia, 
(n=7, 46.6%) gait impairment.  
Comorbidity: depression (n=9, 60%), depression with anxiety (n=3, 
20%), PTSD (n=5, 33.3%). 
Duration: 63.2 ± 73 months. 
 
Krupnik, V. et 






A case study Motor conversion disorder: 'freezing' - inability to move; tics.  









A case report Psychogenic movement disorder: dystonia. 
Duration: 5 years. 
Lidstone, S.C. 









Functional movement disorder: gait disorder and episodic movement 
symptoms.  
Comorbidity: 100% pain and fatigue; pre-morbid anxiety and depression 
(36%) 
Duration: mean 6.2 ± 7.0 years 
 
McCormack, R. 









Severe chronic motor conversion disorder: loss of motor function 
(n=29, 87.9%), abnormal motor function (e.g., tremor, dystonia, ataxia) 
(n=4, 12.1%). 
Comorbidity: non-epileptic dissociative features (n=18, 55%);  
A non-dissociative psychiatric co-morbidity (n=20, 60.6%): somatoform 
pain disorder (n=7, 21.2%); somatisation disorder (n=6, 18.1%); 
Neurological co-morbidity (n=6, 18.2%): epilepsy (n=2; 6%) a 
neurological disorder (n=6, 18.1%), neurogenic bladder (n=2; 6%), MS 
(n=1, 3%). 
Duration: median 48 months; mean not reported. 
 










Conversion disorder, motor type, or somatization disorder with 
motor conversion symptoms: paralysis or paresis (n=38, 86.4%), gait 
disorder (n=25, 56.8%), coordination problems (n=19, 43.2%), tremors 
(n=7, 15.9%), spasms (n=8, 18.2%), myoclonus (n=7, 15.9%).  
Comorbidity: other functional symptoms or pain (n=37, 84.1%);  
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psychiatric Axis I diagnosis in 33.3%. 
Duration: mean 3.9 years with a range of 2 months to 22 years (SD 4.5 
months). 
 
Moene, F.C. et 










Conversion disorder, motor type, or somatization disorder with 
motor conversion symptoms: paralysis or paresis (n=22, 50%), gait 
disorder (n=3, 6.8%), coordination problems (n=16, 36.3%), tremors 
(n=10, 22.7%), spasms (n=7, 15.9%), myoclonus (n=6, 13.6%). 
Comorbidity: other functional symptoms, pain; psychiatric Axis I 
diagnosis in 29.7%. 













Conversion disorder or functional motor or movement symptoms 
without formal diagnosis: weakness, tremor, shakes, jerking, dystonia.  
Comorbidity:  
- other functional disorders (headaches, fibromyalgia, CFS, IBS) - 
38.8%.  
- a current physical health condition in 79.2%.  
Duration: mean 9.9 ±9.6 years. 
 
Papadopoulus, 









Conversion disorder: Paralysis of the arm.  
Comorbidity: somatoform pain disorder in the leg and back; insomnia 
and depression. 
Duration: 2 years. 
 







A case report Conversion disorder (FNSD) with motor dysfunction: bilateral 
paralysis of legs. 
Comorbidity: PTSD and depression; chronic pain, migraines. 
Duration: 2 months. 
 
Saifee, T.A. et 








Functional motor symptoms (FMS): dystonia, jerks, tremor, weakness, 
paralysis. 
Comorbidity: fatigue, headaches, pain, sleep disturbance, dizziness, 
gastrointestinal problems, seizures, anxiety, low mood. 
Duration: most patients (63%) had symptoms for more than 3 years. 
 
Shapiro, A.P. et 






A repeated case 
series, cross-over 
design 
Non-organic (conversion/factitious) motor disorders: paralysis or 
paresis, astasia basia (unsteady gait with lack of coordination) and/or 
ataxic-like symptoms, leg shaking, tremors. 
Comorbidities: pain (33% in the acute and 70% in the chronic group), 
bladder/bowel dysfunction (0% in the acute and 27% in chronic group), 
other functional symptoms (11% in the acute and 60% in the chronic 
group). 
Duration: acute (2 months or less) or chronic (more than 6 months). 
 









Functional movement disorder: shaking/jerky movements (50%) and 
tremor (43%). 
Comorbidity: 13/30 (46%) depression or anxiety, 1 (3%) bipolar 
disorder, 3 (10%) fibromyalgia or/and IBS. 
Duration: mean 3.2 years (range 2 months to 17 years). 
 
Vizcarra, J.A. 












- functional tremor (n=4, 30%), depression (n=5, 38.4%), anxiety (n=4, 
30.4%), panic disorder with or without agoraphobia (n=3, 23.07%), 
obsessive-compulsive disorder (n=2, 5.36%). 
Duration: mean: 4.4 ± 3.4 years in Placebo + Cognitive Behavioural 
Therapy (CBT) and 2.1 ± 3.5 years in BoNT + CBT. 
 







A case study Functional neurological symptom (conversion) disorder (FNSD): 
mixed symptoms, including motor dysfunction: gait disturbance - left-
leg drag, difficulties with balance and fine motor dexterity. 
Comorbidity: anxiety and depression; other FND symptoms: speech 
disturbance and impaired cognition; pain, headaches, insomnia. 
Duration: 5 months. 
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setting and duration 
Conceptualisation of symptoms  Therapeutic tools and targets  
 
Standalone psychological intervention  
 
Baslet, G. et 
al. 2011  
[63] 
Inpatient psychiatric ward. 
 
3 psychoeducational ACT 
based and Morita therapy 
group sessions and 2 
individual sessions. 
Avoidance tendencies and difficulties in verbal 
expression of affect contribute to the development of 
symptoms and are a way of coping with difficult 
affect. 
In group sessions:  
- Defining primary values and actions that would be consistent with their 
life goals; 
- Mindfulness meditation; 
- Psychoeducation facilitating a shift in perceiving - 'reperceiving';  
- Facilitating acceptance instead of avoidance and alexithymia as a 
strategy to cope with aversive internal experiences;  
- Psychoeducation about uncontrollability of thoughts, feelings, and 
body sensations, and controllability of actions.  
In individual sessions:  
- Projective cross-sectional house drawings of family of origin and 
current family; 
- Journaling as a way of shifting focus to a productive activity and 
connecting to emotional experience. 
 
Dalocchio, 
C. et al. 
2016 
[59] 
Outpatient CBT: 60 or 90 
min sessions/week for 12 
weeks. 
Not  described. 
 
CBT protocol adapted from Goldstein et al’s  manual in CBT study for 
NES [69]: 
- Identifying somatic misinterpretations, negative thoughts, and illness 
beliefs maintaining FMD and low mood or anxiety;   
- Establishing alternative hypotheses for the bodily sensations;  
- Distraction techniques were developed;  
- Motor strategies were implemented (for instance tapping at a certain 
frequency with a non-tremulous body region) to be used to 
reduce/interrupt the specific FMD; 
- Planning and review of homework, which included completing records 
about FMD, avoiding behaviours, problem solving. 
 
Espay, A.J. 




CBT using cognitive 
elements from the model 
Symptoms associated with alterations in activity in 
several brain regions, including the anterior 
cingulate/paracingulate cortex - thought to be activated 
in emotional processing and theory of mind; symptom 
CBT protocol adapted from LaFrance et al’s  manual in CBT study for 
NES [72] 
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for PNES - weekly for 12 
weeks. 
associated with increased activity of the brain regions 
during (subliminal) emotion processing.  
 
- Examining and managing automatic thoughts and cognitive 
distortions emerging during symptom exacerbation: Socratic 
questioning, thought monitoring, thought restructuring; 
- Education on relapse prevention – managing re-emergence of 
symptoms. 
Graham, 








(ACT) - 6 sessions. 
Symptoms pathogenesis complex and ambiguous; 
Altered attentional processes often implicated and thus 
treatments altering symptom-focused attention 
indirectly might be useful for reducing symptoms 
interference. 
 
ACT techniques aimed at increasing psychological flexibility and 
orienting the person towards meaningful activity (rather than targeting 
FMD symptoms): 
- Relational framing (  
- Defusion  
- Mindfulness;  
 Perspective taking; 
- Exploring values to underpin committed action; 
- Altering symptom-focussed attention indirectly by focusing on 
meaningful goals 
Gros, D.F. 





CBT for OCD: exposure 
and response prevention – 
1hr/week for 4 weeks. 
 
Symptoms result from psychiatric, rather than organic, 
neurologic disturbance. FMD symptoms as 
compulsions (e.g slowed movements) developed to 
reduce anxious thoughts   resulting from past injuries 
and disability.  
CBT for OCD: exposure and response prevention (ERP) [118] 
- Repeatedly exposing the patient to feared movements - while 
preventing the use of unhelpful coping strategies (slowing movements, 
self-talk, hesitancy). 
Hinson, 










Not  described. Psychotherapy aimed at treating identified psychiatric diagnoses: 
- Exploration of historical and early life experiences, parenting 
dynamics, enduring personality traits; 
- Identifying links between these and current life experiences and 
problematic emotions and behaviours to reshape the intrapsychic 
structure of the patient. 
Kompoliti, 






Short term psychodynamic 
psychotherapy (PDP)- 
hourly sessions every 
week for 12 weeks. 
Symptoms result from an underlying psychiatric 
illness or are representing unconscious conflicts, 
unidentified emotions and can be linked to historical 
and early life experiences. 
- Exploring historical and early life experiences, parenting dynamics, 
enduring personality traits, as well as the links between these and current 
life experiences, problematic emotions and behaviours;  
 
- Developing insight into unconscious phenomena or addressing 
alexithymia with the goal of making unconscious phenomena conscious 
and working through underlying conflicts. 









informed approach based 
on Bayesian model of 
predictive coding.  
Symptoms are a result of dysfunctional predictive 
coding - hyper-precise prior beliefs (priors). Priors can 
be conscious or unconscious from perceptive to 
cognitive. The prior beliefs about causes of sensory 
information acquire an abnormally high value and may 
cause its failure to be appropriately updated and 
corrected by prediction errors. Instead, the brain will 
then ‘fulfil’ the belief by generating a corresponding 
abnormal sensation or movement, or lack thereof in 
case of a negative symptom. These abnormal 
sensations/movements are perceived as involuntary 
and eliminate the prediction error. Thought to stem 
from excessive somatically directed attention. An 
injury or a random sensation may capture attention and 
then be reinforced into a belief/prior. Symptoms can be 
traced back to a 'somatic' triggering event and do not 
need to have a 'symbolic' meaning. 
 
Strategic modification of priors via:  
1. Strategic symptom displacement (targeting prior beliefs at the level of 
symptoms - from the bottom-up, on a pre-cognitive level. Practicing an 
alternative motor behaviour in situations of anticipated triggers and 
generating a strong enough prediction error to affect and correct the 
target priors. 
2. A top-down cognitive processing 
 - Cognitive-educational component through insight about the nature of 
symptom and its links with triggers, and cognitive-experiential 
component testing the mind's impact on the motor symptoms, 
strengthening the prediction error. 
LaFrance, 
W.C. et al. 
2009  
[64] 
Outpatient individual 12 
weekly sessions of CBT. 
 
 
Not  described. Modified from a CBT-informed manual for nonepileptic seizures (NES) 
[70,71]:  
- Monitoring and taking control of movements; 
- Training in healthy communication; 
- Understanding medications; 
- Functional behavioural analysis and examining triggers;  
- Addressing mood‐cognition‐environment connections, automatic 









Hypnosis - manualised - 
10 weekly sessions and 
preceded by a preparatory 
educational session. 
Symptom as an expression of a psychological need or 
conflict. 
Hypnotic techniques manualised for different movement symptoms: 
1. Symptom oriented:  
- Direct and indirect suggestions designed to alter cue-conditionings 
relevant to the specific motor symptoms;  
- Emphasizing and praising every occurrence of small (spontaneous) 
movements.  
2. Expression and insight oriented: 
- Age regression to explore the perceived cause of the symptom or the 
distressing experiences that apparently initiated the symptom; 
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- Expression of the “pent-up'' or dissociated emotions encouraged (when 
the history suggested that a distinct psychological stressor was related to 
the onset or exacerbation of the symptom); 
- Learning self-hypnosis to practice symptom-oriented techniques 1/day 
for 30 minutes. 
 
O’Connell, 






CBT individual therapy, 
weekly, 2-15 weeks. 
Symptoms explained by an information-processing 
account that involves: attentional processes, 
attribution errors, and behavioural avoidance.  
It acknowledges the temporal relationships between 
symptoms and stress, mood, anxiety, or dissociation. 
 
- Psychoeducation; 
- Challenging 'cognitive distortions' that affect motivation, attempting 
to ‘build insight so that patients may learn to accept a psychological 
understanding of symptoms’; 
- Mood and thought diaries; 
- Relaxation and graded exposure to reduce behavioural avoidances; 




et al. 2018 
[53] 




psychological therapy - 50 
weekly sessions over 1.5 
years. 
The symptom as a somatic expression of the body's 
symbolic response to precipitating traumatic life 
events: being numbed, paralysed and impotent. 
Stuckness in a habitual fear based, inappropriate 
survival response.  
- Physical movement and exploring bodily sensations in the context of 
simple warm-up exercises; 
- Deep abdominal breathing and releasing of tension in the voice box 
and throat; 
- Props (balls, beanbags) utilized to experience the body in a positive 
way; 
 - Grounding exercises and movement patterns that support a sense of 
strength, (physical) boundary setting and self-defence. 
 
Rancourt, 
D. et al. 
2019 
[48] 
Primary care mental 
health clinic for veterans.  
 
DBT informed 
psychotherapy – 25 
sessions over 8 months. 
Symptoms as a function of emotion dysregulation; a 
maladaptive coping strategy that occurs in response to 
a stressor in an attempt to get an emotional need met.  
- Teaching distress tolerance and emotion regulation skills: self-
soothing, radical acceptance, emotional awareness training, taking 
opposite action; 
- Problem-solving skills; 
- Interpersonal effectiveness skills; 
- Identifying values; 
- Increasing social support. 
 
Sharma, 







Psychotherapy (PDP) - 
Mean number of sessions 
4.9 (range 1 to 21). 
Symptoms fuelled by unconscious conflicts and 
unresolved past trauma. The physical symptom is a 
way of avoiding the painful awareness of the trauma 
or/and conflict. 
- Exploring early life experiences in the family home of origin to 
identify possible relationship between past experiences and current 
problems; 
- Developing new thought patterns and coping strategies that would 
reduce symptoms. 











CBT weekly sessions – 12 
or less if FMD remitted. 
 
Not described. Not described. 
 
Psychological intervention as a part of multidisciplinary treatments 
 
Hardin, A.S. 
et al. 2019 
[51] 
Inpatient rehabilitation 
(IR) unit – 22 days.  
 
A multidisciplinary 




sessions and consultation 
to other staff to maximize 
adherence to the model. 
Treatment as providing ‘a graceful way out’ of 
symptoms which are seen as non-functional 
behaviours.  
Co-treatment and consultation: 
- Reinforcing functional behaviours while ignoring non-functional 
behaviours; 
- Decisive language used to promote the expectation of functionality and 
expectation of return to full premorbid functioning; 
- Building self-efficacy for physical capabilities. 
Individual intervention: 
- Psychological skill building; 
- Stress management training; 
- Couples counselling; 
- Education on CBT; 
- Interpersonal effectiveness training; 
- DBT based coping skills training; 
- Engendering a biopsychosocial perspective on wellness; 
- Minimizing excessive focus on physical symptoms. 
 
Jacob, A.E. 





CBT 1hr/day for 5 days of 
the inpatient stay. 
 
. Symptoms are the result of abnormal motor control 
thought to be caused by psychological factors, 
However, presence of stress and psychopathology 
often absent and insufficient to explain symptoms. 
Using treatment manual for FND [119]: 
- Identifying factors that may trigger symptoms;  
- Recognizing and improving unhelpful thought and behavioural 
patterns; 
- Mental imagery training. 
Lidstone, 






Biweekly 6 session 
integrated therapy (45min) 
Symptoms as a maladaptive integration of 
“psychological” and “physical” brain functions, such 
as motor–limbic communication, sensorimotor 
integration and agency, symptom-related beliefs and 
expectations, self-directed attention, conditioning, 
autonomic and neuroendocrine changes and others. 
- Desensitization and uncoupling of sensory triggers from motor 
symptoms; 
- Targeting fear of symptoms;  
- Attentional redirection exercises;  
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simultaneously delivered 
by three professionals 
CBT - informed. 
 
Psychiatric comorbidities and psychosocial stressors 
considered as perpetuating rather than causal factors.  
- Integrated body-focused work (e.g. implementing dance and previously 
well practised motor programmes) to address some psychological 
difficulties, e.g. anxiety, lack of confidence or agency. 
McCormack, 








including offer of CBT 
(84.9% accepted), time-
limited but tailored to the 
individual. 
The median length of stay 
was 101 days (IQR 84–
130). 
Symptoms’ link with possible environmental and 
psychological aspects are explored in terms of their 
predisposition, precipitating and maintaining role. 
Links between past experiences and development of 
symptoms are considered but not essential for progress 
in therapy. 
- Challenging cognitive distortions that might affect a patient’s 
motivation, determination or ability to engage;  
- Build insight into a more psychological understanding of symptoms;  
- Shifting the locus of control from external to internal by fostering 
insight and assertiveness; 
- If important - discovering links between past or present experience and 
physical symptoms (not essential); 
- Mood and thought diaries (to link moods and thoughts with 
environmental exposures);  
- Relaxation techniques; 
- Graded exposure (if avoidance is employed as a coping strategy);  
- Neuropsychological testing if needed. 
 
Moene, F.C. 





treatment team (a nurse, a 
group therapist, a creative 
therapy therapist, a sports 
therapist and a 
physiotherapist). 
 
Group psychotherapy and 
psychoeducation, skills 
training. 
Experimental group - 
additional hypnosis (8 
weekly sessions of 1 h, 
preceded by a preparatory 
educational session). 
Symptom as an expression of a psychological need or 
conflict. 
Group psychotherapy and skills training: 
- Cognitive and behavioural techniques to increase problem-solving 
skills; 
- Social skills training; 
- Facilitating recognition of the relationship between the symptoms and 
existing problem areas. 
 
Hypnotic techniques manualised for different movement symptoms 
using operant and cue conditioning: 
1. Symptom oriented:  
- Direct and indirect suggestions designed to alter cue-conditionings 
relevant to the specific motor symptoms; 
- Emphasizing and praising every occurrence of small (spontaneous) 
movements. 
2. Expression and insight oriented: 
- Age regression to explore the perceived cause of the symptom or the 
distressing experiences that apparently initiated the symptom; 
- Expression of the “pent-up'' or dissociated emotions encouraged (when 
the history suggested that a distinct psychological stressor was related to 
the onset or exacerbation of the symptom); 
- Learning self-hypnosis to practice symptom-oriented techniques 1/day 
for 30 minutes. 




et al. 2012  
[62] 
Neuropsychiatry ward - 4 






Movements are volitionally generated yet abnormally 
perceived; cognitive/psychological factors are 
important in the way symptoms are produced. 
Symptoms are reversible via rehabilitation. 
  
-  Developing coping strategies 
- Changing illness beliefs, 
- The treatment does not, unless individually relevant, seek to 










ward on a neurology unit. 
 
Standard and strategic 
behavioural intervention 




Symptoms represent maladaptive behavioural 
responses to stress that are maintained by positive 
support from others and successful avoidance (via 
disability) of stressful life situations. 
Standard behavioural treatment  
- Indirect: staff to praise successful performance and to encourage 
patients to try again if they failed to achieve a desired goal in therapy.  
Strategic-behavioural treatment: ‘masking’ instructions to patients and 
their families about the recovery:  
- That full recovery constituted proof of physical aetiology and failure to 
recover evidenced psychiatric aetiology; 
- That if symptoms were physical, the progress would be rapid and 
recovery complete. If conversion disorder, they would not fully recover 
because of an 'unconscious need to remain disabled';  
- That if they sought pre-mature discharge from treatment that would be 
proof of psychiatric cause; 
- The use of 'deep rest' when patients failed to meet therapy goals – 
withdrawal of activities, visits and rewards- removed from the protocol 
as after first 3 patients;  
-  If no improvements - minor inconsequential changes were introduced 
to physiotherapy;  
- Use of family conferencing to convey the notions of recovery - to 
'overcome resistance' and create pressure and expectation from the 
family.  
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Yam, A. et 









3/week, rooted in CBT 
and ACT; ongoing 
consultation and support 
for staff from other 
disciplines.  
Symptoms as manifestations of anxiety, stress and 
depression. 
1. Individual therapy:  
a) Explanation of symptoms, including reference to “stress” as a 
probable cause; 
b) Relaxation training, including controlled breathing and autogenic 
muscle relaxation;  
c) Promotion of mindfulness and cognitive defusion/de-literalization via 
written thought monitoring and labelling of emotions and thought logs;  
d) Writing therapy; 
e) Examination of core values as guides for committed action; 
f) Establishment of a fear hierarchy to guide exposure-based treatment 
for social anxiety.  
2. Consultation to other therapists:  
a) Educating staff and instructing other therapists in incorporating 
behavioural strategies (differential reinforcement and planned ignoring, 
expectation of positive outcomes);  
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Table 7. Outcome measures and methods of evaluating the interventions by study design 
Study 
design and N 
Outcome measures by outcome 
domain 
How change/effectiveness was evaluated/reported 
GROUP STUDIES 





A pilot, single-blinded 
randomised study. 
CBT versus standard 
care. 
FMS  






HAM-D, BAI, PHQ-9 
Statistical significance of mean group change in scores, 
within and between groups.  
 
Statistical significance of mean group change in scores, 
within and between groups.  
 
Statistical significance of mean group change in scores, 
within and between groups. 
 













4T MRI -functional and anatomic 
brain images. 
Statistical significance of mean group change in scores. 
Proportion of patients with ‘complete’ and ‘near-
complete’ (>75% reduction in score) resolution of 
tremor.  
 
Changes in levels of activation of anterior 
cingulate/paracingulate brain area during emotion 
processing. 
 




A single-blind clinical 
trial of PDP. 
FMS 
PMDRS rated by blinded raters. 
 







Statistical significance of mean group change in scores. 
Proportion of participants whose scores reduced >50% 
or worsened. 
 
Statistical significance of mean group change in scores. 
 
Number of patients whose profiles ‘suggested 
decreased psychopathology’. 
 
Statistical significance of mean group change in scores. 
 








treatment with CBT. 
FMS  






A self-report 7-point Likert scale 
of symptom severity. 
 




HRQoL, SDS  
 
RU 
Self-reported physician visits and 
emergency department visits. 
Proportion of participants who rated themselves as 
‘much’ or ‘very improved at discharge and at follow-
up. 
 
Statistical significance of mean group change in scores. 
Percentage of improvement in mean group scores. 
 
Statistical significance of mean group change in scores. 
 
 
A change in number of people mobilising 
independently, using a cane, a walker or a wheelchair. 
 
 
Statistical significance of mean group change in scores. 
 
 
Statistical significance of mean group change in scores. 









Statistical significance of mean group change in scores, 
within and between groups. 
 




design and N 
Outcome measures by outcome 
domain 




PDP vs standard care.  
PW  





Statistical significance of mean group change in scores, 
within and between groups. 
 
Statistical significance of mean group change of 
severity rating within and between groups. 
Numbers of  ‘improved’, ‘unchanged’ or ‘worse’ cases. 
 


















Neuro Qol  
Proportion of people who were rated by clinicians as 
‘very much improved’ or ‘much improved.  
 
Statistical significance of mean group change in scores. 
Statistical significance of change in mean of a 
subgroup of those whose FMS improved. 
 
Statistical significance of mean group change in scores. 










MRS score assigned by authors at 
admission and discharge by 
reviewing clinical records. 
 
Mobility ranked on ordinal scales 
agreed by the authors by 
reviewing clinical records. 
 







ADL ranked on ordinal scales 
agreed by the authors by 
reviewing clinical records. 
 
Proportion of people who were assessed by authors as 
‘improved’ in MRS score. 
Statistical significance of the change in mean group 
score. 
 
Proportion of people who were assessed by authors as 
‘improved’ in mobility score. 
Statistical significance of the change in mobility. 
 
Change in the proportion of people mobilising unaided 
or with a stick/crutches and those who are wheelchair 
dependent. 
Statistical significance of the change in proportion of 
people using mobility aids. 
 
Proportion of people who were assessed by authors as 
‘improved’ in ADL score. 
Statistical significance of the change in proportion of 
people being independent with ADL. 
 





controlled clinical trial. 
 
Hypnosis versus 
waiting list group. 
 
FMS  
VRMC rated by blinded raters 
using video recordings or 








Statistical significance of the change in group mean 
score within and between the groups. 
Proportion of patients rated by independent raters as 
‘improved’. 
 
Statistical significance of the change in group mean 
score within and between the groups. 
 
Statistical significance of the change in group mean 
score within and between the groups. 





controlled clinical trial. 
 
FMS  
VRMC rated by blinded raters 
using video recordings or 
frequency of symptoms recorded 
by patients and clinicians. 
 
 
Statistical significance of the change in group mean 
score within and between the groups.  
Effect size of the mean change in scores. 
Proportion of patients who were ‘substantially’ to ‘very 
much’ improved. 
 




design and N 
Outcome measures by outcome 
domain 











Statistical significance of the change in group mean 
score within and between the groups. 
 
Statistical significance of the change in group mean 
score within and between the groups. 
 













A 3-point scale created to 
represent improvement: allocation 
based on reviewing notes and 
discharge letters.  
 
PW   
CORE-OM, HoNOS-ABI, PHQ-9  
 
Proportion of people allocated to each category: 




Statistical significance of the change in group mean 
score. 
Changes in descriptive category of the group mean, e.g. 
‘clinically moderate’ to ‘clinically low’. 










Retrospective self-report Likert 
scale evaluating perceived change 











Self-report of receipt of health-
related financial benefits.  
Proportion of people who considered their symptoms 
‘improved to some extent’, ‘not changed’ or ‘worsened 
a lot’. 
Statistical significance of the change in proportion of 
participants in each category at admission, discharge 
and follow-up. 
 
Statistical significance of the change in group mean 
score.  
 
Statistical significance of the change between 
admission and follow-up. 
 
Statistical significance of the change between 
admission and follow-up. 
Statistical significance of the correlation between 
improvement and receipt of benefits. 





A case series, cross-
over design. 
Multidisciplinary with 





Symptoms rated by authors - 
delivering the interventions - by 








Proportion of patients in each category. 





A retrospective study. 
PDP 
FMS  
Outcomes rated by authors on 
review of clinical notes and 
categorised as: ‘good’, ‘near 
complete resolution’ of 




Proportion of patients in each outcome category: 
‘good’, ‘near complete resolution’ of symptoms, 
‘modest to mild’ or ‘poor’. 




design and N 
Outcome measures by outcome 
domain 
How change/effectiveness was evaluated/reported 





















Statistical significance of the change in group mean 
score within and between groups. 
 
 
Statistical significance of the change in group mean 
score within and between groups. 
 
 
Statistical significance of the change in group mean 
score within and between groups. 
SINGLE CASE STUDIES 




A case report - ACT, 
Morita therapy. 
FMS  
Observation and self-report. 
 
PW  
Observation and self-report. 
  
 
Presence/absence of tremor and weakness. 
 
 
Verbal description of changes in mood. 





A case study of ACT. 




PW –AAQ-II, CORE-10 
 
LI - WSAS 
Verbal description of the extent of change: ‘almost 
entirely stopped by the end of treatment’.  
 
 
Reliable Change Index (RCI) and Clinically Significant 
Change (CSC) analysis conducted to ascertain the 
extent of change and indication of clinical recovery. 




A case report. 
CBT 
FMS  
Observation and self-report. 
 
PW  
Observation and self-report. 
 
 
Absence/presence of symptoms at discharge. 
 
Presence/remission of obsessions and compulsions; 
descriptive verbal report: ‘doing great’. 










Frequency and intensity of 
‘cataplectic’ episodes based on 
clinical records. 
 
Physical distance walked without 
assistance, amount of steps 
climbed and use of mobility aids.  
 
Berg Balance Score from and 
Johns Hopkins Fall Risk.  
 
LI 
Observation and self-report 
regarding changes in functioning 
– dressing, personal care. 
 
 




Change described in physical measurements. 
Significance of change not formally analysed. 
Use/disuse of mobility aids. 
 
A change in the category of risk of falls (from “high” 
to "no risk"). 
 
 
Change assessed by the achievement of pre-set goals.  





A case study. 
FMS  
Self-report and observation. Rated 
by clinicians as ‘severe’, 




Change in frequency, severity of symptoms reported, 








design and N 
Outcome measures by outcome 
domain 
How change/effectiveness was evaluated/reported 
 
CBT-informed therapy 
based on the Bayesian 
model. 
CS  
Self-report and observation. 
 
PW -  PCL-5, PHQ-9, GAD-7 
 
 




Presence/absence of symptoms.  
 
 
Change in severity as per descriptive categories of each 
measure, e.g. from ‘moderate’ to ‘mild’. The extent of 
change not evaluated further. 
 
Change in employment status. 









Observation and self-report. 
 
CS  
Observation and self-report. 
 





Absence/presence of symptoms. 
 
 
Absence/presence of symptoms. 
 
 
Change in employment status. 














PW - CORE-OM 
 
LI 




Absence/presence of symptoms. 
 
 
Change in raw scores. 
 
Change in descriptive categories of scores, e.g. from 
‘severe’ to ‘moderate’. 
 
Change in raw scores. 





A case report of DBT 
FMS 





Presence/absence of symptom. 
Use of mobility aids/independent walking. 
 
‘Reliable change’ and ‘clinically significant change’ 
criteria proposed in literature for each of the scales. 




A case study. 
 
Multidisciplinary 
treatment with ACT 
and CBT therapy. 
FMS  










Self report – activities of daily 
living. 
 
Verbal description of the presence/absence of 
symptoms. 
 




Change in the category of scores, e.g. from ‘moderate’ 
to ‘mild’ limitation in adjustment and participation. 
 
Change in employment status.  
Verbal description of changes in independence in 
activities of daily living. 
CS - Comorbid symptoms; PW – psychological wellbeing; LI – Life impact, RU – resource use; AAQ-II - Acceptance and Action 
Questionnaire II [120]; ADL - Katz index of independence in activities of daily living [121]; iADL - Lawton instrumental ADL [122]; 
BAI – Beck Anxiety Inventory [123]; BDI – Beck Depression Inventory [124]; BREF (WHOQOL-BREF) - World Health Organization 
Quality of Life – BREF [125]; CGI - clinical global impression scale change [126]; CGI-SR - Self-report version of the Clinical Global 
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Impression Scale [126]; CORE-OM - Clinical Outcomes in Routine Evaluation-Outcome Measure [127]; CORE-10 - Clinical Outcomes 
in Routine Evaluation 10-item scale [128]; GAD-7 – Generalised Anxiety Disorder Scale [129]; GAF - Global Assessment of Function; 
HAM-A – Hamilton Anxiety Rating Scale [130]; HAM-D – Hamilton Depression Rating Scale [131]; HONOS-ABI - Health of the 
Nation Outcome Scales for Acquired Brain Injury [132]; ICIDH – the International Classification of Impairments, Disabilities and 
Handicaps [133]; MMPI-2 - Minnesota Multiphasic Personality Inventory-2 [134]; MPAI-4 - Mayo-Portland Adaptability Inventory 
[135]; MRS - Modified Rankin Scale [136]; Neuro QoL - the National Institutes of Health Neuro Quality of Life [137]; NSI-22 - 
Neurobehavioural Symptom Inventory [138]; PCL-C - PTSD Checklist–Civilian Version [139]; PCL-5 - The Posttraumatic Stress 
Disorder Checklist for DSM-5 [140]; PHQ-9 – Patient Health Questionnaire-9 [141]; PHQ-15 - Patient Health Questionnaire-15 [142]; 
PMDRS - Psychogenic Movement Disorder Rating Scale [25]; SCL-90 - The Symptom Checklist-90 [143]; SDS - Sheehan Disability 
Scales [144]; STAI - State/Trait Anxiety Inventory [145]; VRMC – The Video Rating Scale for Motor Conversion Symptoms [26]; 
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Records identified through database 
searching 
(n =  1287 ): 
EMBASE (n=311); PsychInfo (n=374); 































Additional records identified 
through other sources 
(n = 3) 
Records after duplicates removed 
(n = 921) 
Records screened – titles 
and abstracts read 
(n = 921) 
Records excluded 
(n = 889) 
Full-text articles assessed 
for eligibility 
(n = 34) 
Full-text articles excluded, 
with reasons 
(n = 11) 
• theoretical paper, n=2,  
• seizures only, n=1 
• mixed FND, not all with 
movement symptoms, n=3 
• not a report of 
psychological intervention, 
n=4 




Studies included  
(n = 23) 
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2 The database search was conducted on 8th March 2020 so the count for 2020 is low as it only includes the first 
two months. 
3 Some studies used a combination of two diagnostic names, e.g. Conversion Disorder/Functional Movement 






























































































TERMINOLOGY USED TO DESCRIBE SYMPTOMS
Functional Conversion Psychogenic Factitious Somatisation
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• Randomized controlled trial - CONSORT 
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Whilst the use of such guidelines is supported, due to the multi-disciplinary nature of 
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Your paper should be compiled in the following order: title page; abstract; keywords; main 
text, introduction, materials and methods, results, discussion; acknowledgments; 
declaration of interest statement; references; appendices (as appropriate); table(s) with 
caption(s); figures; figure captions (as a list). 
In the main text, an introductory section should state the purpose of the paper and give a 
brief account of previous work. New techniques and modifications should be described 
concisely but in sufficient detail to permit their evaluation. Standard methods should simply 
be referenced. Experimental results should be presented in the most appropriate form, with 
sufficient explanation to assist their interpretation; their discussion should form a distinct 
section. 
Tables and figures should be referred to in text as follows: figure 1, table 1, i.e. lower case. 
The place at which a table or figure is to be inserted in the printed text should be indicated 
clearly on a manuscript. Each table and/or figure must have a title that explains its purpose 
without reference to the text. 
The title page should include the full names and affiliations of all authors involved in the 
preparation of the manuscript. The corresponding author should be clearly designated, with 
full contact information provided for this person. 
 
Word count 
Please include a word count for your paper. There is no word limit for papers submitted to 
this journal, but succinct and well-constructed papers are preferred. 
Style guidelines 
Please refer to these style guidelines when preparing your paper, rather than any published 
articles or a sample copy. 
Please use any spelling consistently throughout your manuscript. 
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Please note that long quotations should be indented without quotation marks. 
For tables and figures, the usual statistical conventions should be used. 
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and details of manufacturers of scientific instruments should be given only if the 
information is important to the evaluation of the experimental data. 
 
Formatting and templates 
Papers may be submitted in any standard format, including Word and LaTeX. Figures 
should be saved separately from the text. To assist you in preparing your paper, we provide 
formatting template(s). 
Word templates are available for this journal. Please save the template to your hard drive, 
ready for use. 
A LaTeX template is available for this journal. Please save the template to your hard drive, 
ready for use. 
 
References 
Please use this reference guide when preparing your paper. An EndNote output style is also 
available to assist you. 
 
Taylor & Francis Editing Services 
To help you improve your manuscript and prepare it for submission, Taylor & Francis 
provides a range of editing services. Choose from options such as English Language 
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Editing, which will ensure that your article is free of spelling and grammar errors, 
Translation, and Artwork Preparation. For more information, including pricing, visit this 
website. 
 
Checklist: what to include 
1. Author details. Please ensure everyone meeting the International Committee of 
Medical Journal Editors (ICJME) requirements for authorship is included as an 
author of your paper. All authors of a manuscript should include their full name and 
affiliation on the cover page of the manuscript. Where available, please also 
include ORCiDs and social media handles (Facebook, Twitter or LinkedIn). One author 
will need to be identified as the corresponding author, with their email address normally 
displayed in the article PDF (depending on the journal) and the online article. Authors’ 
affiliations are the affiliations where the research was conducted. If any of the named 
co-authors moves affiliation during the peer-review process, the new affiliation can be 
given as a footnote. Please note that no changes to affiliation can be made after your 
paper is accepted. Read more on authorship. 
2. A structured abstract of no more than 200 words. A structured abstract should cover (in 
the following order): the purpose of the article, its materials and methods (the design 
and methodological procedures used), the results and conclusions (including their 
relevance to the study of disability and rehabilitation). Read tips on writing your 
abstract. 
3. You can opt to include a video abstract with your article. Find out how these can help 
your work reach a wider audience, and what to think about when filming. 
4. 5-8 keywords. Read making your article more discoverable, including information on 
choosing a title and search engine optimization. 
5. A feature of this journal is a boxed insert on Implications for Rehabilitation. This 
should include between two to four main bullet points drawing out the implications for 
rehabilitation for your paper. This should be uploaded as a separate document. Below 
are examples: 
Example 1: Leprosy 
• Leprosy is a disabling disease which not only impacts physically but restricts quality of 
life often through stigmatisation. 
• Reconstructive surgery is a technique available to this group. 
• In a relatively small sample this study shows participation and social functioning 
improved after surgery. 
Example 2: Multiple Sclerosis 
• Exercise is an effective means of improving health and well-being experienced by 
people with multiple sclerosis (MS). 
• People with MS have complex reasons for choosing to exercise or not. 
6. Acknowledgement. Please supply all details required by your funding and grant-
awarding bodies as follows: For single agency grants: This work was supported by the 
under Grant . For multiple agency grants: This work was supported by the under Grant 
; under Grant ; and under Grant . 
7. Declaration of Interest. This is to acknowledge any financial interest or benefit that 
has arisen from the direct applications of your research. Further guidance on what is a 
declaration of interest and how to disclose it. 
8. Data availability statement. If there is a data set associated with the paper, please 
provide information about where the data supporting the results or analyses presented in 
the paper can be found. Where applicable, this should include the hyperlink, DOI or 
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submission. You will be asked to provide the DOI, pre-reserved DOI, or other persistent 
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supplemental material online via Figshare. Find out more about supplemental material 
and how to submit it with your article. 
11. Figures. Figures should be high quality (1200 dpi for line art, 600 dpi for grayscale and 
300 dpi for colour). Figures should be saved as TIFF, PostScript or EPS files. 
12. Tables. Tables should present new information rather than duplicating what is in the 
text. Readers should be able to interpret the table without reference to the text. Please 
supply editable files. 
  
13. Equations. If you are submitting your manuscript as a Word document, please ensure 
that equations are editable. More information about mathematical symbols and 
equations. 
14. Units. Please use SI units (non-italicized). 
Using third-party material in your paper 
You must obtain the necessary permission to reuse third-party material in your article. 
The use of short extracts of text and some other types of material is usually permitted, 
on a limited basis, for the purposes of criticism and review without securing formal 
permission. If you wish to include any material in your paper for which you do not hold 
copyright, and which is not covered by this informal agreement, you will need to obtain 
written permission from the copyright owner prior to submission. More information 
on requesting permission to reproduce work(s) under copyright. 
 
Declaration of Interest Statement 
Please include a declaration of interest statement, using the subheading "Declaration of 
interest." If you have no interests to declare, please state this (suggested wording: The 
authors report no conflicts of interest). For all NIH/Wellcome-funded papers, the grant 
number(s) must be included in the disclosure of interest statement. Read more on 
declaring conflicts of interest. 
 
Clinical Trials Registry 
In order to be published in a Taylor & Francis journal, all clinical trials must have been 
registered in a public repository at the beginning of the research process (prior to patient 
enrolment). Trial registration numbers should be included in the abstract, with full 
details in the methods section. The registry should be publicly accessible (at no charge), 
open to all prospective registrants, and managed by a not-for-profit organization. For a 
list of registries that meet these requirements, please visit the WHO International 
Clinical Trials Registry Platform (ICTRP). The registration of all clinical trials 
facilitates the sharing of information among clinicians, researchers, and patients, 
enhances public confidence in research, and is in accordance with the ICMJE 
guidelines. 
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Complying with ethics of experimentation 
Please ensure that all research reported in submitted papers has been conducted in an 
ethical and responsible manner, and is in full compliance with all relevant codes of 
experimentation and legislation. All papers which report in vivo experiments or clinical 
trials on humans or animals must include a written statement in the Methods section. 
This should explain that all work was conducted with the formal approval of the local 
human subject or animal care committees (institutional and national), and that clinical 
trials have been registered as legislation requires. Authors who do not have formal 
ethics review committees should include a statement that their study follows the 
principles of the Declaration of Helsinki. 
 
Consent 
All authors are required to follow the ICMJE requirements on privacy and informed 
consent from patients and study participants. Please confirm that any patient, service 
user, or participant (or that person’s parent or legal guardian) in any research, 
experiment, or clinical trial described in your paper has given written consent to the 
inclusion of material pertaining to themselves, that they acknowledge that they cannot 
be identified via the paper; and that you have fully anonymized them. Where someone 
is deceased, please ensure you have written consent from the family or estate. Authors 
may use this Patient Consent Form, which should be completed, saved, and sent to the 
journal if requested. 
 
Health and safety 
Please confirm that all mandatory laboratory health and safety procedures have been 
complied with in the course of conducting any experimental work reported in your 
paper. Please ensure your paper contains all appropriate warnings on any hazards that 
may be involved in carrying out the experiments or procedures you have described, or 
that may be involved in instructions, materials, or formulae. 
Please include all relevant safety precautions; and cite any accepted standard or code of 
practice. Authors working in animal science may find it useful to consult 
the International Association of Veterinary Editors’ Consensus Author Guidelines 
on Animal Ethics and Welfare and Guidelines for the Treatment of Animals in 
Behavioural Research and Teaching. When a product has not yet been approved by 
an appropriate regulatory body for the use described in your paper, please specify this, 
or that the product is still investigational. 
 
Submitting your paper 
This journal uses ScholarOne to manage the peer-review process. If you haven't 
submitted a paper to this journal before, you will need to create an account in the 
submission centre. Please read the guidelines above and then submit your paper in the 
relevant Author Centre, where you will find user guides and a helpdesk. By 
submitting your paper to Disability and Rehabilitation you are agreeing to originality 
checks during the peer-review and production processes. 
The Editor of Disability and Rehabilitation will respond to appeals from authors 
relating to papers which have been rejected. The author(s) should email the Editor 
outlining their concerns and making a case for why their paper should not have been 
rejected. The Editor may choose to accept the appeal and secure a further review, or to 
not uphold the appeal. In case of the latter, the Editor of Disability and Rehabilitation: 
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Data Sharing Policy 
This journal applies the Taylor & Francis Basic Data Sharing Policy. Authors are 
encouraged to share or make open the data supporting the results or analyses presented 
in their paper where this does not violate the protection of human subjects or other valid 
privacy or security concerns. 
Authors are encouraged to deposit the dataset(s) in a recognized data repository that can 
mint a persistent digital identifier, preferably a digital object identifier (DOI) and 
recognizes a long-term preservation plan. If you are uncertain about where to deposit 
your data, please see this information regarding repositories. 
Authors are further encouraged to cite any data sets referenced in the article and 




































Detailed Database Search Strategy 
PUBMED SEARCH STRATEGY 
Query Items 
found 
Search (((((((((("functional neurologic* disorder"[Title/Abstract] OR 
"functional disorder*"[Title/Abstract] OR "Functional 
symptom*"[Title/Abstract] OR hysteria[Title/Abstract] OR 
hysterical[Title/Abstract] OR ""conversion disorder*"[Title/Abstract] OR 
""conversion symptom*"[Title/Abstract] OR somatoform[Title/Abstract] OR 
psychogenic[Title/Abstract])))) OR conversion disorder[MeSH Terms]) OR 
((movement disorder[MeSH Terms]) AND (((functional[Title] OR non-
organic[Title] OR ""non organic"[Title] OR psychogenic[Title])) AND 
movement disorders[MeSH Terms]))) OR ((mFND[Title/Abstract] OR 
"functional motor disorder*"[Title/Abstract] OR "functional movement 
disorder*"[Title/Abstract] OR "functional motor symptom*"[Title/Abstract] OR 
"functional movement symptom*"[Title/Abstract] OR "psychogenic movement 
disorder*"[Title/Abstract] OR "psychogenic movement 
symptom*"[Title/Abstract] OR "psychogenic motor disorder*"[Title/Abstract] 
OR "psychogenic motor symptom*"[Title/Abstract])))) AND 
((motor[Title/Abstract] OR movement[Title/Abstract] OR ""limb 
weakness"[Title/Abstract] OR ""arm weakness"[Title/Abstract] OR ""leg 
weakness"[Title/Abstract] OR ""muscle weakness"[Title/Abstract] OR 
paralysis[Title/Abstract] OR tremor[Title/Abstract] OR spasm*[Title/Abstract] 
OR myoclonus[Title/Abstract] OR dystonia[Title/Abstract] OR 
gait[Title/Abstract])))) AND (((((((Psychotherapy[Title/Abstract] OR 
therapy[Title/Abstract] OR hypnosis[Title/Abstract] OR 
hypnotherapy[Title/Abstract] OR intervention[Title/Abstract] OR 
treatment[Title/Abstract]))))) OR ((psychotherapy[MeSH Terms]) OR 
counseling[MeSH Terms])) Filters: Case Reports; Clinical Study; Clinical 
Trial; Comparative Study; Controlled Clinical Trial; Evaluation Study; 
Multicenter Study; Observational Study; Randomized Controlled Trial; English 
261 
 
PSYCHINFO SEARCH STRATEGY 
Search  Search Options Results 
S13 S10 AND S11  
Filters applied:  
• 18years and over 
• Methodology: treatment outcome, clinical trial, prospective study, 
follow-up study, retrospective study, longitudinal study, clinical 
case study, quantitative study, empirical study 
• English language 
423 
S12 S10 AND S11   1,252 
S11 S1 OR S4   1,049,402 
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S10 S9 AND S7   3,814 
S9 S3 OR S5 OR S6 OR S8   18,821 
S8 (TI functional OR non-organic OR “non organic” OR psychogenic) 
AND (S2)  
 3,868 
S7 AB motor OR movement OR “limb weakness” OR “arm weakness” 
OR “leg weakness” OR “muscle weakness” OR paralysis OR 
tremor OR spasm* OR myoclonus OR dystonia OR gait  
 236,246 
S6 AB "functional neurologic* disorder" OR "functional disorder*" 
OR "Functional symptom*" OR hysteria OR hysterical OR 
“conversion disorder*” OR “conversion symptom*” OR 
somatoform OR psychogenic  
 14,844 
S5 AB mFND OR "functional motor disorder*" OR "functional 
movement disorder*" OR "functional motor symptom*" OR 
"functional movement symptom*" OR "psychogenic movement 
disorder*" OR "psychogenic movement symptom*" OR 
"psychogenic motor disorder*" OR "psychogenic motor 
symptom*"  
 215 
S4 AB Psychotherapy or therapy or hypnosis or hypnotherapy or 
intervention or treatment  
 978,866 
S3 DE "Conversion Disorder" OR DE "Hysterical Paralysis"   1,691 
S2 DE "Movement Disorders" OR DE "Alien Limb Syndrome" OR 
DE "Apraxia" OR DE "Ataxia" OR DE "Athetosis" OR DE 
"Catalepsy" OR DE "Cataplexy" OR DE "Chorea" OR DE 
"Dyskinesia" OR DE "Dyspraxia" OR DE "Myasthenia Gravis" OR 
DE "Paralysis" OR DE "Spasms" OR DE "Tics" OR DE 
"Torticollis" OR DE "Tremor"  
 22,718 
S1 (DE "Psychotherapeutic Counseling" OR DE "Family Therapy" OR 
DE "Psychotherapeutic Techniques" OR DE "Active Listening" OR 
DE "Animal Assisted Therapy" OR DE "Autogenic Training" OR 
DE "Brief Relational Therapy" OR DE "Centering" OR DE 
"Cotherapy" OR DE "Dream Analysis" OR DE "Empty Chair 
Technique" OR DE "Ericksonian Psychotherapy" OR DE "Free 
Association" OR DE "Guided Imagery" OR DE "Life Review" OR 
DE "Mirroring" OR DE "Morita Therapy" OR DE "Motivational 
Interviewing" OR DE "Mutual Storytel ... 
 211,544 
 
EMBASE SEARCH STRATEGY 
# Query Results 
20 limit 19 to (human and english language and article and journal and 
(adult <18 to 64 years> or aged <65+ years>)) 
372 
19 15 and 18 1673 
18 5 or 16 or 17 6858414 
17 (Psychotherapy or therapy or hypnosis or hypnotherapy or intervention 
or treatment).ab. 
6755795 
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16 (psychotherapy* or psychological therapy* or psychological 
intervention* or psychological treatment* or psychosocial 
intervention*).kw. 
12864 
15 13 and 14 3719 
14 (motor or movement or limb weakness or arm weakness or leg weakness 
or muscle weakness or paralysis or tremor or spasm* or myoclonus or 
dystonia or gait).ab. 
761209 
13 2 or 3 or 4 or 6 or 8 or 9 or 12 24441 
12 10 and 11 1021 
11 1 or 7 27737 
10 (functional or non-organic or non organic or psychogenic or conversion 
or hysteri*).ti. 
304953 
9 (functional neurological disorder or functional disorder* or Functional 
symptom* or hysteria or hysterical or conversion disorder* or 
conversion symptom* or somatoform or psychogenic).ab. 
22675 
8 (mFND or "functional motor disorder*" or "functional movement 
disorder*" or "functional motor symptom*" or "functional movement 
symptom*" or "psychogenic movement disorder*" or "psychogenic 
movement symptom*" or "psychogenic motor disorder*" or 
"psychogenic motor symptom*").ab. 
607 
7 movement disorder*.kw. 3595 
6 (Functional movement disorder* or functional neurological disorder* or 
functional motor disorder* or conversion disorder* or hysteria or 
hysterical).kw. 
1199 
5 psychotherapy/ or exp assertive training/ or exp autogenic training/ or 
exp aversion therapy/ or exp balint group/ or exp behavior contracting/ 
or exp behavior modification/ or exp behavior therapy/ or exp catharsis/ 
or exp client centered therapy/ or exp cognitive behavioral therapy/ or 
exp cognitive rehabilitation/ or exp cognitive therapy/ or exp couple 
therapy/ or exp emotion-focused therapy/ or exp "eye movement 
desensitization and reprocessing"/ or exp family therapy/ or exp gestalt 
therapy/ or exp group therapy/ or exp guided imagery/ or exp hypnosis/ 
or exp logotherapy/ or exp marital therapy/ or exp mentalization-based 
treatment/ or exp milieu therapy/ or exp mindfulness/ or exp narrative 
therapy/ or exp psychodrama/ or exp psychodynamic psychotherapy/ or 
exp rational emotive behavior therapy/ or exp reality therapy/ or exp 
relaxation training/ or exp role playing/ or exp sex therapy/ or exp short 
term psychotherapy/ or exp sociotherapy/ or exp therapeutic community/ 
or exp validation therapy/ 
234592 
4 exp functional disease/th [Therapy] 368 
3 exp hysteria/th [Therapy] 329 
2 exp conversion disorder/th [Therapy] 284 
1 exp motor dysfunction/th [Therapy] 24442 
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SCOPUS SEARCH STRATEGY 
Search Terms Results 
( ( ( TITLE-ABS-KEY ( "conversion disorder*" ) )  OR  ( ( TITLE-ABS-
KEY ( "movement disorder*" ) )  AND  ( TITLE ( functional  OR  non-
organic  OR  "non 
organic"  OR  psychogenic  OR  conversion  OR  hysteri* ) ) )  OR  ( TITLE-
ABS-KEY ( mfnd  OR  "functional motor disorder*"  OR  "functional 
movement disorder*"  OR  "functional motor symptom*"  OR  "functional 
movement symptom*"  OR  "psychogenic movement 
disorder*"  OR  "psychogenic movement symptom*"  OR  "psychogenic motor 
disorder*"  OR  "functional neurological 
disorder"  OR  hysteria  OR  hysterical ) ) )  AND  ( TITLE-ABS-
KEY ( motor  OR  movement  OR  "limb weakness"  OR  "arm 
weakness"  OR  "leg weakness"  OR  "muscle 
weakness"  OR  paralysis  OR  tremor  OR  spasm*  OR  myoclonus  OR  dysto
nia  OR  gait ) ) )  AND  ( TITLE-ABS-
KEY ( psychotherapy*  OR  "psychological therapy"  OR  "psychological 
intervention*"  OR  "psychological 
treatment"  OR  hypnosis  OR  hypnotherapy  OR  therapy ) )  AND  ( LIMIT-
TO ( DOCTYPE ,  "ar" ) )  AND  ( LIMIT-
TO ( LANGUAGE ,  "English" ) )  AND  ( LIMIT-TO ( SRCTYPE ,  "j" ) )   
460  
( ( ( TITLE-ABS-KEY ( "conversion disorder*" ) )  OR  ( ( TITLE-ABS-
KEY ( "movement disorder*" ) )  AND  ( TITLE ( functional  OR  non-
organic  OR  "non 
organic"  OR  psychogenic  OR  conversion  OR  hysteri* ) ) )  OR  ( TITLE-
ABS-KEY ( mfnd  OR  "functional motor disorder*"  OR  "functional 
movement disorder*"  OR  "functional motor symptom*"  OR  "functional 
movement symptom*"  OR  "psychogenic movement 
disorder*"  OR  "psychogenic movement symptom*"  OR  "psychogenic motor 
disorder*"  OR  "functional neurological 
disorder"  OR  hysteria  OR  hysterical ) ) )  AND  ( TITLE-ABS-
KEY ( motor  OR  movement  OR  "limb weakness"  OR  "arm 
weakness"  OR  "leg weakness"  OR  "muscle 
weakness"  OR  paralysis  OR  tremor  OR  spasm*  OR  myoclonus  OR  dysto
nia  OR  gait ) ) )  AND  ( TITLE-ABS-
KEY ( psychotherapy*  OR  "psychological therapy"  OR  "psychological 
intervention*"  OR  "psychological 
treatment"  OR  hypnosis  OR  hypnotherapy  OR  therapy ) )  
838  
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( ( TITLE-ABS-KEY ( "conversion disorder*" ) )  OR  ( ( TITLE-ABS-
KEY ( "movement disorder*" ) )  AND  ( TITLE ( functional  OR  non-
organic  OR  "non 
organic"  OR  psychogenic  OR  conversion  OR  hysteri* ) ) )  OR  ( TITLE-
ABS-KEY ( mfnd  OR  "functional motor disorder*"  OR  "functional 
movement disorder*"  OR  "functional motor symptom*"  OR  "functional 
movement symptom*"  OR  "psychogenic movement 
disorder*"  OR  "psychogenic movement symptom*"  OR  "psychogenic motor 
disorder*"  OR  "functional neurological 
disorder"  OR  hysteria  OR  hysterical ) ) )  AND  ( TITLE-ABS-
KEY ( motor  OR  movement  OR  "limb weakness"  OR  "arm 
weakness"  OR  "leg weakness"  OR  "muscle 
weakness"  OR  paralysis  OR  tremor  OR  spasm*  OR  myoclonus  OR  dysto
nia  OR  gait ) )  
3,041  
TITLE-ABS-KEY ( motor  OR  movement  OR  "limb weakness"  OR  "arm 
weakness"  OR  "leg weakness"  OR  "muscle 
weakness"  OR  paralysis  OR  tremor  OR  spasm*  OR  myoclonus  OR  dysto
nia  OR  gait )  
2,206,21
6  
( TITLE-ABS-KEY ( "conversion disorder*" ) )  OR  ( ( TITLE-ABS-
KEY ( "movement disorder*" ) )  AND  ( TITLE ( functional  OR  non-
organic  OR  "non 
organic"  OR  psychogenic  OR  conversion  OR  hysteri* ) ) )  OR  ( TITLE-
ABS-KEY ( mfnd  OR  "functional motor disorder*"  OR  "functional 
movement disorder*"  OR  "functional motor symptom*"  OR  "functional 
movement symptom*"  OR  "psychogenic movement 
disorder*"  OR  "psychogenic movement symptom*"  OR  "psychogenic motor 
disorder*"  OR  "functional neurological 
disorder"  OR  hysteria  OR  hysterical ) )  
15,055  
TITLE-ABS-KEY ( mfnd  OR  "functional motor disorder*"  OR  "functional 
movement disorder*"  OR  "functional motor symptom*"  OR  "functional 
movement symptom*"  OR  "psychogenic movement 
disorder*"  OR  "psychogenic movement symptom*"  OR  "psychogenic motor 
disorder*"  OR  "functional neurological 
disorder"  OR  hysteria  OR  hysterical )  
11,935  
( TITLE-ABS-KEY ( "movement 
disorder*" ) )  AND  ( TITLE ( functional  OR  non-organic  OR  "non 
organic"  OR  psychogenic  OR  conversion  OR  hysteri* ) )  
1,171  
TITLE ( functional  OR  non-organic  OR  "non 
organic"  OR  psychogenic  OR  conversion  OR  hysteri* )  
514,021  
TITLE-ABS-KEY ( "movement disorder*" )  41,822  
TITLE-ABS-KEY ( "conversion disorder*" )  3,651  
TITLE-ABS-KEY ( psychotherapy*  OR  "psychological 
therapy"  OR  "psychological intervention*"  OR  "psychological 
treatment"  OR  hypnosis  OR  hypnotherapy  OR  therapy )  
4,517,33
4  




Studies excluded after reading full text – with reasons 
 
Study Title  Reason for exclusion 
Andrade et 
al., 2009 
"Systematic enhancement of functioning as a 
therapeutic technique in conversion disorder." 
Indian Journal of Psychiatry 51(2): 134-136. 
  





"Outlining the psychopathology behind a case 
of conversion syndrome: Is a holistic approach 
beneficial?" Psych J 5(1): 31-35. 
  
No report of psychological therapy, for 
which the patient was referred out 
elsewhere.  
Ayaz et al., 
2015 
"Conversion disorder; an unusual etiology of 
unilateral foot drop." Acta Neurol Taiwan 
24(2): 47-51. 
  




"Road traffic accidents: more than just 
whiplash?" BMJ Case Rep 2013. 
  
Not a report of psychological intervention 
Graham et 
al., 2018 
"A case series of Acceptance and Commitment 
Therapy (ACT) for reducing symptom 
interference in functional neurological 
disorders." Clinical Psychology and 
Psychotherapy 25(3): 489-496. 
  
The study participants’ with FND, not all 
had FMD; not possible to extract data for 
FMD only. 
Hubschmid, 
et al. 2015 
"Efficacy of brief interdisciplinary 
psychotherapeutic intervention for motor 
conversion disorder and nonepileptic attacks." 
General Hospital Psychiatry 37(5): 448-455. 
  
Participants with FMD or non-epileptic 




"Inpatient rehabilitation approach for a young 
woman with conversion hemiparesis and 
sensory deficits." PM and R 5(1): 66-69. 
  
Participant aged 16 year old. 
Kizilkurt et 
al., 2018 
"An approach to conversion disorder with 
comorbid major depression using 
pharmacotherapy and psychodrama 
techniques: A case report." Dusunen Adam 
31(4): 413-420. 
  
Seizures only, not FMD. 
O'Neal & 
Baslet, 2018 
"Treatment for patients with a functional 
neurological disorder (conversion disorder): 
An integrated approach." American Journal of 
Psychiatry 175(4): 307-314. 
 
Theoretical paper. 
Sharpe et al., 
2011 
"Guided self-help for functional (psychogenic) 
symptoms: a randomized controlled efficacy 
trial." Neurology 77(6): 564-572. 
  




"A case of functional dystonia with associated 
functional neurological symptoms: Diagnostic 
and therapeutic challenges." Harv Rev 
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Living with functional movement disorders 
Abstract  
Purpose: Functional movement disorders (FMD) have poor prognosis, high physical 
and psychological co-morbidity and low quality of life. Their pathogenesis remains 
unclear and clinicians often find it difficult to treat. This qualitative study aimed to 
explore the experiences of living with FMD to improve understanding of its impact and 
patients’ needs.  
Method: Interpretative Phenomenological Analysis (IPA) was used to analyse semi-
structured interviews. Ten participants from the UK were recruited and interviewed. 
Results: Three superordinate themes were generated: (1) The tug of war with the secret 
agent within: the power struggle with symptoms; (2) Navigating risks of disclosing the 
diagnosis: stigma and self-preservation (3) Pursuing hope, knowledge and treatments 
against helplessness and passivity. 
Conclusion: For participants in this study living with FMD involved internal and 
interpersonal battles to maintain hope, control and identity. Perceived ignorance and 
passivity in healthcare professionals was seen as promoting hopelessness and an 
unnecessary burden adding to the already depleting internal resources. A sense of 
oppression, loss of control and stigma have been described in the context of 
discriminatory power distribution in the society and healthcare settings. Antonovsky’s 
model of salutogenesis could offer a useful framework for facilitating empowerment of 
patients and clinicians in healthcare services. 
Keywords: functional movement disorder, functional neurological disorder, IPA, 
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Introduction 
Functional movement disorders (FMD) involve disrupted movement functions which are 
incongruent with patterns of pathophysiological (organic) disease [1]. People with FMD 
might experience one or a variety of symptoms, such as unsteady gait, tremor, spasms, 
muscle weakness, paralysis or dystonia. The symptoms might be episodic or continuous. 
Their severity or frequency might fluctuate, with an inconsistent or escalating pattern. The 
disorder’s trajectory often involves the occurrence of new symptoms with time although it 
can sometimes remit spontaneously [2].  
FMD are part of a wider diagnostic category of functional neurological disorders 
(FND) which account for 16% of outpatient neurology referrals in the UK [3] and with an 
incidence of four to five new cases per 100 000 of population per year for FMD [4]. The 
prognosis is poor [5-7] with a symptom remission rate comparable to organic neurological 
disorders, and with higher mortality rates [6]. People affected by FMD are reported to 
experience poorer physical and mental health and greater impact of their symptoms on 
functioning, quality of life and financial status than in people with similar symptoms that are 
due to an organic neurological disease [8]. Despite this FMD patients are traditionally left 
without effective treatments [9] even though symptoms are persistent and disabling, and 
active and targeted therapy is recommended [6,10].  
Originally a diagnosis of exclusion based on lack of organic pathology, the diagnosis 
of FMD is now made on the basis of positive signs, such as tremor entrainment or Hoover’s 
sign [10,11] to improve diagnostic credibility and reliability [12,13]. The symptoms’ 
variability and inconsistency are also believed to be positive clinical features supporting the 
diagnosis [1,11]. Co-morbidity with other physical, functional and non-functional symptoms 
is common in FMD, often making it more difficult to treat the movement symptoms, e.g. 
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when fatigue and pain are severe [14] and triggering or being triggered by the movement 
symptom [15].  
FMD and its parent category FND are included in the Diagnostic and Statistical 
Manual of Mental Disorders 5th edition (DSM-5) [16]. This reflects the traditional views of 
FND as a psychiatric condition caused by a ‘conversion’ of emotional distress or trauma into 
a physical symptom [17,18] and thus also called a conversion disorder (CD). Various other 
labels have also been used including hysteria, somatoform and psychogenic disorder and 
even feigning or factitious disorder [19-21]. However, the understanding of FND has evolved 
and the lack of an obvious stressor or psychological trauma in many people with FMD has 
led to changes in the DSM-5 diagnostic criteria which no longer require an identification of a 
psychological stressor. In addition, in the newest version of the International Classification of 
Diseases 11th Revision (ICD-11) [22] the separate symptoms of FMD (e.g. functional tremor) 
have been placed in neurological as well as psychiatric categories. 
Renewed interest in FMD, developments in neuroimaging and pathophysiological 
studies [23-27] and increased recognition that not all cases of FMD can be explained by 
psychological trauma or adversity led to developments of newer models of FMD that revised 
or expanded the conversion models. The contemporary models incorporate neurobiological 
processes, such as sensorimotor integration and agency [26,28], autonomic and 
neuroendocrine function [29] or motor-limbic communication [30,31] as well as the role of 
emotional, cognitive and behavioural processes, such as symptom-related beliefs and body-
focused attention [32,33], maladaptive conditioning [34] and emotional processing [24]. This 
shift towards a broader multifactorial conceptualization of FMD emphasizes the unique 
interaction of biological, environmental and psychological factors in FMD generation and 
expression for each individual [35-38].  
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However, the inconsistency in terminology still exists, often depending on the 
professional discipline of those who use it [41]. To respect the preferences of people with 
FMD [40] and to reflect its biopsychosocial determinants the term ‘functional’ over 
‘psychogenic’ or ‘conversion’ was chosen for this study. 
In the last 20 years a variety of treatments for FMD have been explored including 
physiotherapy, multidisciplinary rehabilitation, psychotherapy, transcranial magnetic 
simulation, botulinum toxin, therapeutic sedation, hypnosis, electromyographic biofeedback 
[4] and recently virtual-reality-delivered mirror visual feedback [42]. The most robust 
evidence currently exists for intensive FMD-specific physical rehabilitation with some 
psychological input [43]. However, specialist treatment centres are scarce and a lack of clear 
care pathways and clinical guidelines present challenges to accessing treatments [44,45]. The 
evidence for the effectiveness of interventions is growing but limited and many researchers 
and clinicians emphasise the importance of tailoring the interventions to the individual needs 
of the patients, their goals, and potential barriers [41,46,47].  
Partnership and collaboration have become especially significant in the light of 
patients’ dissatisfaction with care [48], oversimplified explanations for FMD [45] and low 
uptake of psychological therapies that assume underlying psychological issues [49]. Patients 
have often been labelled ‘resistant’ to psychological accounts of symptoms and lack of 
progress in therapy was attributed to lack of insight [50,51]. Patients have been marginalised 
in the medical system for decades [52] and their perspectives overlooked in research studies. 
As the revision of current terminology and understanding of FMD is ongoing, it is crucial that 
patients are heard and involved in shaping the understanding of FMD and its treatments [48]. 
An exploration of the experiences of people with FMD through qualitative studies is needed 
to facilitate representation of their perspectives to inform treatment planning and service 
developments. 
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However, there is scarcity of qualitative research in this area with most studies 
conducted with people with non-epileptic seizures (NES) [53-57]. NES, like FMD, are a 
subset of the wider FND category but have a different symptoms phenomenology. A 
systematic qualitative synthesis conducted in 2016 [58] highlighted the interpersonal burden 
of having NES and conflicts between patients and healthcare practitioners regarding the 
symptom’s nature. A report on experiences of living with FND, including FMD, emphasised 
its debilitating impact on patients and their families, and a lack of affordable healthcare 
provision in Australia [44]. Only one qualitative study was conducted in the UK and used 
thematic analysis to investigate experiences of people with FMD [45]. This study was 
undertaken as part of a randomised controlled trial of physiotherapy. The participants were 
recruited from the physiotherapy waiting list in a specialist tertiary care centre after an initial 
consultation with a leading neurologist in the field. Most people with FMD do not have 
access to specialist services or even physiotherapy and thus their experiences of having FMD 
and its treatment might be very different to those from the sample used in the study. 
The current study was proposed to explore experiences of people living with FMD 
across the UK, regardless of their treatment access or engagement with national health 
services.  Interpretative phenomenological analysis (IPA) was chosen to provide an in-depth 
exploration of participants’ idiographic experiences embedded in their individual 
circumstances and interpreted from within that framework. It is hoped that this method may 
facilitate the previously neglected and dismissed narratives of people with FMD. 
Method 
Design 
A qualitative methodology was adopted to examine the experiences of living with FMD. IPA 
was chosen as an approach particularly suited to under-examined topics [59] and which 
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privileges the narratives and meaning making [60] of the participants. IPA has a dual focus 
combining phenomenology – the study of what is being experienced – with hermeneutics, the 
theory of interpreting it [61]. It can facilitate rich understanding through the analytical 
process of exploring unique experiences embedded in the individuals’ context whilst 
acknowledging an interpretative stance when doing so [61]. 
Ethical approval for the study was granted by the Faculty of Health and Medicine 
Research Ethics Committee at Lancaster University (see Ethics section: Appendix 4-D). An 
additional approval was gained from FND Hope, a charity organisation involved in the study 
recruitment. Three experts by experience who were members of FND Hope were consulted 
regarding the recruitment and design to ensure that relevant ethical and practical issues were 
adequately addressed, and to enhance the study’s contextual sensitivity, and the results of the 
study to validate the findings and enrich the discussion and inform practical implications. The 
structure of the interview guide was informed by the recommendations by Smith et al. [61] 
Recruitment 
The first ten participants who met the inclusion criteria and consented to the study were 
accepted and the recruitment was then closed.  Potential participants were required to confirm 
(but not to evidence) that they had been diagnosed with functional movement symptoms. The 
formal diagnosis could include labels such as functional movement/motor disorder (FMD), 
functional neurological disorder (FND), functional neurological symptoms disorder (FNSD), 
psychogenic movement disorder (PMD), somatoform disorder, conversion disorder or others 
using the main symptom as the diagnostic label, such as functional dystonia. At least one 
movement symptom as part of the functional disorder was required: paralysis or weakness in 
an arm or leg, muscle spasms, dystonia, myoclonus, tremor or gait disturbance. People who 
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had co-morbid conditions were not excluded provided that they did not have another 
neurological disorder that could account for their symptoms. 
Eligible participants needed to be 18 years old or over and living in the UK to ensure 
a homogenous group in terms of received healthcare and exposure to common cultural 
influences that might have shaped their understanding of their condition. The diagnosis had to 
have been received at least twelve months prior to the interview to ensure sufficient time had 
elapsed to reflect on living with the condition and the impact of the diagnosis.  
Participants were recruited through FND Hope who advertised the study on their 
website, social media and patient engagement platforms: Twitter, Facebook and Health 
Unlocked. The posts included a link to the study information on the Lancaster University 
DClinPsy student research page.  
Nineteen people expressed their interest in the study and contacted the researcher via 
email or phone. Five people did not meet the eligibility criteria: one lived outside the UK and 
four had had the diagnosis for less than twelve months. Four people did not follow up after 
the initial response and ten decided to proceed with the study and were interviewed. 
Participants’ symptoms and time since diagnosis are presented in Table 1. All participants 
were given pseudonyms to protect their anonymity. 
 
[table 1 around here] 
 
The sample consisted of eight women and two men, aged between 24 and 66 years 
old. Time since diagnosis varied between one and six years, with majority of participants 
having the diagnosis for one to three years. Three people were working full time, one was 
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retired, one was a student and one was caring for a disabled child. The remaining four were 
unemployed as a result of FMD. Four of the participants’ occupation was in healthcare, two 
in social care, two in teaching, one in performing arts and one in law.  Symptoms experienced 
were tremors, spasms, twitches, limb weakness and numbness, paralysis of legs and of the 
whole body, gait disturbance, leg drag and drop attacks. All participants also experienced 
pain or fatigue or both, and many had other functional neurological symptoms, such as 
speech problems, cognitive difficulties or seizures. 
Data collection 
Ten semi-structured video interviews were conducted over Skype (due to geographical 
distance) ranging in length from 54 to 98 minutes. Participants were encouraged to talk about 
the issues that were most salient to them, and the interview schedule (Ethics section: 
Appendix 4-A) was used as a flexible guide to facilitate the discussions.  
Data analysis 
The interviews were transcribed verbatim by the researcher and an idiographic approach 
adopted to analysis. Each transcript was analysed separately and fully before moving on to 
others. Notes were taken during transcription to capture initial impressions and capture the 
researcher’s potential pre-conceptions and automatic associations. These were then further 
examined to identify the researcher’s bias in line with IPA’s principles [61]. Further analysis 
involved taking thorough analytical notes including the descriptive, conceptual and linguistic 
nature of participants’ line-by-line utterings (for a sample of a coded transcript – see 
Appendix 2-B). The notes were then organised into code clusters and initial themes 
(Appendix 2-C). The main themes and subthemes were then generated for each participant 
(Appendix 2-D). This process was followed for each transcript. The generated themes for all 
participants were clustered together to seek patterns, similarities and differences. The 
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superordinate and subordinate themes resulting from this stage of analysis were noted and 
underwent further scrutiny to check for internal validity and reliability. As the transcripts 
provided rich and extensive material, the most salient themes were chosen for the purpose of 
this project and to highlight clinically relevant issues. The table of final themes, subthemes 
and corresponding quotes is attached in Appendix 2-E.  
Validity and reflexivity 
A number of steps were undertaken to ensure the validity of the study, informed by a 
framework of principles for qualitative research developed by Yardley [62]. Triangulation of 
interpretative perspectives [62] was used when analysing data.  One transcript was coded 
separately by the researcher and one supervisor and then compared. The codes were then 
checked by a second supervisor. The emerging themes were modified in discussions with 
both supervisors to increase consistency and reliability of the analysis.  Further validation 
was strengthened by a final re-reading of the transcripts with the emergent themes in mind to 
check whether the themes were supported or challenged by the data. As a result, amendments 
were made to the themes to include examples of significant divergence and convergence 
within and across themes.  
Transparency and a reflexive stance were maintained throughout the process of 
planning, collecting and analysing data. Every attempt at understanding a phenomenon is 
inevitably influenced by the researcher's own beliefs, expectations and experiences [63]. In 
qualitative research this is not considered an error [62] but an inherent part of learning about 
the interaction between the explored phenomena and those who engage with it. A reflexive 
approach helps to capture some of those interactions and consider their meaning. The use of a 
reflective diary helped the researcher consider her own bias and its potential impact on the 
study. Noticing and bracketing of explicit and implicit judgements might highlight not only 
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personal but also cultural, societal or a professional bias resulting from accepted discourses. 
Dialogue between the various interpretations and alternative perspectives helps to enrich the 
analysis through triangulation of interpretations and their embeddedness in specific contexts.   
The main researcher is a woman in her late thirties with a professional background in 
psychotherapy and a special interest in the interrelatedness of physical and psychological 
aspects of health. She worked with people with persistent physical symptoms during her 
clinical placement in physical health psychology. The researcher became aware of her desire 
to challenge the use of theoretical concepts when they seem to override the lived experiences 
of individuals affected by functional conditions and their expressed treatment needs. It is the 
researcher’s belief that full ‘bracketing’ of one’s own assumptions is not achievable or 
necessary as every interpretation is embedded in a specific context that introduces bias.  The 
researcher aimed therefore to contextualise the assumptions and interpretations, especially 
those in the dominant narratives available in psychological research and theory. 
Results 
Three superordinate themes were generated from the data: (1) The tug of war with the secret 
agent within: the power struggle with symptoms; (2) Navigating risks of disclosing the 
diagnosis: stigma and self-preservation; (3) Pursuing hope, knowledge and treatments against 
helplessness and passivity.   
Theme 1: The tug of war with the secret agent within. The power struggle with symptoms. 
This theme relates to participants’ efforts to control symptoms and their own body, which 
was perceived as a host to or a hostage of a forceful entity to be wrestled with for control and 
identity.  
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The symptoms, seen as unpredictable and uncontrollable, fuelled a sense of fear, 
frustration, bafflement, and urge to regain control. Gemma felt trapped and protested at the 
loss of control when experiencing paralysis: “I couldn’t talk, I couldn’t move my mouth, I was 
just making noises, sort of screaming and wailing because I was angry and scared”. 
Participants described the FMD as a powerful force orchestrating the symptoms 
according to its own agenda and having a mind of its own – capricious, uncontrollable, and 
resistant. “My head will rock back and will stay there for however long it feels like staying 
for” (Frances). Sometimes symptoms were envisaged as an expression of the body acting as 
a ‘safety valve’ in response to overload from specific triggers, e.g. exertion, emotional or 
physical strain or sensory stimulation: “If I push through pain, which I quite often have to 
do… It’s almost as if my body goes: actually, this is enough, you need to just stop” (Gemma). 
However, the speculated protection was also viewed as excessive, leaving Gemma feeling 
oppressed, rather than relieved by the symptoms: “It’s not an escape, it’s a terrifying trap!”. 
The perceived lack of satisfactory biological explanation for symptoms made some 
participants question their sanity or led to self-blame for lack of influence over their own 
body. Distraction techniques were employed to prevent or postpone symptoms and regain 
some sense of control and agency. However, some participants viewed this strategy as only 
effective in the short term and often prolonging the struggle. Lynn frequently attempted to 
ignore symptoms out of fear of becoming overpowered by them: “I think my main fear was 
that if I acknowledged what was happening… that it would suddenly overwhelm me” (Lynn). 
Paradoxically, this exacerbated symptoms and was leaving her feeling defeated and retaliated 
against: “The more I tried to ignore it, the more it would slap me around my face” (Lynn). 
Frances felt that letting the symptoms run their course was the only way of extinguishing 
them. For those who found their symptoms unresponsive to any influence, fighting felt futile. 
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Symptoms were seen as an inescapable force dictating the rules and the only way to respond 
was to accept them and not waste the little valuable energy that was left.  
Some participants understood symptoms as an error of their malfunctioning nervous 
system that could be corrected. They engaged in persistent efforts to overpower symptoms 
with training of motor functions, taking pride in setting and achieving goals, which provided 
a sense of triumph: “I’m trying to teach my body: look, shut up, I’m gonna do this. It’s… [a] 
psychological way of winning over” (Peter). However, Peter found the body to be a fierce 
opponent resisting the conscious mind’s influence. “It is very difficult to impose a conscious 
decision on top of those… you try it and the mismanagement signals make your feet stop or 
not walk, walk a little bit then stop and fall over”. Successfully overcoming symptoms was 
described as involving unrelenting persistence, counterintuitive actions and mind tricks. 
Leyla described undergoing mirror therapy as one of the mind-tricking techniques to 
overcome the faulty neurological processing: “You’ve got to look in the mirror and imagine 
that you’re seeing the other leg and for the first few attempts I kept thinking: it’s a mirror, I 
know it’s a mirror!... but over time it’s easier” (Leyla). 
The battle with symptoms was fought not only for the control over one’s own body 
but also to retain a sense of self. FMD was experienced as claiming and violating the 
individuals’ identity. Participants had to make conscious attempts to retain or re-build the 
sense of who they are despite feeling permanently changed.  
Harriett spoke about developing a dual identity to maintain her previous sense of self: 
“I’m two different people, the one that is covering up that I have a condition versus the one 
that actually now needs to recover from that condition” (Harriett). The perception of self as 
independent, competent and able whilst witnessing oneself with FMD as dependent, 
restricted and disabled was a big challenge and felt irreconcilable: “It’s really hard ’cause it’s 
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like being in somebody else’s body… you’re left with this kind of not-you trying to be you… I 
think that was harder than learning to walk” (Lisa). 
Peter explicitly rejected the notion of disability: “No, no, no, no, I’m somebody who 
has limits on my ability, that’s what I’ve got, I’m not disabled, big difference [laughs]”. All 
participants wanted to preserve an identity that was built on positive experiences rather than 
defined by the deficits: “You have to look at the positive things... I just started up drawing, I 
never knew I could draw, you know, stuff like this. Finding a hobby that I can do, rather than 
one I can’t” (Mark). This, however, often required a continuous effort and re-defining of own 
identity. 
Theme 2: Navigating risks of disclosing the diagnosis: stigma and self-preservation. 
This theme relates to the participants’ experience of the FMD diagnosis carrying unwelcome 
consequences as a result of misconceptions and stigmatising attitudes from other people, 
including healthcare professionals. The participants had to navigate carefully the perceived 
risks and employed various strategies to mitigate them by concealing symptoms, using 
alternative diagnostic labels or withdrawing from contacts. Educating others was also 
attempted and seen as aspirational but practiced when the resources to mitigate the potential 
risks were available or outweighed the risk. 
Participants experienced their symptoms as bizarre, unpredictable and attracting 
unwanted curiosity, suspicion or exasperation from others. Some participants felt insecure 
about being unable to identify a clear cause or give an explanation that would be 
understandable to others: “Even though I knew that what was happening to me was real, I 
still worried that because I couldn’t explain why it happened and what it was, that people 
wouldn’t believe me” (Leyla). Explaining the diagnosis to others was daunting and 
burdensome. A lack of traditional tests to evidence the condition, its conceptual complexity, a 
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lack of consensus amongst healthcare professionals and a lack of awareness of FMD in 
general left the participants feeling deprived of the usual concepts and ways of 
communicating a health condition.  
Many participants experienced stigmatising attitudes to be the result of the 
assumptions of a psychological cause of FMD or associated characterological deficits.  They 
experienced the diagnostic label as a prompt for others to scrutinise their behaviour or sanity 
and to undermine their credibility as a person or a professional. Mark felt that those 
assumptions, once acquired, were impenetrable and the attempts to challenge them were 
futile: “Some people have a fixed idea that it’s a psychological condition and that’s what 
hurts the most because they won’t listen. They think you’re just lazy or not bothered, that 
you’ve just given up. I don’t have the energy to try and put them right because you could be 
going on days, weeks, months and years… it’s an endless task.” (Mark). He chose to 
communicate his symptoms as ‘myoclonus’ avoiding the FMD label and hurtful judgements. 
Harriett feared that the diagnosis, if known to others, would undermine her competence as a 
professiona: “[colleagues] don’t know about what the condition is… I didn’t tell them. I 
didn’t want to appear weak… I liked being good at what I did and I didn’t want anyone to 
think that I couldn’t perform my job”. She told people she had a ‘natural tremor’ and took 
annual leave on days when she was too unwell to come to work. Emma found that by telling 
people she had a brain injury made it easier for them to understand: “Some people can’t 
comprehend it, it’s hard to put into perspective for them, so by going: ‘I’ve got a brain 
injury’… I found that the easiest way”.  
Most participants underwent a process of figuring out how and whether to disclose 
their diagnosis to others. Those conversations were difficult even with some family members, 
who struggled to grasp or empathise with the physical or the emotional aspects of the 
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condition. Some participants sought professional support to prepare them for conversations 
with their partners and families.  
Many participants found themselves particularly vulnerable when seeking medical 
help and disclosing their diagnosis. They felt silenced, shamed and often struggled to 
challenge communication conveying disbelief or blame: “I had a GP say to me: ‘[it’s]a 
unicorn condition’ which I found quite offensive… I was taken aback and didn’t say anything 
but I wish that I had” (Hannah). The usual coping strategies used, such as concealing or re-
labelling symptoms, withdrawing from contacts or educating others were particularly difficult 
in healthcare settings as they violated the unspoken rules of engagement and were challenged 
by the experienced differences in power between the professional and the patient. The 
combination of perceived prejudice and power of health professionals made participants feel 
unsafe in healthcare settings. They perceived their physical complaints being overattributed 
to FND and their diagnosis creating a barrier to receiving standard care for other ailments. 
“Now it’s on my medical record, I am really concerned that if I do have a stroke – because I 
can still get strokes or anything else – they’re gonna just assume it’s FND and write me off” 
(Hannah). Perceived stigmatisation created mistrust and many participants decided to conceal 
their diagnosis, when possible and practical. Lynn felt she did not have the capacity to 
educate others or deal with potential prejudice when feeling vulnerable and in need of 
immediate medical care. Peter, who by his profession was used to speaking up and 
challenging others, willingly educated his doctors about FMD and often experienced it as 
rewarding, contributing to a positive change. He, however, also found it a tiring task, 
mentally and emotionally.  
 A unique perspective was presented by those who were both patients and healthcare 
professionals. They feared disclosing their symptoms in their workplace knowing their 
colleagues’ misunderstanding of functional symptoms and fearing a negative judgement.  
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Lynn described her shock when the consultant explained her diagnosis in detail: “I was like: 
oh my God. How have I come this far as a professional and not been told about what this 
really was?… I myself stigmatised against functional patients because I didn’t know any 
better… My colleagues had taught me: ‘it’s functional, they’re just making it up, there’s 
nothing we can do to help them, but you just have to go along with it’”. Those participants 
feared the shift in the position from a ‘professional’ to a ‘functional patient’, sensing it would 
endanger their credibility and ability to make themselves heard.  Emma used her professional 
healthcare background to challenge her interviewer during a psychology assessment, striving 
to establish an equal, professional to professional relationship and feel protected from the 
‘functional patient’ narrative.  
The participants experienced an internal conflict between the desire to address the 
stigma and the strain of doing so. They negotiated their position between disclosure and 
withholding of the diagnosis, weighing up the physical, social and emotional burdens against 
their available internal and external resources. Fighting stigma through self-disclosure was 
often seen as virtuous or liberating but could lead to further depletion and exhaustion, already 
inherent to the condition. Avoiding disclosure of FMD maintained energy needed for 
recovery but often involved guilt or a sense of disconnection and exclusion from others.  
Theme 3: Pursuing hope, knowledge and treatments against helplessness and 
passivity. 
This theme  relates to the participants’ relentless striving to maintain and pursue hope. This 
powerful but fragile process was experienced as constantly threatened by an equally powerful 
force of hopelessness and helplessness when dealing with uncertainty, dismissal by 
healthcare professionals and fears of the deterioration or permanence of symptoms.  
Most participants emphasised the importance of holding on to hope to maintain 
wellbeing and to find the right treatments. Leyla, Lisa, Lynn and Peter have all accessed 
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helpful treatments but only after a long and arduous journey that demanded stubborn 
determination and hope against self-doubts, despair and resignation. Most participants 
engaged in some form of coaching self-talk to prevent feelings of helplessness: “Part of me is 
scared that it won’t get any better but I’ve just got to keep hoping for the best and preparing 
for the worst” (Leyla).  
The pursuit of hope through seeking knowledge and treatments was often endangered 
by perceived passivity, helplessness or ignorance of healthcare professionals, seen as 
jeopardising the recovery. This was seen as additional, though avoidable, burden when they 
were already grappling with fear: “I couldn’t sit in a wheelchair without falling out because 
my tremors were so bad and they said, ‘maybe you should just go home, sometimes these 
things happen’” (Lisa). Even when under ongoing neurological care, Frances experienced her 
appointments as wasteful and disheartening as they lacked an active plan and felt 
purposeless: “You go and see the neurologist, but they can’t do anything for you – ‘we’ll see 
you at the next appointment’ – which makes you think, why go to the next appointment 
because what’s the point?... it feels like a waste of time”. 
Participants often experienced healthcare professionals as passive and leaving the 
participants to learn about and manage the symptoms on their own.  However, when 
researching FMD independently, they often found the information confusing, abstract or 
impractical. Emma, despite being a healthcare professional herself and an avid reader of 
research, found it challenging to make sense of her symptoms: “There is so much literature 
out there that takes you off on different tangents and you’re trying to look at ‘OK, what box 
do I fit in?” It is very confusing to say the least”. Participants looked to professionals for 
guidance and practical support with the symptoms, not just theoretical explanation: “I 
understood in principle what was going on… but I found it very difficult to apply it to me, just 
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by reading it or just by having someone tell me… rather than work through it with me…” 
(Lynn).  
With a lack of clear guidance many participants employed random, chaotic or 
unhelpful strategies, ending up feeling helpless, lost or discouraged: “It’s like trudging 
through mud in a maze” (Hannah). Some participants felt disheartened and hopeless after 
undergoing ineffective treatments. They felt given up on and abandoned, reinforcing the 
sense of FMD being a lost cause or ‘unworthy’ of investment. At the same time healthcare 
professionals were seen as crucial to the recovery, holding the expertise the participants felt 
themselves lacking. They continued to seek support and guidance, maneuvering between 
hope of finding a helpful and interested professional, the despair of being untreatable and fear 
of being dismissed and shamed. 
The instances of meeting professionals with knowledge of FMD and a proactive 
approach to treatment was often experienced as a turning point for the recovery, an antidote 
and a stark contrast to previously seen passivity and inertia, a renewal of hope that change is 
possible. Lisa, after feeling helpless and given up on by doctors, met a movement disorder 
specialist and things changed dramatically: “He just went, ‘it’s FMD… your brain’s 
malfunctioning and the good thing is that we can get it functioning better again, we just need 
to do rehab…’ and that’s what I did. As soon as I started rehab, I got a lot better”. Leyla felt 
stunned by the neurologist who worked out an active care plan with her, reinstating her hope 
and a sense of direction: “She was really amazing, it was almost like the starting gun for the 
start of a race… Instead of constantly being fobbed off by everybody else… she listened and 
said, ‘OK, let’s see what we can do’ ”.  
After numerous rejections or lack of adequate care some participants found support 
outside the NHS: “The only professional support I get from a neurologist and from 
neurophysio I pay for… very good, extremely” (Peter). Like Peter, Lynn and Lisa spoke 
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about hope being the key to accessing effective treatments. These required unrelenting 
perseverance, private funding or social influence to find the right support against the systemic 
barriers: “I have a very persistent wife, she made a meeting with all the head people from the 
department and she just wen,: ‘we’ve got to figure it out because this is ridiculous’ and that’s 
when they found me a movement specialist” (Lisa)’. 
There were also many participants who could not afford private treatments or did not 
have the same social or personal resources. Mark experienced benefits from physiotherapy, 
but he could not sustain it as the input in the NHS was limited. He has experienced gradual 
worsening of his symptoms since. 
Advancing knowledge was seen by all as the main driver of change that could 
improve the understanding and treatment of FMD. Most participants spoke about taking part 
in this study to make their own contribution. They saw research as a beacon of hope and an 
active stance against uncertainty and resignation. Some were actively involved in their own 
initiatives and research projects, raising awareness and educating the public and health 
professionals. It provided a sense of hope and influence in an environment that otherwise felt 
stagnated, indifferent and resistant to change. 
Discussion 
The purpose of this study was to explore experiences of living with FMD. Through the 
process of IPA, three main themes were generated (1) The tug of war with the secret agent 
within: the power struggle with symptoms; (2) Navigating risks of disclosing the diagnosis: 
stigma and self-preservation (3) Pursuing hope, knowledge and treatments against 
helplessness and passivity.   
The first theme represented an internal battle – with the malfunctioning body and a 
powerful alien force within it that threatened the body’s integrity and selfhood. Reported 
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experiences of loss of control, feelings of oppression, confusion, powerlessness and 
entrapment by the symptoms reflect the findings of previous studies on living with FND 
[44,56,57,64]. Loss of control over the body had been previously described as triggering a 
series of losses in life choices, activities and opportunities [44] which in turn led to a loss of 
valued self-representations [65] and a crisis of identity, often reported as inherent to chronic 
conditions generally [66]. Some authors have proposed that identity changes in chronic 
illness are forced by the split between the disabled body and the ‘old’ self [67]. A study of 
men with FND identified a fight between two identities – with and without symptoms – 
generating a sense of disconnection or estrangement from the dysfunctioning body and 
having to fight to ‘not lose oneself’ [64], which was also reflected in the present study. 
Similar experiences of lost selfhood, betrayal and alienation from the body are reported in 
other neurological and movement disorders. For example, people with Parkinson’s reported 
their self taken over by ‘an evil twin’ [68] and women with multiple sclerosis depicted their 
bodies as ‘unrecognisable’ and a hindrance [69].  
Negotiating and bargaining for control was present in the accounts of all participants 
in this study. However, the coping strategies employed varied depending on the extent of 
control they experienced and how they conceptualised FMS: as an unfathomable force with 
its own agenda, an oppressor and abuser, an authoritarian protector, an error of the nervous 
system or a representation of their inadequacy or weakness. Many of the participants in this 
study endorsed a mixture of different conceptualisations, fluctuating between them in a 
dynamic process of meaning making. According to the self-regulation model (SRM) of health 
and illness people construct common-sense illness representations to help them make sense of 
their experiences which then shapes their coping responses [70]. Illness beliefs were shown in 
Stone’s study to predict reduction in functional symptoms more than the number of 
symptoms, disability or distress [7]. In the SRM model, perceived illness controllability is 
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postulated as one of five key dimensions of illness beliefs and has been found to affect coping 
strategies [71], health outcomes, psychological wellbeing, social functioning [72] quality of 
life and engagement with health services [73] across various physical conditions. Leventhal 
et al. divided illness controllability further into treatment control and personal control [70]. 
Failure to explore illness perceptions early in participants’ care, lack of shared understanding 
and collaborative care plan might have led to participants’ increased anxiety and reduced 
treatment control [74].  
Personal control and the broader concept of perceived control has been extensively 
researched for its importance in general health and wellbeing [75-77]. Maier and Seligman in 
their reviewed theory of helplessness posited that the active personal experience of control 
over adverse stimulus inhibits a default neurological response of passivity. This time-limited 
effect prevents feelings of helplessness and is generalised to other situations even when faced 
with uncontrollable circumstances [78]. Related concepts of self-efficacy, sense of agency 
and a sense of mastery have also been shown to facilitate a reduced sense of powerlessness 
[79] and improved health-related quality of life [80] in chronic conditions.  
However, attempts to exert direct conscious influence over symptoms were found by 
some participants in this study to be frustrating or counterproductive, which is supported by 
findings in other qualitative studies [44,64]. Indeed, common physiotherapy interventions for 
FMS involve training the affected motor function whilst diverting attention away from it [81] 
based on theoretical models explaining FMS as a failure in explicit movement control with 
automatic processes being preserved [82].  In this case, paradoxically, regaining control 
might be achieved through relinquishing efforts to control. Some psychological interventions, 
especially acceptance and commitment therapy (ACT) propose shifting the attention from the 
control over FMS towards achieving valued goals and in this way regaining a general sense 
of control over one’s life direction and meaning [83]. Aujoulat et al. [84] argued that the 
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process of exerting control as well as relinquishing control are not mutually exclusive and 
that empowerment can be achieved by integrating both.  
The internal struggle for control was made even more wearisome by others’ 
assumptions and expectations of such control. This leads onto the theme of the interpersonal 
struggle with stigmatising views and oppressive attitudes experienced from other people. 
Movement symptoms are often visible and expose the individual to others’ attention and 
curiosity. However, initial unfavourable judgements can instantly change to empathy when 
an organic diagnosis, such as Parkinson’s, is disclosed [85]. Conversely, the labels 
‘functional’ or ‘psychogenic’ were found in this and other studies [44,45,58] to evoke 
withdrawal of empathy, negative judgement, scepticism or confusion in social interactions 
and in healthcare settings. Goffman [86] defined stigma as a mark of undesired difference, 
causing rejection by society as a deviation from the established ‘norm’. The threat of 
rejection drives stigmatised individuals to employ coping strategies aimed at minimising the 
harm of exclusion or securing acceptance by concealing their unwelcome difference to pass 
as the society’s ‘normals’. In this study the participants navigated between self-disclosure and 
its withdrawal depending on the significance of potential losses (e.g. losing valued 
professional credibility, dignity, loss of relationships), an individual’s resources to mitigate 
the risks (e.g. strong supportive social network, socioeconomic status), perceived chances of 
a positive outcome and perceived costs of a negative outcome (e.g. mental and emotional 
exhaustion, shame, guilt).  
Some studies on liberation movements have highlighted the health impact of secrecy 
in the context of stigma, describing it as ‘private hell’, leading to preoccupation with the 
stigma and reduced wellbeing [87]. It has been suggested that self-disclosure can facilitate 
empowerment and improve self-esteem. In this study some participants reported guilt or 
disconnection from others as a result of concealing their diagnosis but did so to protect 
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themselves from anticipated more burdensome consequences, such as shame, negative 
judgements and blame. Corrigan [88] recognised the tensions inherent in disclosure in 
stigmatised groups and advocated ‘strategic disclosure’, driven by the individual’s 
circumstances and cost–benefit analysis. Many participants in this study engaged in a 
strategic disclosure of their symptoms and used alternative socially acceptable and recognised 
labels, such as myoclonus, brain injury or essential tremor. Those alternative labels were 
chosen due to the perceived lack of adequate narratives that could be safely shared with and 
understood by others. The challenges experienced by the participants might also reflect the 
lack of consensus in the literature, as the terminology and theoretical explanations of FMD 
are being revised and disputed [39,43,89]. 
Despite a rapid growth of research uncovering the complexity of biological, physical 
and psychosocial factors implicated in FMD there are still new studies being published which 
describe functional symptoms as a psychiatric illness [90] or state the presence of ‘severe 
deficits in personality functioning' in people with FND [91,p.546]. This, as well as a sole 
reliance on psychological explanations in clinical practice, is likely to fuel potential 
misconceptions and attract stigma associated with mental illness or psychological difficulties 
[48,86,92], making it hard for the participants to share the diagnosis with others or to see 
value in psychological approaches to treatment. 
Dissatisfaction with psychological explanations has been identified as one of the 
dominant experiences in patients awaiting physiotherapy for FMD in a qualitative study by 
Nielsen et al. [45] and the present study partially confirms this. However, Nielsen et al. 
suggested that individuals’ rejection of psychological explanations might be driven by an 
attempt to distance themselves from the stigmatised population of people with mental health 
problems. Most participants in this study either had or were planning to have psychological 
therapy and many openly admitted to some psychological difficulties, past or present. All 
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participants actively engaged in examining the role of psychological factors in their 
symptoms but most found them insufficient to account fully for the symptoms. Some 
participants wished for the psychological cause to be true as they felt more equipped to deal 
with it. One participant chose to state depression and anxiety as a reason for absence at work 
rather than reveal the FMD diagnosis. This might suggest that for some people the 
dissatisfaction with psychological explanations might go beyond avoiding the stigma of 
psychological difficulties, and that the label of FMD itself might carry an additional, distinct 
layer of stigma and prejudice. 
A study by Rawlings et al. reported that patients with functional seizures perceived 
psychological explanations as lacking personal relevance and being inconsistent with their 
experience of symptoms [58]. An explanation should be applicable to the unique 
circumstances of the individual for it to be acceptable, and this has been increasingly 
emphasised when communicating the diagnosis of FMD to patients [13]. However, 
participants in this study reported feeling unsafe, stigmatised and disbelieved in healthcare 
settings. This might bring into question the potential for acceptable and shared meaning 
making to inform a treatment plan. In a UK survey in 2011 44% of consultant neurologists 
believed there was an overlap between conversion disorder and feigning symptoms [93]. 
Such views, alongside perceptions of personality pathology as an underlying factor in FND 
[91], are likely to translate into patients’ experiences of being invalidated and shamed, which 
was found in this and other studies [44,45]. The negative impact of repeated invalidation on 
wellbeing is well established [94,95] and some studies suggest that the invalidation by 
clinicians of patients’ experience also influences wellbeing and experience of pain, as shown 
in a study of a different functional disorder, fibromyalgia [96]. A multidisciplinary expert 
review of stigma associated with FND highlighted its impact on poor service provision, poor 
treatments and poor prognosis for patients [48]. Link and Phelan [97] argue that 
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stigmatisation occurs on multiple levels simultaneously: intrapersonal, interpersonal and 
structural (e.g. discriminatory and/or exclusionary policies and systems) and thus should be 
addressed on all levels.  
Some participants in this study accessed effective treatments at the cost of enduring 
numerous rejections and experiences of shame and resentment. This required a vast array of 
personal resources, resilience, energy and tenacity to avoid being thrown into despair and 
self-blame whilst already feeling vulnerable and depleted. They also did so thanks to private 
financial and social resources. This highlights significant health inequalities in accessing 
treatments, potentially reducing chances for recovery in the disadvantaged groups. 
Implications for practice 
The participants’ experiences of battling through FMD point to important issues of power and 
control in relation to their bodies, identity, place in the society and in accessing healthcare. 
Specialist interventions as well as wider systemic changes are needed to facilitate provision 
of adequate, stigma-informed care for this population, focusing on issues of empowerment 
and engagement for both the patients and the clinicians.  
A model of salutogenesis [98,99] has been found useful for informing health 
education for chronic illnesses [100] and could offer a framework for guiding service design 
and care provision for FMD. The model’s core concept – a sense of coherence (SOC) – is a 
construct expressing the degree to which a person has a pervasive feeling that the internal and 
external stimuli and stressors in their environment are (a) comprehensible – can be 
understood, are ordered and explicable, (b) manageable – there are resources to cope with 
them and (c) meaningful – the demands and challenges are worthy of investment. SOC was 
found to have strong associations with good health outcomes and adaptive coping [101]. It is 
proposed that interventions and services are designed and delivered with the view to facilitate 
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SOC. The experiences of individuals with FMD in this study could be understood as a result 
of threat to SOC’s three elements. Interventions could be shaped around those needs for 
regaining the sense of (i) comprehensibility – through supporting individuals and their 
families to develop shared, empowering and understandable narratives of FMD that are 
communicable to others and so identifying internalised stigma and negotiation of new valued 
identities, (ii) manageability – through developing resources to strengthen a sense of control 
with symptom-focused and coping-focused strategies, and involvement in shaping the 
treatment, (iii) meaningfulness – through setting up workable plans towards valued, 
meaningful goals.  
Clinical psychologists are uniquely positioned not only to implement those 
recommendations in direct clinical practice, but to drive systemic changes and develop 
stigma-sensitive and accessible services through education, influencing and leadership as part 
of their everyday jobs. The power threat meaning framework (PTMF), developed by 
psychologists, highlights how a set of diagnostic ideas imposed by the powerful groups in the 
society can reinforce oppression of those given the diagnosis, trapping them in an inescapable 
disempowered position. Clinical psychologists have a role in highlighting and challenging the 
power-laden unhelpful narratives about FMD and facilitating culture of non-defensive 
inclusive practice. 
Limitations and strengths  
This study is a unique study in its exploration of experiences of FMD using IPA 
methodology. This method facilitated insight into individuals’ lived experiences from a 
context-sensitive perspective of the current organisation of healthcare provision and societal 
dynamics. The study sample consists of people across the UK, reaching people in different 
locations and stages of treatment and recovery with different resources and different levels of 
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disability. Conducting interviews using teleconferencing facilitated access for those who 
would otherwise be excluded from the study. Healthcare practitioners made up 40% of the 
study sample, providing a unique insight from both patient and professional’s perspectives, 
exposing the power dynamics and stigma in healthcare from an insider’s perspective. Future 
research investigating the perspectives of professionals who provide FMD services and have 
the diagnosis might be particularly insightful and potentially helping to shift the stigma of 
this diagnosis. The relatively high representation of healthcare professionals in this study can 
be considered a strength and a limitation of the study, potentially amplifying the recruitment 
bias. The participants recruited through social media were self-selecting, with access to IT 
technology and following FND Hope’s updates. It is possible that they were more informed 
and educated about their condition than those without engagement with information-based 
sites and online peer support. It is also possible that participants represented those who 
demonstrated greater persistence and determination or had greater personal and social 
resources to participate in research despite the many challenges that FMD presents, including 
fear of judgement. The interviewer’s identity as a psychologist may have influenced who 
volunteered to take part and the content of the interview. The recruitment strategy may have 
excluded those who did not agree with their diagnosis of FMD. Future research could benefit 
from engaging those populations as well as those who accepted the diagnosis but did not 
access any support or services.  
Conclusions 
Participants in this study described continuous internal and interpersonal battles as part of 
living with FMD. Perceived ignorance and passivity in healthcare professionals was seen as 
promoting hopelessness, actively preventing recovery and being an unnecessary burden. This 
added to the already depleted internal resources, fear and helplessness. A number of barriers 
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to positive engagement with healthcare services and provision of effective interventions have 
been identified. A sense of oppression, loss of control and stigma in the participants have 
been described in the context of discriminatory power distribution in the society and 
healthcare settings. Antonovsky’s model of salutogenesis could offer a useful framework to 
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Table 1. Participant characteristics  
PARTICIPANT
1 
Age TIME SINCE 
DIAGNOSIS  
MAIN MOVEMENT SYMPTOMS 
Mark 53 6 years 
 
tremors, spasms, limb weakness 
Hannah 34 2 years 
 
weakness in legs, drop attacks, 
 muscles twitches, gait disturbance 
Gemma 43 3 years 
 
episodic paralysis, leg drag 
Emma 50 2 years arm weakness, leg drag 
Harriett 32 14 months tremor, leg weakness 
Frances 45 13 months gait disturbance, dystonia, body jerks,  
muscle weakness, episodic paralysis 
Peter 66 2 years gait disturbance, myoclonus 
Leyla 35 18 months spasms, gait disturbance, limb weakness 
Lynn 24 18 months one sided weakness, twitches, gait 
disturbance 
Lisa 34 2 years tremor, gait disturbance, legs weakness, 
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on publishing ethics. 
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Principles of Psychologists and Code of Conduct. 
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and methods, results, discussion; acknowledgments; declaration of interest statement; references; appendices (as 
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figure is to be inserted in the printed text should be indicated clearly on a manuscript. Each table and/or figure must 
have a title that explains its purpose without reference to the text. 
The title page should include the full names and affiliations of all authors involved in the preparation of the manuscript. 
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Word count 
Please include a word count for your paper. There is no word limit for papers submitted to this journal, but succinct and 
well-constructed papers are preferred. 
LIVING WITH FUNCTIONAL MOVEMENT DISORDERS                                            2-42 
 
Style guidelines 
Please refer to these style guidelines when preparing your paper, rather than any published articles or a sample copy. 
Please use any spelling consistently throughout your manuscript. 
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For tables and figures, the usual statistical conventions should be used. 
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Formatting and templates 
Papers may be submitted in any standard format, including Word and LaTeX. Figures should be saved separately from 
the text. To assist you in preparing your paper, we provide formatting template(s). 
Word templates are available for this journal. Please save the template to your hard drive, ready for use. 
A LaTeX template is available for this journal. Please save the template to your hard drive, ready for use. 
If you are not able to use the templates via the links (or if you have any other template queries) please contact us here.  
 
References 
Please use this reference guide when preparing your paper. An EndNote output style is also available to assist you. 
 
Taylor & Francis Editing Services 
To help you improve your manuscript and prepare it for submission, Taylor & Francis provides a range of editing 
services. Choose from options such as English Language Editing, which will ensure that your article is free of spelling and 
grammar errors, Translation, and Artwork Preparation. For more information, including pricing, visit this website. 
 
Checklist: what to include 
1. Author details. Please ensure everyone meeting the International Committee of Medical Journal Editors 
(ICJME) requirements for authorship is included as an author of your paper. All authors of a manuscript should 
include their full name and affiliation on the cover page of the manuscript. Where available, please also 
include ORCiDs and social media handles (Facebook, Twitter or LinkedIn). One author will need to be identified as 
the corresponding author, with their email address normally displayed in the article PDF (depending on the journal) 
and the online article. Authors’ affiliations are the affiliations where the research was conducted. If any of the 
named co-authors moves affiliation during the peer-review process, the new affiliation can be given as a footnote. 
Please note that no changes to affiliation can be made after your paper is accepted. Read more on authorship. 
2. A structured abstract of no more than 200 words. A structured abstract should cover (in the following order): 
the purpose of the article, its materials and methods (the design and methodological procedures used), 
the results and conclusions (including their relevance to the study of disability and rehabilitation). Read tips 
on writing your abstract. 
3. You can opt to include a video abstract with your article. Find out how these can help your work reach a wider 
audience, and what to think about when filming. 
4. 5-8 keywords. Read making your article more discoverable, including information on choosing a title and search 
engine optimization. 
5. A feature of this journal is a boxed insert on Implications for Rehabilitation. This should include between two to 
four main bullet points drawing out the implications for rehabilitation for your paper. This should be uploaded as a 
separate document. Below are examples: 
Example 1: Leprosy 
• Leprosy is a disabling disease which not only impacts physically but restricts quality of life often through 
stigmatisation. 
• Reconstructive surgery is a technique available to this group. 
• In a relatively small sample this study shows participation and social functioning improved after surgery. 
Example 2: Multiple Sclerosis 
• Exercise is an effective means of improving health and well-being experienced by people with multiple sclerosis 
(MS). 
• People with MS have complex reasons for choosing to exercise or not. 
• Individual structured programmes are most likely to be successful in encouraging exercise in this cohort. 
6. Acknowledgement. Please supply all details required by your funding and grant-awarding bodies as follows: For 
single agency grants: This work was supported by the under Grant . For multiple agency grants: This work was 
supported by the under Grant ; under Grant ; and under Grant . 
7. Declaration of Interest. This is to acknowledge any financial interest or benefit that has arisen from the direct 
applications of your research. Further guidance on what is a declaration of interest and how to disclose it. 
8. Data availability statement. If there is a data set associated with the paper, please provide information about 
where the data supporting the results or analyses presented in the paper can be found. Where applicable, this 
should include the hyperlink, DOI or other persistent identifier associated with the data set(s). Templates are also 
available to support authors. 
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9. Data deposition. If you choose to share or make the data underlying the study open, please deposit your data in 
a recognized data repository prior to or at the time of submission. You will be asked to provide the DOI, pre-
reserved DOI, or other persistent identifier for the data set. 
10. Supplemental online material. Supplemental material can be a video, dataset, fileset, sound file or anything which 
supports (and is pertinent to) your paper. We publish supplemental material online via Figshare. Find out more 
about supplemental material and how to submit it with your article. 
11. Figures. Figures should be high quality (1200 dpi for line art, 600 dpi for grayscale and 300 dpi for colour). Figures 
should be saved as TIFF, PostScript or EPS files. 
12. Tables. Tables should present new information rather than duplicating what is in the text. Readers should be able 
to interpret the table without reference to the text. Please supply editable files. 
  
13. Equations. If you are submitting your manuscript as a Word document, please ensure that equations are editable. 
More information about mathematical symbols and equations. 
14. Units. Please use SI units (non-italicized). 
Using third-party material in your paper 
You must obtain the necessary permission to reuse third-party material in your article. The use of short extracts of 
text and some other types of material is usually permitted, on a limited basis, for the purposes of criticism and 
review without securing formal permission. If you wish to include any material in your paper for which you do not 
hold copyright, and which is not covered by this informal agreement, you will need to obtain written permission 
from the copyright owner prior to submission. More information on requesting permission to reproduce work(s) 
under copyright. 
 
Declaration of Interest Statement 
Please include a declaration of interest statement, using the subheading "Declaration of interest." If you have no 
interests to declare, please state this (suggested wording: The authors report no conflicts of interest). For all 
NIH/Wellcome-funded papers, the grant number(s) must be included in the disclosure of interest statement. Read 
more on declaring conflicts of interest. 
 
Clinical Trials Registry 
In order to be published in a Taylor & Francis journal, all clinical trials must have been registered in a public 
repository at the beginning of the research process (prior to patient enrolment). Trial registration numbers should 
be included in the abstract, with full details in the methods section. The registry should be publicly accessible (at no 
charge), open to all prospective registrants, and managed by a not-for-profit organization. For a list of registries 
that meet these requirements, please visit the WHO International Clinical Trials Registry Platform (ICTRP). The 
registration of all clinical trials facilitates the sharing of information among clinicians, researchers, and patients, 
enhances public confidence in research, and is in accordance with the ICMJE guidelines. 
 
Complying with ethics of experimentation 
Please ensure that all research reported in submitted papers has been conducted in an ethical and responsible 
manner, and is in full compliance with all relevant codes of experimentation and legislation. All papers which 
report in vivo experiments or clinical trials on humans or animals must include a written statement in the Methods 
section. This should explain that all work was conducted with the formal approval of the local human subject or 
animal care committees (institutional and national), and that clinical trials have been registered as legislation 
requires. Authors who do not have formal ethics review committees should include a statement that their study 
follows the principles of the Declaration of Helsinki. 
 
Consent 
All authors are required to follow the ICMJE requirements on privacy and informed consent from patients and 
study participants. Please confirm that any patient, service user, or participant (or that person’s parent or legal 
guardian) in any research, experiment, or clinical trial described in your paper has given written consent to the 
inclusion of material pertaining to themselves, that they acknowledge that they cannot be identified via the paper; 
and that you have fully anonymized them. Where someone is deceased, please ensure you have written consent 
from the family or estate. Authors may use this Patient Consent Form, which should be completed, saved, and sent 
to the journal if requested. 
 
Health and safety 
Please confirm that all mandatory laboratory health and safety procedures have been complied with in the course 
of conducting any experimental work reported in your paper. Please ensure your paper contains all appropriate 
warnings on any hazards that may be involved in carrying out the experiments or procedures you have described, 
or that may be involved in instructions, materials, or formulae. 
Please include all relevant safety precautions; and cite any accepted standard or code of practice. Authors working 
in animal science may find it useful to consult the International Association of Veterinary Editors’ Consensus 
Author Guidelines on Animal Ethics and Welfare and Guidelines for the Treatment of Animals in Behavioural 
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Research and Teaching. When a product has not yet been approved by an appropriate regulatory body for the use 
described in your paper, please specify this, or that the product is still investigational. 
 
Submitting your paper 
This journal uses ScholarOne to manage the peer-review process. If you haven't submitted a paper to this journal 
before, you will need to create an account in the submission centre. Please read the guidelines above and 
then submit your paper in the relevant Author Centre, where you will find user guides and a helpdesk. By 
submitting your paper to Disability and Rehabilitation you are agreeing to originality checks during the peer-review 
and production processes. 
The Editor of Disability and Rehabilitation will respond to appeals from authors relating to papers which have been 
rejected. The author(s) should email the Editor outlining their concerns and making a case for why their paper 
should not have been rejected. The Editor may choose to accept the appeal and secure a further review, or to not 
uphold the appeal. In case of the latter, the Editor of Disability and Rehabilitation: Assistive Technology will be 
consulted. 
On acceptance, we recommend that you keep a copy of your Accepted Manuscript. Find out more about sharing 
your work. 
 
Data Sharing Policy 
This journal applies the Taylor & Francis Basic Data Sharing Policy. Authors are encouraged to share or make open 
the data supporting the results or analyses presented in their paper where this does not violate the protection of 
human subjects or other valid privacy or security concerns. 
Authors are encouraged to deposit the dataset(s) in a recognized data repository that can mint a persistent digital 
identifier, preferably a digital object identifier (DOI) and recognizes a long-term preservation plan. If you are 
uncertain about where to deposit your data, please see this information regarding repositories. 
Authors are further encouraged to cite any data sets referenced in the article and provide a Data Availability 
Statement. 
At the point of submission, you will be asked if there is a data set associated with the paper. If you reply yes, you 
will be asked to provide the DOI, pre-registered DOI, hyperlink, or other persistent identifier associated with the 
data set(s). If you have selected to provide a pre-registered DOI, please be prepared to share the reviewer URL 
associated with your data deposit, upon request by reviewers. 
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APPENDIX 2-B Example of the coded interview for one participant - withheld from the final online version of the thesis to protect the participant’s 
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This critical appraisal summarises the main research findings and considers them further in 
the context of interpersonal and systemic power dynamics, and in relation to the findings 
from the literature review. Strengths and limitations of the main study are further discussed, 
followed by personal reflections on the engagement with the study from a critical theory 
perspective, and the role of clinical psychology in advancing research and practice. 
The qualitative research study 
The qualitative study described experiences of people living with functional movement 
disorders (FMD) as engaged in internal and interpersonal battles to regain control, dignity 
and hope. This was represented by three superordinate themes: (1) The tug of war with the 
secret agent within: the power struggle with symptoms; (2) Navigating risks of disclosing the 
diagnosis: stigma and self-preservation; (3) Pursuing hope, knowledge and treatments against 
helplessness and passivity. Perceived ignorance and passivity in healthcare professionals was 
seen as promoting hopelessness and actively preventing recovery. This was seen as an 
unnecessary burden adding to the already depleted internal resources, reinforcing fear and 
helplessness. Furthermore, access to treatment often required unrelenting determination and 
social and financial resources, which meant additional barriers for those who were socially 
and economically disadvantaged.  
A sense of oppression, loss of control, personal and social identity were described by 
the participants as inherent to this diagnosis and could be understood in the context of stigma 
and discriminatory power distribution in society and healthcare settings. The experience of 
being dismissed, overpowered or misunderstood was common and made the participants feel 
unsafe and vulnerable when seeking medical care or social support. However, it seemed that 
they were not always seen as vulnerable or requiring help. It has been emphasised in the 
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literature that acknowledging vulnerabilities of particular groups highlights the responsibility 
and moral obligation to protect them, crucial to eliciting caring attitudes [1].  
Even though the participants had a clear diagnosis, they reported many clinicians 
perceiving their FMD as medically unexplained and viewed them as having no medical cause 
to be treated. A review of literature offers useful insights into the interpersonal dynamics 
between health professionals and patients whose symptoms are not seen as attributable to 
known organic pathology, often called ‘medically unexplained symptoms’ (MUS). Such 
patients, pursuing treatments, explanations and care, are reported to elicit feelings of 
frustration, helplessness and inadequacy in healthcare professionals who feel coerced into 
providing more care whilst believing that medical care is not required [2-4]. Patients’ pursuits 
of help are not seen as an admirable perseverance but as undermining the doctors’ authority 
and trigger defensiveness, resentment and power struggles [5]. As a result, doctors have been 
reported to be ‘more firm’ and to take a more paternalistic stance, leading to a break in 
collaboration, drop out and discharges [6]. The perception of one’s role and possession of 
specialist knowledge might be crucial to professionals’ attitudes. In O’Connell’s study [7], 
health professionals saw their role in managing functional stroke symptoms as mostly 
providing re-assurance and psychological support, and acting as gatekeepers to prevent 
unnecessary investigations and procedures. It could be argued that seeing oneself as a ‘gate-
keeper’ rather than a facilitator of an active treatment is likely to shape the direction of the 
consultation towards reassuring and dissuading from seeking treatment, which is experienced 
as dismissal by the patients, who are still left with the same troublesome symptoms after such 
consultations. 
In the current study participants reflected that some professionals seemed caring and 
empathic to their suffering but at the same time lacked knowledge about FMD and its 
treatment. As a result, the clinicians were perceived as making harmful clinical decisions that 
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overrode the participants’ requests and dismissed their concerns. Lack of knowledge about 
FMD and broader functional neurological disorders (FND) amongst healthcare professionals 
has been identified in previous studies [8-10].  In contrast, some participants encountered 
professionals who expressed empathy towards their struggles as well as understanding of 
FMD, and offered a clear treatment plan that was mutually agreed, workable and made sense 
to the patient. The perception of vulnerability or expression of empathy may not be sufficient 
to facilitate adequate care. Paradoxically, in the context of imbalance of power and lack of 
agreement between professionals and patients, it can encourage paternalism [6]. Power, 
agency and vulnerability have been proposed as interconnected and fluid and should not be 
separated [11]. The participants in the current study grappled with vulnerability, helplessness, 
and self-doubts whilst also demonstrating determination, influence, tenacity, and creativity. 
Defining a group of people by their vulnerability might foster assumptions of weakness or 
fragility, and facilitate paternalistic, patronising practice and disempowering attitudes 
[12,13]. In healthcare settings it could further deprive people with FMD the chance to assert 
their needs and access treatment. Recognising the agency, power and the right to exert 
influence alongside vulnerability may help prevent paternalism and promote truly 
collaborative care [6].  
The salutogenesis model [14,15] has been found useful for informing health education 
for chronic illnesses [16] and could offer a framework for guiding service design for FMD. It 
could also be used to address potential feelings of inadequacy, frustration or helplessness in 
healthcare professionals. The model describes factors that help people maintain health and 
wellbeing in adverse circumstances. Its core concept - a sense of coherence (SOC) expresses 
the degree to which a person has a general feeling that the internal and external stimuli in 
their environment are (a) comprehensible – are ordered and explicable, (b) manageable -  
there are resources available to cope with the demands they present and (c) meaningful - the 
CRITICAL APPRAISAL                                                                                                               3-5 
 
demands and challenges are worthy of engagement and investment. Providing education for 
healthcare professionals about FMD and its modern frameworks could increase the sense of 
comprehensibility. The sense of manageability could be strengthened through clear care 
pathways, interdisciplinary working or access to specialist supervision to address 
intrapersonal, interpersonal and systemic barriers to positive engagement with patients.  
Sense of meaningfulness, the motivational and emotional component of SOC, is strengthened 
when individuals believe they can influence decisions and outcomes. If the professionals see 
their input as stimulating collaborative partnerships with patients, they are likely to 
experience less anxiety, reducing defensive practice and power struggle with patients. 
Literature review 
The literature review explored psychological interventions for functional movement 
symptoms (FMS) usually constituting the diagnosis of FMD. The psychological therapies 
were, for a long time, a treatment of choice for this population on the assumption that the 
physical symptoms were an expression of psychological distress, past trauma or internal 
conflict [17]. Therefore, FMD were seen as a mental health issue, not a medical one. 
However, the evidence base for psychological interventions is still insufficient and 
understanding of FMD has significantly changed in the last 20 years [18-21]. 
The scoping review highlighted that different psychological interventions use 
different conceptualisations of FMD and target different assumed underlying mechanisms. 
Additionally, a variety of outcomes are measured, suggesting that different researchers 
consider different outcome domains as important in FMD. Evaluation of the interventions 
usually did not incorporate any measures of acceptability of the interventions, which is 
disappointing in the context of reported dissatisfaction with psychological explanations for 
FMD and low uptake of the referrals to psychology. The available explanations for this in the 
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literature quote patients’ lack of insight [22] resistance [23] or investment in secondary gains, 
coming from the sick role [24]. It is striking that these narratives have been repeated for 
decades and little evidence exists to support them. Patients are often not offered alternative 
treatments if they do not accept the provided explanations. In one study, patients who did not 
accept the rationale for having cognitive behavioural therapy (CBT) were not accepted into 
the multidisciplinary treatment programme [25]. Similarly, one of the participants in the 
current qualitative study spoke of conditional access to physiotherapy only upon completion 
of psychotherapy. Such conditions are unsupported by evidence and it is physiotherapy, not 
psychotherapy, that has accumulated most evidence for its effectiveness in FMD [21,26,27] 
These findings support the main study’s results regarding presence of judgemental 
narratives and the exclusion of people with FMD from shaping the understanding or 
treatments of FMD. The implications of this will be explored further in the personal 
reflections section.  
Strengths, limitations and future projects 
It is acknowledged that participants in the research study might not be representative of the 
whole of FMD population. To access the advert about this study, the participants had to be 
engaged with social media and subscribe to updates from an international FND charity 
organisation.  Having potentially experienced the stigmatising attitudes and 
misunderstandings of healthcare professionals, the thought of participating in research 
conducted by a psychologist may understandably have been aversive to some, and likely the 
research would have appealed only to those people who felt prepared and resourced enough 
to deal with such self exposure. It is possible that others, who felt more vulnerable, hopeless 
or had no access to supportive communities, would not take the risk of speaking up about 
their experiences and hence their experiences might not be reflected in this study. However, 
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this in itself poses an important issue. Participants in the research study described  
considerable emotional, physical, social and material investments needed to persevere to 
access treatments despite rejection, humiliation or passivity from healthcare professionals. If 
a group of fairly informed, determined, resourced people, most of whom occupied 
professional roles, are experiencing fear, helplessness, self-doubt and lack of power and 
control in healthcare services, then people who do not have social, financial or personal 
resources are likely to struggle even more. The Health Stigma and Discrimination Framework 
[11] emphasises that stigma in healthcare intersects with other axes of disempowerment and 
marginalization making some people more disadvantaged by health-related stigma. Due to 
this, it is reasonable to suspect that people with FMD from disadvantaged or marginalised 
groups are at particular risk of suffering from stigma, health inequalities and poor outcomes.  
This study used online recruitment and video interviews. This facilitated access to the 
study across UK and for those whose physical disability would make it difficult to attend in 
person. It was the first study exploring experiences of FMD nationally and with participants 
recruited regardless of their engagement with the health service or stage in treatment. This  
allowed a wide breadth of experiences and perspectives. Employing interpretative 
phenomenological analysis facilitated in-depth exploration of the individuals’ meaning 
making, embedded in the wider societal context.  
People who fully recovered from FMD might have not considered themselves as 
eligible for the study and might no longer be engaged with symptom-related websites. 
Although case studies describing full recovery exist, narratives of people who recovered are 
missing from the literature and could contribute important insights about the process and 
factors enabling recovery from the participants’ point of view. 
Qualitative methodology should be employed by future researchers to further examine 
different aspects of the experiences of people with FMD whose perspectives have been 
CRITICAL APPRAISAL                                                                                                               3-8 
 
neglected. A number of issues were highlighted in the scoping literature review that could 
benefit from qualitative enquiry. For example, studies examining reasons and experiences of 
rejecting referrals to psychological therapies or experiences of undergoing psychological 
therapies - of different therapeutic modalities (e.g. CBT, psychodynamic psychotherapy, 
hypnosis, acceptance and commitment therapy). Additionally, regular evaluation by the 
patients’ of the acceptability of these interventions, their particular techniques, therapeutic 
goals and achieved outcomes – would help understand patients’ needs and improve social 
validity of treatments. Research and practice-based projects involving education and 
collaborative, multidisciplinary re-formulation of FMD could help revitalise the field and 
inspire dialogue about new ways of delivering psychological therapies, that would 
incorporate novel biopsychosocial models and patients’ perspectives. 
Personal reflections 
Interpretative phenomenological analysis [28] posits that the researcher introduces their own 
interpretation to the collected data and those interpretations and assumptions need to be 
identified and ‘bracketed off’ so as  not to be imposed on the experience of the participants of 
the study. By keeping a research journal and a reflective stance during the project I was able 
to identify many of the emerging interpretations, impressions and emotions. I became aware 
how my life experiences have influenced the choice of the topic, the type of the analysis and 
the interpretative stance.  
As a child I had numerous illnesses which influenced my relationship with pain, 
illness and others affected by it. In my adult life, I had an episode of medically unexplained 
symptoms and have a family member who frequently experiences a variety of symptoms 
during times of intense stress or worry. These experiences contributed to the development of 
beliefs about the complexity and diversity of ways in which the body and mind interact as 
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well as the appreciation of pain and physical illness’ impact on emotional wellbeing, identity 
and self-worth. Striving to avoid theoretical oversimplifications, to respect and learn from the 
insights of those with lived experiences and to critically appraise dominant narratives - have 
undoubtedly influenced my engagement with the study. 
During the project I observed in myself a growing sense of obligation and a debt to 
the participants, for their courage and for entrusting me with their stories and their hope. I 
found myself feeling the weight of responsibility for carrying their messages so that they 
could be heard. I did not want to disappoint, to let them down by giving up and joining the 
passive and indifferent crowds they encountered before. I recognised this as potentially a 
common phenomenon that happens in therapy called, in the psychoanalytical tradition, a 
projective identification [29]. Through this lens I could see myself identifying with the 
projected hope, responsibility and longing for a positive change, for the voices to be heard 
and understood - with the ‘good’ nurturing figure that was needed and that I wanted to be. 
However, I also noticed the discomfort of being in this position, of being indebted and feeling 
pressure to use what I’ve been given to good effect. It felt tiring as I did not know whether I 
could fulfil the expectations, the task seemed big and I felt too small for it. Part of me wanted 
to get out of this obligation. Perhaps by explaining it as a collusion with the unconscious 
transference processes I could distance myself from it and describe it as the participants’ 
‘stuff’, not mine, to carry. I could just ‘name’ it, ‘bracket it off’ and stand aside.  
Another way of interpreting the emotional and motivational impact of listening to the 
participants’ stories would be that their passion and determination were contagious and their 
suffering and struggle humbling and evoked a natural instinct to help. Another, a political 
motivation, would be to call out prejudice and oppression in the society. It is possible that 
coming from a non-privileged group myself made me identify with those who are treated 
with a patronising tone and approached with dominance and superiority. Such interpretation 
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introduced a risk that perhaps this was my battle and I projected it onto the participants. In 
such case this narrative might need to be put aside, to not blur the participants’ experience. 
There were many motives and many possible interpretations of them. The question of which 
one was more accurate or less biased and therefore should guide my approach, was gradually 
replaced with the question of who benefits from which interpretation and who is 
disadvantaged by it. It is my belief that full ‘bracketing’ of own assumptions and bias is not 
achievable nor necessary and I attempted to contextualise different perspectives instead in 
line with critical theorists’ propositions that ‘a theory is always for someone and for some 
purpose’ [30]. 
Critical approaches to epistemology have been useful in providing a wider systemic 
lens. They see all knowledge and interpretations as embedded in the social and political 
context produced in tensions between power relations [30]. Dominant narratives carry bias of 
underrepresenting the underprivileged narratives and interpreting reality from the positions of 
privileged groups. From this framework, my role as the researcher would be to examine the 
power relations underlying the participants’ experiences and to challenge the social order that 
creates identified inequality or injustice.  
This study confirmed that people with FMD have not had enough power to have their 
stories heard – they have felt their narratives have been  misrepresented, misunderstood and 
misjudged. Their protest has traditionally been interpreted by researchers and clinicians as 
resistance, reluctance, denial, lack of insight, or a personality disorder. For critical theorists 
individual problem solving without challenging the social order, is not the purpose [30]. It is 
argued that when information and knowledge are gathered and interpreted from within the 
existing order, the problem solving will only reproduce existing injustice and legitimise 
inequality and serve interests of the privileged groups [30]. 
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Using critical theory made me appreciate that improving patients’ experience in 
healthcare services might be difficult if done from within paternalistic frameworks where 
patients are seen as lacking insight and resisting sensible interventions. A shift in paradigm 
challenging the underlying assumptions on which the previous knowledge was based is 
needed to create a new order, where patients’ perspectives are privileged and respected, and 
understanding of FMD and treatment needs is co-produced. 
Reflections on the role of clinical psychology 
The current study highlighted the role of psychological theory and practice in shaping 
treatments for FMD, and professionals’ continuing attachment to psychological explanations 
of FMD which are so often contested by patients [10] and challenged by new neurobiological 
findings [19,31]. Incorporating insights from other disciplines seems to be slow and there is 
no consensus framework for psychological interventions for FMD. As the interest and 
research in FMD is rapidly growing, the time seems ripe for psychology to revise its current 
theories and practice and join in the development of new effective and acceptable treatments.  
In mental health settings, clinical psychologists are encouraged to challenge the 
dominance of the medical model and to counterweight what has been described as 
colonisation of the biopsychosocial model by the medical model [32]. It might be that the 
opposite process has been happening for people with FMD where the biopsychosocial model 
has been colonised by psychological models. Patients have been raising concerns about the 
excessive focus on psychosocial factors but their voices have not been sufficiently validated 
in the past. 
Psychological theory has been used in unhelpful ways and potentially perpetuating 
stigma and misunderstanding of people with FMD. Disseminating psychological knowledge 
in this area needs to be done thoughtfully and tentatively to prevent overly simplistic and 
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unfounded claims. It is often at the point of diagnosis when psychological factors are 
introduced and explained and which often leads to the communication breakdown [33]. 
Involvement in education of other professionals about the role and extent of possible 
psychosocial factors in FMD and ways of communicating it in a non-assuming and non-
imposing way might facilitate access to psychological interventions, where appropriate. 
The skill set of clinical psychologists places them in a unique position to address 
many of the identified issues. They are reflexive scientist practitioners [34] who are trained to 
critically appraise and evaluate research and current practice [35]. The British Psychological 
Society’s Practice Guidelines emphasise that all interventions need to be based on provisional 
hypotheses and modified in the light of new data “to ensure compatibility with service user 
needs” [35]. Collaborative care and partnership towards mutually agreed goals [34] and 
supporting people to assert their needs and find their voice are at the core of clinical 
psychology’s philosophy [32]. Clinical psychologists can play a significant role in 
challenging the disempowering narratives, systemic and interpersonal barriers to accessing 
effective treatments and facilitating organisational change through engagement in leadership, 
education.  
However, a recent survey in Australia [9] reported 84% of psychologists admitted to  
insufficient education about FMD. This, alongside the quickly changing landscape of 
evidence for FMD, suggests that clinical psychologists could benefit from specialist training 
themselves. Additionally, the skills of critical analysis could be used to revisit and challenge 
some of  the underlying assumptions about FMD in psychological interventions that might be 
facilitating paternalistic care or perpetuating unhelpful attitudes. Lastly, collaborating with 
professionals from other disciplines could promote broader perspectives on FMD, prevent 
psychological bias and contribute to development of novel theoretical frameworks that might 
advance the field of FMD treatments. 
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Conclusions 
In conclusion, this research has highlighted the complexities of understanding and 
conceptualising FMD and the challenges it presents to patients, researchers and clinicians. 
The uncertainty and lack of consensus surrounding FMD are a source of misconceptions, 
stigma and interpersonal power struggles between healthcare professionals and patients. The 
helplessness and lack of control in the context of unpredictable and disabling symptoms has a 
detrimental impact on the wellbeing and quality of life of those affected by FMD and 
motivates them to seek hope and care from health professionals. However, the evidence base 
for effective treatments is limited and psychological therapies, frequently offered as the 
treatment of choice, have often been rejected by patients. Incorporating neurobiological as 
well as psychosocial models of FMD might improve the perception of relevance of 
psychological therapies for physical symptoms. Furthermore, a systematic and regular 
evaluation of acceptability of offered interventions is needed. Clinical psychologists are well 
placed to facilitate critical revision and development of psychological theoretical frameworks 
for FMD, to challenge disempowering narratives and contribute to systemic change through 
leadership and service delivery activities.  
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n o  
4d. If you are only using those sites that are open access and do not require registration, have you 
made your intentions clear to other site users? n o  
 
4e. If no, please give your reasons         
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5. What plans are in place for the storage, back-up, security and documentation of data (electronic, 
digital, paper, etc)?  Note who will be responsible for deleting the data at the end of the storage 
period.  Please ensure that your plans comply with General Data Protection Regulation (GDPR) and 
the (UK) Data Protection Act 2018.  
      
 
6a. Is the secondary data you will be using in the public domain? n o  
6b. If NO, please indicate the original purpose for which the data was collected, and comment on 
whether consent was gathered for additional later use of the data.   
      
Please answer the following question only if you have not completed a Data Management Plan for an 
external funder 
7a. How will you share and preserve the data underpinning your publications for at least 10 years 
e.g. PURE?  
      
7b. Are there any restrictions on sharing your data?  
      
 
8.  Confidentiality and Anonymity 
a. Will you take the necessary steps to assure the anonymity of subjects, including in subsequent 
publications? yes 
b. How will the confidentiality and anonymity of participants who provided the original data be 
maintained?        
 
9.  What are the plans for dissemination of findings from the research?  
      
 
10. What other ethical considerations (if any), not previously noted on this application, do you think 
there are in the proposed study?  How will these issues be addressed?   
 
SECTION THREE 
Complete this section if your project includes direct involvement by human subjects 
 
1. Summary of research protocol in lay terms (indicative maximum length 150 words):   
 
 Functional Movement Disorder (FMD) is a condition where a person’s movement is affected and is 
believed to be caused by an error in the nervous system’s functioning rather than a structural 
damage to the brain or muscles. Despite FMD being thought of as treatable, people with FMD have 
poor outcomes and accurate diagnosis is often delayed. There is a lack of sufficient evidence about 
effectiveness of currently provided psychological interventions to help people manage their 
symptoms and improve quality of life.  
 
This study will explore their experiences of people living with FMD, their treatments, how they make 
sense of their condition and how it impacts their life. I will interview up to 12 people and analyse 
their responses.  The findings will be summarised to capture important themes within and across 
individual stories. It is hoped to inform treatments and support that would respond better to the 
needs highlighted by the study. 
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2. Anticipated project dates (month and year only)   
 
Start date:  March 2019  End date: May 2020 
 
Data Collection and Management 
For additional guidance on data management, please go to Research Data Management webpage, or 
email the RDM support email: rdm@lancaster.ac.uk 
 
3. Please describe the sample of participants to be studied (including maximum & minimum number, 
age, gender):   
 
I will be recruiting from 6 up to 12 people, as a typical sample for an Interpretative 
Phenomenological Analysis (IPA) study (Smith et al. 2009). Participants recruited will be aged 18 and 
over, any gender, and living in the UK (to ensure a fairly homogenous group in terms of received 
healthcare and support by the national health system) who have been diagnosed with any type of  
functional movement disorder at least 12 months prior to the interview (to ensure sufficient time 
and experience of living with the disorder and to be able to reflect on the course, treatment and 
impact of the diagnosis as well as the symptoms).  
Participants would need to self-report that they have a diagnosis of Functional Movement Disorder 
(FMD) or Functional Neurological Disorder (FND) or Functional Neurological Symptoms Disorder or 
Psychogenic Movement Disorder or Somatoform/somatisation Disorder or Conversion Disorder or 
Functional Weakness or Functional Dystonia or other similar diagnosis that is found to be caused by 
a disturbance in functioning of the nervous system rather than structural damage in the brain or 
muscles. The participants would also need to experience at least one of the following symptoms: 
- paralysis (or episodic paralysis) or weakness in an arm or leg 
- muscles spasms affecting movement 
- dystonia – involuntary muscle contractions that cause slow repetitive movements or abnormal 
postures 
- myoclonus – sudden, involuntary jerking of a muscle or a group of muscles, affecting movement or 
posture 
- tremor affecting movement or posture 
- gait disturbances 
 
Exclusion criteria: 
- functional movement disorder as secondary to organic or structural (resulting from a damage to 
the brain or muscles) neurological disorder. 
 
Participants with other medical conditions and other functional disorders in addition to FMD will not 
be routinely excluded. However, prior to arranging an interview, I will confirm that the movement 
disorder is their primary medical concern to preserve homogeneity of the sample. 
 
4. How will participants be recruited and from where?  Be as specific as possible.  Ensure that you 
provide the full versions of all recruitment materials you intend to use with this application (eg 
adverts, flyers, posters). 
At the recruitment stage I will be collaborating with FND Hope – an international not-for-profit 
organisation who agreed to assist with the study. FND Hope has a registry of people who had already 
expressed their interest in taking part in research relating to FND and had submitted demographic 
and FND related information via the registry survey.  There are currently 84 people registered on this 
list in the UK. Individuals who are believed to meet the inclusion criteria would be targeted and 
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contacted by FND Hope via email inviting them to take part in the current study. The email will 
include the participant information sheet and the consent form for information.  
 
FND Hope will publicise information about the study on their website (https://fndhope.org/), social 
media and patient engagement platforms: Twitter, Facebook, Instagram and Health Unlocked 
(https://healthunlocked.com/). I will provide a link to the information about the study on 
https://www.lancaster.ac.uk/shm/study/doctoral_study/dclinpsy/research/. 
 
As a contingency plan, if not enough participants were recruited, I would contact the Dystonia 
Society – a charity organisation supporting people with all forms of dystonia, including functional 
dystonia. I would ask for the link to the study to be posted on their website and social media sites. If 
there was still a need to recruit more participants, I would circulate the link to the study on Twitter 
via personal contacts. The Twitter account would be opened solely and exclusively for the purpose of 
the research study. 
 
If they decide they would like to take part, the participants will need to contact me via email or 
phone. I would then contact them to discuss the study further. If they are happy to proceed, an 
interview will be arranged. At that point I would also ask them for their address in case of immediate 
risk becoming apparent during the interviews so that the emergency services could be contacted. I 
might also use their address to post the participant information sheet and the consent form if they 
don’t have access to an email, with their agreement. The addresses will be stored on the main 
investigator’s secure storage space on the Lancaster University’s server. They will be encrypted, 
password protected and will be deleted once the interviews are completed unless the participants 
wished to have to study findings sent to them by post. In such case, the addresses will be deleted 
after the study findings were sent via post.  
 
I would also ask about other medical concerns they might have that might be impacting their 
experience of the movement disorder to establish eligibility for the study 
 
 
5. Briefly describe your data collection and analysis methods, and the rationale for their use.   
 
       
 
Data would be collected through semi- structured interviews lasting around an hour each. 
Participants will be encouraged to talk about the issues that are most salient to them, so the 
interview schedule will serve as a guide rather than a comprehensive list of questions. The interviews 
would be conducted through the phone, Skype or Zoom. A face to face interviews might be possible 
if participants are based in Lancashire or Cumbria, within accessible distance for the researcher and a 
suitable, local community venue is available and accessible to the participants. There would also be a 
possibility of an interview via email or WhatsApp messaging if a face-to-face/audio/video medium 
would be a barrier for people in accessing the study (for example, if their speech was affected).  
 
Additional demographic information will be collected: age, gender, living situation (alone or with 
others), occupational status (working or not), time since the diagnosis, duration of symptoms, type 
of symptoms, psychological treatments offered and accepted, comorbid conditions – to situate the 
sample and assist in the analysis of the data. This data will be recorded in a table of the study sample 
characteristics in an electronic version and stored on the main investigator’s secure storage space on 
the Lancaster University’s server, separately from the personal data and the interview transcripts.  
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The participants’ addresses will be collected in case of immediate risk becoming apparent during the 
interviews so that the emergency services could be contacted. They will be stored on the main 
investigator’s secure storage space on the Lancaster University’s server. They will be encrypted, 
password protected and will be deleted once the interviews are completed unless the participants 
wished to have to study findings sent to them by post. In such case, the addresses will be deleted 
after the study findings were sent via post.  
 
The study will adopt interpretative phenomenological analysis (IPA) as it is particularly suited to 
exploring under-examined topics (Smith & Osborne, 2015). Through an inductive analytical process, 
it would provide a detailed understanding of the participants’ lived experiences of FMD and their 
subjective meaning making of that experience. To aid that process the interviews will be transcribed 
verbatim to create written transcripts. As I intend to focus on the individual’s unique experience 
embedded in their context and perspective, IPA is ideal as it’s idiographic in its nature and facilitates 
exploring particular perspectives in their specific contexts (Smith et al. 2009). 
 
6. What plan is in place for the storage, back-up, security and documentation of data (electronic, 
digital, paper, etc.)?  Note who will be responsible for deleting the data at the end of the storage 
period.  Please ensure that your plans comply with General Data Protection Regulation (GDPR) and 
the (UK) Data Protection Act 2018.  
 
Interviews will be recorded on a digital audio recorder (using a recorder earpiece when conducting 
phone interviews to ensure best quality) and then transferred as soon as possible to and stored on 
the main investigator’s secure storage space on the Lancaster University’s server for the duration of 
the study. The transcribed interviews and copies of typed interviews held via email or WhatsApp will 
be anonymised and stored in the file with the interview recordings on the main investigator’s secure 
storage space on the Lancaster University’s server. Original emails and WhatsApp messages will be 
deleted immediately after copying them into the secure location. Participants will also be advised to 
delete the copies of interviews from their emails or WhatsApp.  
 
Audio recordings of the consent and written consents will be encrypted, password protected and 
stored with a code to link them with their respective interview transcripts but in a separate file from 
non-personal data, such as interview transcripts.  
 
Once the project has been completed and examined, audio recordings of the interviews will be 
deleted. The remaining files will be transferred securely using the university’s encrypted file transfer 
software (currently Box) to the Research Co-ordinator at the Doctorate in Clinical Psychology 
programme and stored on the university’s secure server.   
 
If any participants request the interviews to be conducted via email exchange, they will be informed 
that those means cannot be entirely secure. They will be encouraged to use password protected 
attachments when sending emails to increase the security of data but will be advised that the 
security still could not be guaranteed. The contents of the emails would be uploaded to the secure 
space on the university server and the original emails deleted. Participants would be asked to also 
delete the email exchanges. 
 
Participants’ addresses and other contact details (email addresses, phone numbers, Skype ID) and 
table with information about email/phone exchanges (not including interview contents) will be 
encrypted, password protected and stored with audio and written consents. They will be deleted 
immediately after the interview is concluded unless the participants wish to be sent the study report 
with findings. In such case their contact details will be deleted after the study findings report is sent 
out to them.  
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The electronic data will be stored for ten years after which it will be deleted by the Research Co-
ordinator at the Doctorate in Clinical Psychology programme under the direction of the university 
supervisor.  
 
7. Will audio or video recording take place?         no                 audio              video 
a. Please confirm that portable devices (laptop, USB drive etc) will be encrypted where they are used 
for identifiable data.  If it is not possible to encrypt your portable devices, please comment on the 
steps you will take to protect the data.  
 
The interviews will be recorded on a digital audio recorder that cannot be encrypted so the audio 
data will be transferred immediately after each interview (when interviews are conducted from the 
researcher’s home - phone/video link interviews) to a secure storage space on the Lancaster 
University server. When interviews are conducted face-to-face the data will be transferred onto an 
encrypted memory stick immediately after the interview. It will then be transferred to the secure 
storage space on the Lancaster University server as soon as possible – either when the researcher 
returns home or arrives at Lancaster University campus, whichever is the sooner.  
 
b What arrangements have been made for audio/video data storage? At what point in the research 
will tapes/digital recordings/files be destroyed?   
 
Audio recordings of the interviews will be stored on secure space on Lancaster University’s server 
and destroyed after the research project has been completed and examined as part of the the 
Doctorate in Clinical Psychology qualification.  Audio recordings of the consent will be encrypted, 
password protected and stored with a code to link them with their respective interview transcripts 
but in a separate file from non-personal data, such as interview transcripts. Audio recordings of the 
consent will be stored for 10 years. 
 
      
Please answer the following questions only if you have not completed a Data Management Plan for 
an external funder 
8a. How will you share and preserve the data underpinning your publications for at least 10 years 
e.g. PURE?  
 
The raw data will not be shared for confidentiality reasons. The transcripts of interviews are likely to 
contain individuals’ unique and cohesive narratives that, if shared in their entirety, might 
compromise confidentiality even if specific identifiable data are removed.  The data will be 
transferred to the Research Co-ordinator at the Doctorate in Clinical Psychology programme who will 
have it stored for ten years after which it will be deleted under the direction of the university 
supervisor. 
 
8b. Are there any restrictions on sharing your data ?  
      Sharing of the raw data will not be appropriate so there will be no access to it for people who 
have not been working on the study. 
 
9. Consent  
a. Will you take all necessary steps to obtain the voluntary and informed consent of the prospective 
participant(s) or, in the case of individual(s) not capable of giving informed consent, the permission 
of a legally authorised representative in accordance with applicable law?  yes 
 
b. Detail the procedure you will use for obtaining consent?   
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Participants identified in the FND Hope Registry as eligible to take part will be emailed the consent 
form together with participant information sheet in the initial email inviting them to take part in the 
study so that they can familiarise themselves with the project and with the consenting process. 
Those who express their interest in the study in response to seeing an advertisement of the project, 
will be sent out the same information after they make an initial contact expressing their interest in 
the study.  
 
Participants will be encouraged to voice their concerns, questions and any issues regarding the 
project, the consent and its withdrawal. They will be given the opportunity to do so via email, to 
request a telephone call to discuss it further and at the start of the interviews. The concerns, 
requests and other information included in email exchanges and phone calls will be recorded in a 
table to keep track of the exchanges with participants to ensure effective communication and 
transparent consent process.  
 
They will be advised and reminded that they can withdraw their consent at any point in the study up 
to the data analysis stage after which point it might be impossible to extract the data. This advice will 
be included in the consent form, participant information sheet and re-iterated at the start of the 
interviews. In the process of seeking informed consent, the participants’ attention would be drawn 
to potential upset and distress and we would discuss their current sources of personal and 
professional support to seek before or after the interviews. 
 
The participants will be asked to read the consent forms prior to interviews. They will be informed 
they don’t need to return it as it will be reviewed with them at the start of the interview. They will be 
asked to confirm  they understand and agree to participate in the study. I will audio record the 
consent process into a standalone recording, separate from the interview recording (in the case of 
phone/video link interviews). Asking the participants to sign a written consent and return it prior to 
the interview would be impractical as we would rely on the prompt return of the forms to arrange or 
proceed with interviews which could cause long delays and disruptions. In the case of face-to-face 
interviews, the participants will be asked to sign a paper consent form at the start of their interviews. 
In the case of email/WhatsApp interviews, the participants will be asked to sign, scan and return the 
consent forms via email or WhatsApp message.  
 
10. What discomfort (including psychological eg distressing or sensitive topics), inconvenience or 
danger could be caused by participation in the project?  Please indicate plans to address these 
potential risks.  State the timescales within which participants may withdraw from the study, noting 
your reasons. 
 
There is a potential for distressing material to arise during interviews given the personal emphasis of 
the research question and many challenges associated with living with functional neurological 
disorders. In the process of seeking informed consent, the participants’ attention would be drawn to 
potential upset and distress and we would discuss their current sources of personal and professional 
support to seek before or after the interviews.  
Participants will be given the contact information of relevant support services as part of their 
participant information sheet.  
 
Participants will be informed they can withdraw from the study at any point before and during the 
interview and then up to the data analysis stage when the themes are merged and after which data 
might not be possible to be extracted.  
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Participants will be advised they can stop the interview at any point to have a break, postpone to 
another time or cancel it altogether. I will be mindful of signs of distress in participants during the 
interview and remind them of the option to pause, postpone or withdraw. I will also seek 
participants’ consent to continue discussing a topic/aspect that is the source of distress to them. In 
the event of participants becoming severely distressed and expressing thoughts of harm to 
themselves or someone else I will follow the process agreed with them prior to the start of the 
interview – I could contact the person named by them and in the case of immediate risk - the local 
emergency services. I would also discuss this with my field and university supervisors – Dr Fiona 
Eccles and DR Catherine Parker 
 
11.  What potential risks may exist for the researcher(s)? Please indicate plans to address such risks 
(for example, noting the support available to you; counselling considerations arising from the 
sensitive or distressing nature of the research/topic; details of the lone worker plan you will follow, 
and the steps you will take).   
 
     There are no physical risks anticipated for the researcher when the interviews will be 
conducted via telephone or online from the researcher’s home. The phone number that might be 
used for the participants to contact the researcher or to arrange interviews will be obtained from the 
Doctorate in Clinical Psychology programme and will not be the researcher’s personal phone 
number. The researcher might use a personal mobile phone for conducting the interviews (when 
telephone interviews are requested by the participants) in which case a ‘141’ number will be used to 
anonymise the caller’s ID and the participants will be advised of it to ensure they accept the call. The 
choice of personal mobile phone for the interviews would be made to reduce the project’s cost as 
phone calls are free of charge from the researcher’s personal mobile phone. However, a DClinPsych 
programme’s phone number will be used for the participants to be able to contact the researcher 
before or after the interview. When using Skype, a professional Skype ID will be created for the 
purpose of the interviews.  
 
When interviews are conducted face-to-face, the researcher will adhere to Lancaster University Lone 
Working Policy. Interviews will be arranged in suitable community venues with reception facility or 
where other people would be working in physical proximity and will be aware of the researcher’s 
presence and estimated time of the interviews. Researcher will also make sure that somebody else – 
a colleague or a friend is aware of the location and time of the interviews. 
 
In case of any distress to the researcher as a result of the interviews, the research supervisors will be 
contacted for advice and support if needed.  
 
12.  Whilst we do not generally expect direct benefits to participants as a result of this research, 
please state here any that result from completion of the study.   
 
There are no direct benefits to participants from taking part in this study, however the participants 
might be interested in contributing to the evidence base that could shape the care and treatments 
they might receive in the future.  
 
13. Details of any incentives/payments (including out-of-pocket expenses) made to participants:   
      There will be no incentives to participate. 
 
14. Confidentiality and Anonymity 
a. Will you take the necessary steps to assure the anonymity of subjects, including in subsequent 
publications? yes 
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b. Please include details of how the confidentiality and anonymity of participants will be ensured, 
and the limits to confidentiality.  
      There are limits to confidentiality regarding the content of the interviews and the participants 
will be advised of them  at the beginning of the interviews, on the participant information sheet and 
on the consent form:  In the case of significant risk being highlighted in the interviews regarding the 
participants or other people, it will be discussed with the field or research supervisor and an 
appropriate action agreed (unless there is an immediate danger to the participant or other people, in 
which case the appropriate emergency services will be contacted first).  
At the start of the interviews participants will be reminded that internet is not a secure medium of 
communication and will be reminded of their right to withdraw from the study. The interviews will 
be transcribed by the researcher herself. The transcripts of the interviews will be anonymised and all 
identifiable information removed or changed. Whenever direct quotes are used to illustrate a 
theme/sub-theme or a reflection, all care will be taken for the person not to be identifiable from it 
and pseudonyms will be used.   
 
The data from the study will be stored securely on the university's server with access to it by the 
researcher, the research supervisor and the research co-ordinator on the Doctorate in Clinical 
Psychology programme. 
 
15.  If relevant, describe the involvement of your target participant group in the design and conduct 
of your research.  
 
I have consulted with two members of FND Hope who are or have been living with FMD to seek their 
views and advice regarding the design, recruitment and interview schedule of the research project. 
They have also provided initial feedback on participant information form and consent form. FND 
Hope will review the project protocol after it’s been approved by the university ethics committee 
and will provide further feedback before the study commences. If any changes need to be made as a 
result of this, I would submit an application to the university ethics committee for approval of the 
amendment.  
 
16.  What are the plans for dissemination of findings from the research?  If you are a student, include 
here your thesis.  
 
The findings will be written up into a thesis as part of the doctorate in clinical psychology. The 
findings will be summarised in a brief report and shared with FND Hope and potentially publicised on 
their website and social media sites. The report will also be sent to those participants who declare at 
the interview that they want to receive it. It is intended that the research will be submitted to a peer 
reviewed journal. The findings will be presented at a thesis presentation day at Lancaster university 
as part of the Clinical Psychology programme. If the opportunity arises, the findings would also be 
presented at academic conferences. 
      
17. What particular ethical considerations, not previously noted on this application, do you think 
there are in the proposed study?  Are there any matters about which you wish to seek guidance from 
the FHMREC? 
     none 
 
 
SECTION FOUR: signature 
 
Applicant electronic signature: Sylwia Bazydlo    Date 14/02/2019 
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Student applicants: please tick to confirm that your supervisor has reviewed your application, and 
that they are happy for the application to proceed to ethical review  x 




1. Submit your FHMREC application by email to Diane Hopkins 
(fhmresearchsupport@lancaster.ac.uk) as two separate documents: 
i. FHMREC application form. 
Before submitting, ensure all guidance comments are hidden by going into ‘Review’ 
in the menu above then choosing show markup>balloons>show all revisions in line.   
ii. Supporting materials.  
Collate the following materials for your study, if relevant, into a single word 
document: 
a. Your full research proposal (background, literature review, 
methodology/methods, ethical considerations). 
b. Advertising materials (posters, e-mails) 
c. Letters/emails of invitation to participate 
d. Participant information sheets  
e. Consent forms  
f. Questionnaires, surveys, demographic sheets 
g. Interview schedules, interview question guides, focus group scripts 
h. Debriefing sheets, resource lists 
 
Please note that you DO NOT need to submit pre-existing measures or handbooks which 
support your work, but which cannot be amended following ethical review.  These should 
simply be referred to in your application form. 
2. Submission deadlines: 
i. Projects including direct involvement of human subjects [section 3 of the form was 
completed].  The electronic version of your application should be submitted to Becky 
Case by the committee deadline date.  Committee meeting dates and application 
submission dates are listed on the FHMREC website.  Prior to the FHMREC meeting 
you may be contacted by the lead reviewer for further clarification of your 
application. Please ensure you are available to attend the committee meeting (either 
in person or via telephone) on the day that your application is considered, if required 
to do so. 
ii. The following projects will normally be dealt with via chair’s action, and may be 
submitted at any time. [Section 3 of the form has not been completed, and is not 
required]. Those involving: 
a. existing documents/data only; 
b. the evaluation of an existing project with no direct contact with human 
participants;  
c. service evaluations. 
3. You must submit this application from your Lancaster University email address, and copy 
your supervisor in to the email in which you submit this application 
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THESIS PROTOCOL  
Living with functional movement disorders.  
 
Principal Investigator: Sylwia Bazydlo, Trainee Clinical Psychologist, Lancaster University 
University Project Supervisor: Dr Fiona Eccles, Lecturer in Research Methods, Lancaster 
University 




Functional movement disorders (FMD) are part of a wider cluster of functional neurological 
disorders (FND) but refer specifically to neurological disorders of movement caused by a 
disturbance in functioning of the nervous system, rather than a damage to the brain or the 
muscles. Although thought of as treatable, the outcomes for FMD are poor with prevalence of 
the condition at 3%– 20% amongst the general movement disorder clinic patients (Hallett, 
2006) and high levels of disability and psychological problems (Pringsheim & Edwards, 
2017).  
FMD were traditionally considered to be caused by psychological factors and has also 
been known as Psychogenic Movement Disorder or Conversion Disorder. People affected 
often fall between neurology and psychiatry or psychology without a clear and effective 
pathway for treatment, causing frustration and anguish to both the professionals and the 
service users (Pringsheim & Edwards, 2017). Due to uncertain aetiology, lack of sufficient 
understanding and adequate services people with FMD face stigma, isolation and lack of 
adequate care. Pharmacological and psychological approaches tend to focus on assumed 
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underlying psychological issues and trauma, though it has been noted that ‘compliance is a 
major concern’ (Thomas & Jankovic, 2004, p. 437) and that there is little evidence to guide 
treatment decisions (Ricciardi & Edwards, 2014).   
In the last decade there has been a growing shift in the understanding of FMD 
reflected in the fact that the term functional rather than psychogenic or conversion disorder is 
increasingly proposed as a more adequate and acceptable diagnosis, as this acknowledges a 
variety of potential causes and a need for a multidisciplinary approach (Demartini, 
D'Agostino, & Gambini, 2016; Ding & Kanaan, 2017; Stone et al., 2011). As part of that 
shift, there is an emphasis on validating the service users’ experience of their symptoms as 
‘real’ and offering appropriate, acceptable treatment. However, despite the growing interest 
and research in the FMD, there is no research exploring what the people affected experience 
when living with FMD and how they are affected by the treatment or its lack.  
Previous studies have focused on quantitative measures of psychological profiles of 
individuals with the condition (Ekanayake et al., 2017; Tomic et al., 2017), their neurological 
(Voon et al., 2016) or psychological (Ludwig et al., 2018) predictive factors for the disorders 
or means for differential diagnosis to separate an organic disorder from a psychogenic one 
(Pastore et al., 2018; Scheidt et al., 2014).  None so far asked the individuals with the 
condition an exploratory question to increase our understanding of the challenges faced and 
needs to be met when designing and choosing treatments. There are no current guidelines by 
the National Institute of Health and Care Excellence for the treatment of FMD. In a draft 
consultation guideline for suspected neurological conditions, NICE (2017) mentions 
functional symptoms as mimicking neurological disease, triggered by emotional and 
psychological factors and recommending referral for an unspecified ‘psychological support’.  
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Despite the recommendation and practice of referring people with FMD for psychological 
support or therapy in the hope of addressing the underlying emotional causes and reducing 
the physical symptoms, there is little evidence for effectiveness of any psychological therapy 
with FMD. There have been studies of cognitive behavioural therapy (CBT) for treatment of 
the wider category of Functional Neurological Disorders (FND) and the results are varied 
between the different studies and different treatment designs (Ricciardi & Edwards, 2014). 
Moreover, CBT or psychological input is often regarded by the service users as inappropriate 
and unacceptable form of treatment (Sharpe et al., 2011).  
A multidisciplinary expert review made recommendations to reduce stigma for people 
with FND and improve access to adequate treatments (Rommelfanger et al., 2017). One of 
three identified pathways to achieve that is to empower people with FMD ‘to be heard and 
drive changes in care’ through gaining insight from the patient to inform treatment plans and 
goals (Rommelfanger et al., 2017).  
The current study would address the gap in the research base, exploring the 
experiences of people with FMD and facilitating their perspectives to be heard. The findings 
from the project could contribute to reduction of stigma and would inform the design of 




Qualitative methodology using Interpretative Phenomenological Analysis (IPA) 
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Participants 
I will be recruiting from 6 up to 12 people, as a typical sample for an IPA study (Smith et al. 
2009). Participants recruited will be aged 18, any gender, and over and living in the UK (to 
ensure a fairly homogenous group in terms of received healthcare and support by the national 
health system) who have been diagnosed with any type of  functional movement disorder at 
least 12 months prior to the interview (to ensure sufficient time and experience of living with 
the disorder and to be able to reflect on the course, treatment and impact of the diagnosis as 
well as the symptoms).  
Participants would need to self-report that they have a diagnosis of Functional 
Movement Disorder (FMD) or Functional Neurological Disorder (FND) or Functional 
Neurological Symptoms Disorder or Psychogenic Movement Disorder or 
Somatoform/somatisation Disorder or Conversion Disorder or Functional Weakness or 
Functional Dystonia or other similar diagnosis that is found to be caused by a disturbance in 
functioning of the nervous system rather than structural damage in the brain or muscles. The 
participants would also need to experience at least one of the following symptoms: 
- paralysis (or episodic paralysis) or weakness in an arm or leg 
- muscles spasms affecting movement 
- dystonia – involuntary muscle contractions that cause slow repetitive movements or 
abnormal postures 
- myoclonus – sudden, involuntary jerking of a muscle or a group of muscles, affecting 
movement or posture 
- tremor affecting movement or posture 
- gait disturbances 
Exclusion criteria: 
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- functional movement disorder as secondary to organic or structural (resulting from a 
damage to the brain or muscles) neurological disorder. 
Participants with other medical conditions and other functional disorders in addition 
to FMD will not be routinely excluded. However, prior to arranging an interview, I will 
confirm that the movement disorder is their primary medical concern to preserve 
homogeneity of the sample.  
 
Data Collection/Procedure 
At the recruitment stage I will be collaborating with FND Hope – an international not-for-
profit organisation who agreed to assist with the study. FND Hope has a registry of people 
who have already expressed their interest in taking part in research relating to FND and have 
submitted demographic and FND related information via the registry survey.  There are 
currently 84 people registered on this list in the UK. Individuals who are believed to meet the 
inclusion criteria would be targeted and contacted by FND Hope via email inviting them to 
take part in the current study. The email will include the participant information sheet and the 
consent form for information.  
FND Hope will publicise information about the study on their website 
(https://fndhope.org/), social media and patient engagement platforms: Twitter, Facebook, 
Instagram and Health Unlocked (https://healthunlocked.com/). I will provide a link to the 
information about the study on the Doctorate in Clinical Psychology student research page: 
https://www.lancaster.ac.uk/shm/study/doctoral_study/dclinpsy/research/.  
As a contingency plan, if not enough participants were recruited, I would contact the 
Dystonia Society – a charity organisation supporting people with all forms of dystonia, 
including functional dystonia. I would ask for the link to the study to be posted on their 
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website and social media sites. If there was still a need to recruit more participants, I would 
circulate the link to the study on Twitter via personal contacts. The Twitter account would be 
opened solely and exclusively for the purpose of the research study.  
If they decide they would like to take part, the participants will need to contact me via 
email or phone. I would then contact them to discuss the study further. If they are happy to 
proceed, an interview will be arranged. At that point I would also ask them for their address 
in case of immediate risk becoming apparent during the interviews so that the emergency 
services could be contacted. I might also use their address to post the participant information 
sheet and the consent form if they don’t have access to an email, with their agreement. The 
addresses will be stored on the main investigator’s secure storage space on the Lancaster 
University’s server. They will be encrypted, password protected and will be deleted once the 
interviews are completed unless the participants wished to have to study findings sent to them 
by post. In such case, the addresses will be deleted after the study findings were sent via post.  
I would also ask about other medical concerns they might have that might be impacting their 
experience of the movement disorder to establish eligibility for the study. 
Participants will also be given an option of email exchanges or WhatsApp messaging 
instead of video/phone/face-to-face interviews if they would like to participate but would 
otherwise be unable to engage in video/phone/face-to-face communication, for example due 
to speech difficulties.  
Participants will be sent the participant information sheet and the consent form to read 
before the interview. Participants will be informed they don’t need to return the consent form. 
When the interview is conducted face-to-face, as I will review the consent form with them at 
the start of the interview and ask them to sign it if they want to proceed. In the case of 
phone/video link interviews I will read the consent form to them and ask them to confirm if 
 
ETHICS PROPOSAL                                                                                                           4-19 
 
   
 
they understand and agree to participate in the study. I will audio record the consent process 
into a standalone recording, separate from the interview recording.  
Data would be collected through semi- structured interviews lasting around an hour 
each. Participants will be encouraged to talk about the issues that are most salient to them, so 
the interview schedule will serve as a guide rather than a comprehensive list of questions. The 
interviews would be conducted through the phone, Skype or Zoom. A face to face interviews 
might be possible if participants are based in Lancashire or Cumbria, within accessible 
distance for the researcher and a suitable, local community venue is available and accessible 
to the participants. There would also be a possibility of an interview via email or WhatsApp 
messaging if a face-to-face/audio/video medium would be a barrier for people in accessing 
the study (for example, if their speech was affected). Additional demographic information 
will be collected: age, gender, living situation (alone or with others), occupational status 
(working or not), time since the diagnosis, duration of symptoms, type of symptoms, 
psychological treatments offered and accepted, comorbid conditions – to situate the sample 
and assist in the analysis of the data. The participants’ addresses will be collected in case of 
immediate risk becoming apparent during the interviews so that the emergency services could 
be contacted. These will be destroyed once the interviews are completed. 
Data Analysis 
The study will adopt interpretative phenomenological analysis (IPA) as the approach as it is 
particularly suited to exploring under-examined topics (Smith & Osborne, 2015). Through an 
inductive analytical process, it can provide a detailed understanding of the participants’ lived 
experiences of FMD and their subjective meaning making of that experience. To aid that 
process the interviews will be transcribed verbatim to create written transcripts. As I intend to 
focus on the individual’s unique experience embedded in their context and perspective, IPA 
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is ideal as it’s idiographic in its nature and facilitates exploring particular perspectives in their 
specific contexts (Smith et al. 2009). 
Data Storage 
Interviews will be recorded on a digital audio recorder and then transferred as soon as 
possible to and stored on the main investigator’s secure storage space on the Lancaster 
University’s server for the duration of the study. The transcribed interviews will be 
anonymised and stored as described above. Audio recordings of the consent and written 
consent forms will be encrypted, password protected and stored with a code to link them with 
their respective interview transcripts but in a separate file from non-personal data, such as 
interview transcripts. Once the project has been completed and examined, audio recordings of 
the interviews will be deleted. The remaining files will be transferred securely using the 
university’s encrypted file transfer software (currently Box) to the Research Co-ordinator at 
the Doctorate in Clinical Psychology programme and stored on the university’s secure server.   
If any participants request the interviews to be conducted via email exchange, they 
will be informed that those means cannot be entirely secure. They will be encouraged to use 
password protected attachments when sending emails to increase the security of data but will 
be advised that the security still could not be guaranteed. The contents of the emails would be 
uploaded to the secure space on the university server and the original emails deleted. 
Participants would be asked to also delete the email exchanges. 
Participants’ addresses and other contact details will be collected to provide to local 
emergency services in the case of immediate risk becoming apparent during the interviews. 
Those details will be destroyed immediately after the interview is concluded unless the 
participants wish to be sent the study report with findings. In such case their details will be 
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stored as described above in an encrypted file with audio and written consents and destroyed 
after the findings are sent out to them.  
The electronic data will be stored for ten years after which it will be deleted by the 
Research Co-ordinator at the Doctorate in Clinical Psychology programme under the 
direction of the university supervisor. 
Ethical Considerations 
There is a potential for distressing material to arise during interviews given the personal 
emphasis of the research question and many challenges associated with living with functional 
neurological disorders. In the process of seeking informed consent, the participants’ attention 
would be drawn to potential upset and distress and we would discuss their current sources of 
personal and professional support to seek before or after the interviews.  
Participants will be given the contact information of relevant support services as part 
of their participant information sheet. Participants will be informed they can withdraw from 
the study at any point before and during the interview and then up to the data analysis stage 
when the themes are merged and after which data might not be possible to be extracted. 
Participants will be advised they can stop the interview at any point to have a break, postpone 
to another time or cancel it altogether. I will be mindful of signs of distress or fatigue in 
participants during the interview and remind them of the option to pause, postpone or 
withdraw. I will also seek participants’ verbal consent to continue discussing a topic/aspect 
that is the source of distress to them, if this should arise. In the event of participants 
becoming severely distressed and expressing thoughts of harm to themselves or someone else 
I will follow the process agreed with them prior to the start of the interview – in the case of 
immediate risk I will contact the local emergency services. I would also discuss this with my 
field and university supervisors.  
 
ETHICS PROPOSAL                                                                                                           4-22 
 
   
 
Dissemination 
The findings will be written up into a thesis as part of a doctorate in clinical psychology for 
the principal investigator. The findings will be summarised in a brief report and shared with 
FND Hope and potentially publicised on their website and social media sites. The report will 
also be sent to those participants who declare at the interview that they want to receive it. It is 
intended that the research will be submitted to a peer reviewed journal. The findings will be 
presented at a thesis presentation day at Lancaster University as part of the Clinical 
Psychology programme. If the opportunity arises, the findings would also be presented at 
academic conferences.  
Service User involvement 
I have consulted with two members of FND Hope (who are or have been living with FMD) to 
seek their views and advice regarding the design, recruitment and interview schedule of the 
research project. They have also provided feedback on drafts of participant information form 
and consent form. FND Hope will review the project protocol after it’s been approved by the 
university ethics committee and will provide further feedback before the study commences. If 
any changes need to be made as a result of this, I would submit an application to the 
university ethics committee for approval of the amendment.  
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APPENDIX 4-A 
INTERVIEW TOPIC GUIDE 
1. What diagnosis have you been given and when?  
- What sorts of symptoms/problems do you experience? 
 
2. Sense making of the disorder and the experience of having it  
- How would you describe it/explain it to someone? /what would you compare it with?  
- What's your understanding of the condition and your symptoms? What explanation seems to 
have most sense in relation to your difficulties? Has that changed? 
- How do others understand it? (family, friends, health care staff) 
 
3. What is the impact of your condition on your functioning and wellbeing? 
- on work, leisure, relationships (family life, intimate relationships, friends) relationship with - 
on how you view yourself?  
- on your mental health and wellbeing – how was it before you had the condition? 
- Is there anything you think people aren't talking about when speaking about their condition 
and its impact? 
 
4. What is your experience of getting a diagnosis and treatment? 
- Experience of treatments so far - What's been helpful, why, and how? What’s not been 
helpful? What do you think would be more helpful? 
- What is your understanding and experience of psychological treatments for functional 
movement disorders?  
- If accessed psychological interventions – what was the impact on distress and on severity or 
frequency of symptoms? What's not been helpful and why? What would be more helpful? 
 
5. What do you wish health professionals knew or understood that you know now? 
 
6. If recovered or recovering: what do you think helped the recovery the most? If not recovering – 
what do you think are the barriers to your recovery? What would help it? 
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Study Title: Living with functional movement disorders. 
We are asking if you would like to take part in a research project exploring experiences of 
living with functional movement disorders. Before you consent to participating in the study, 
we ask that you read the participant information sheet and this consent form. You do not 
need to return the forms. If you consent to take part in the study, we will review the 
statements below at the start of the interview and I will ask you to confirm that you agree to 
each of them – orally (if your interview is on the phone/via internet video link) or in writing (if 
your interview is face-to-face). I will audio record the consent process if we are not meeting 
face-to-face. If you have any questions or queries before consenting please speak to the 
principal investigator, Sylwia Bazydlo at s.bazydlo@lancaster.ac.uk or tel. 07508406248 
 
 
1. I confirm that I have read the information sheet and fully understand 
what is expected of me within this study.  
2. I confirm that I have had the opportunity to ask any questions and to have 
them answered.  
3. I understand that my interview will be audio recorded and then made into an 
anonymised written transcript. 
4. I understand that audio recordings will be kept until the research 
project has been examined. 
5. I understand that my participation is voluntary and that I am free 
to withdraw at any time without giving any reason, without my 
legal rights being affected.  
6. I understand that once my data have been anonymised and 
incorporated into themes it might not be possible for it to be withdrawn. 
7. I understand that the information from my interview will be pooled 
with other participants’ responses, anonymised and may be 
published. 
8. I consent to anonymised information and quotations from my 
interview being used in reports, conferences and training events.  
9. I understand that the researcher will discuss data with their 
supervisors as needed. 
10. I understand that any information I give will remain confidential 
and anonymous unless it is thought that there is a risk of harm 
to myself or others, in which case the principal investigator will 
need to share this information with their supervisors.  
11. I consent to Lancaster University keeping written transcriptions 
of  the interview for 10 years after the study has finished. 
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 Participant information sheet 
 
LIVING WITH FUNCTIONAL MOVEMENT DISORDERS. 
 
For further information about how Lancaster University processes personal data for research purposes and 
your data rights please visit our webpage: www.lancaster.ac.uk/research/data-protection 
 
My name is Sylwia Bazydlo and I am a student on the Clinical Psychology Doctorate programme at 
Lancaster University, LancaCter, United Kingdom. I would like to invite you to take part in a research 
study about living with functional movement disorders. 
Please take time to read the following information carefully before you decide whether or not you wish to 
take part. 
What is the study about? 
This study aims to explore experiences of people living with functional movement disorders: their views, 
thoughts and feelings. 
Why have I been invited? 
You have been approached because the study requires views and thoughts of people who have had a 
diagnosis of any form of functional movement disorders for at least 12 months. This includes diagnoses 
such as: Functional Movement Disorder (FMD), Functional Neurological Disorder (FND), Psychogenic 
Disorder, Somatoform/Somatisation Disorder, or other similar diagnoses.  
I would like to hear from you if, as part of your condition, you are experiencing symptoms affecting your 
movement or posture, such as: paralysis or weakness, muscle spasms, dystonia, myoclonus,, tremor or 
gait disturbances.  
What will I be asked to do if I take part? 
If you decided to take part in the study, you would need to let me know on s.bazydlo@lancaster.ac.uk or 
07508406248. I would then contact you to talk more about the project. If you are happy to go ahead with 
it, we would then arrange a suitable time for the interview. At that point I would also ask you about other 
medical concerns you might have that might be impacting on your experience of the movement disorder 
to ensure your participation in the study would be appropriate and possible at this time. 
  
The interview can be held via WebEx, Skype, Zoom or telephone – whichever is best for you. A face to 
face interview might be possible if you’re based in Lancashire or Cumbria and a suitable venue is 
available and accessible for you.  
During the interview you will be asked about what it is like for you to have a functional movement 
disorder, its impact on your life and your experience of care and treatments. The interview will last up to 
approximately one hour and will be audio recorded.  
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You will be asked to read the attached consent form before the interview. There will be no need to return 
the consent form. If we meet in person, I will give you a copy of the form to sign before we start the 
interview. If the interview is held over the phone or internet video link, I will read its contents to you and 
ask whether you confirm to understand and agree to participate in the study. I will audio record your 
consent in a separate file from the interview. In the case of email/WhatsApp interviews, I will ask you to 
sign and scan the consent form and email it or send via WhatsApp to me prior to the interview. 
 
If you would like to take part in the study but there are barriers to taking part in a video/phone/face-to-
face interview, please let me know and we can discuss other means such as email exchanges or 
WhatsApp. However, whilst WhatsApp uses encryption to increase security of the data, you need to be 
aware that email exchanges are less secure means of communication. 
 
What are the possible benefits from taking part? 
There are no direct, immediate benefits for participants, but it is hoped the results will inform care and 
research relating to functional movement disorders, helping those who live with FMD. 
 
Do I have to take part?  
No. It’s completely up to you to decide whether or not you take part. Your participation is voluntary.  
 
What if I change my mind? 
If you change your mind, you are free to withdraw your participation in this study. If you want to 
withdraw, please let me know, and if possible, I will extract information you contributed to the study and 
destroy it. However, once your data has been anonymised and pooled together with other people’s data, it 
might not be possible to extract it.  
 
What are the possible disadvantages and risks of taking part? 
There are no risks anticipated with participating in this study. However, if you experience any distress 
following participation you are encouraged to inform the researcher and contact the resources provided at 
the end of this sheet.  
  
Will my data be identifiable? 
I will remove any personal information from the written record of our interview so that you are not 
identifiable from it. Any personal information collected will be stored separately from the interview data 
in an encrypted and password protected file to preserve your anonymity and confidentiality.  
 
Please note that although internet applications and tools (such as Skype) are widely used in research, it 
cannot be guaranteed to be completely secure means of communication. 
 
How will we use the information you have shared with us and what will happen to the results of the 
research study? 
The results of the study will be summarised in a report and shared with FND Hope and will form a part of 
my doctoral thesis for Doctorate in Clinical Psychology programme. I might present the results at 
professional conferences and submit for publication in an academic or professional journal to inform 
other researchers and clinicians working in this field.  
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When writing up the findings from this study, I might use direct quotes (e.g. from my interview with you) 
but they would be anonymised which means you would not be identified.   
 
If something you tell me suggests that you or somebody else might be at risk of harm, I will need to share 
this information with my supervisors. If possible, I will inform you of this. If I think you might be at 
immediate risk of harm, I might contact the emergency services in your local area to ensure that you can 
access immediate help. To make it possible, I will ask you to provide your address before the start of the 
interview.  
 
How my data will be stored 
The data collected for this study will be stored on a secure university server and only the 
researchers involved in this study and the research co-ordinator at the Doctorate in Clinical 
Psychology will have access to it. They will be kept for 10 years after which they will be 
deleted. 
o Your interview will be transcribed to a typed version by the researcher herself and 
made anonymous by removing any identifying information including your name.  
o Audio recording of your interview will be deleted once the work has been examined. 
Audio recording of your consent or a written signed consent form will be stored 
separately from non-personal information (such as your views about a topic) for 10 
years. 
o Your personal details, such as telephone number, address or email address will be 
deleted/destroyed after the interview is completed. However, if you would like to hear 
about the study findings, your address or email address will be kept until the findings 
are sent out to you. After that time, they will be deleted.  
o Anonymised direct quotations from your interview may be used in the reports or 
publications from the study 
 
What if I have a question or concern? 
If you have any queries or if you are unhappy with anything that happens concerning your participation in 
the study, please contact myself, 
 
Sylwia Bazydlo: s.bazydlo@lancaster.ac.uk                         tel.  07508406248      
 
Or the project supervisors:  
Dr Fiona Eccles                                                                        tel. 01524 592807 
Dr Catherine Parker                                                                 tel. 01228 814781 
 
Or the Head of Research at the Doctorate in Clinical Psychology: 
Professor Bill Selwood: b.sellwood@lancaster.ac.uk         tel:  01524 59399      
Division of Health Research, Lancaster University 
 
If you have any concerns or complaints that you wish to discuss with a person who is not directly 
involved in the research, you can also contact: 
 
Professor Roger Pickup:  r.pickup@lancaster.ac.uk           tel: 01524 593746  
Associate Dean for Research     
Faculty of Health and Medicine (Division of Biomedical and Life Sciences)  
Lancaster University 
 
ETHICS PROPOSAL                                                                                                           4-30 
 









Sources of support 
If you feel distressed either as a result of taking part in the study, or in the future, the following resources 
may be of help. It may also be appropriate in such situations to speak with your GP. 
 
FND Hope Support Groups via FND Hope website: https://fndhope.org/ 
 
Mind  
Info line: 0300 123 3393  
Website address: http://www.mind.org.uk/ 
 
The Samaritans  
Info line: 08457 90 90 90  
Website address: http://www.samaritans.org/ 
 
Thank you for considering your participation in this project. 
This study has been reviewed and approved by the Faculty of Health and Medicine Research 
Ethics Committee at Lancaster University. 
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Letter of approval from the Faculty of Health and Medicine Research Ethics Committee (FHMREC) 
 
 
 
 
 
 
 
